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The theme o f maternal m orta lity and morbidity is  of transcending macroethical impor­
tance. High rates o f maternal m orta lity and morbidity can be s ig n ifica n tly  reduced by cost- 
e ffective  means that are not dependent on advanced biotechnology. I t  has been shown that a 
major cause of maternal m ortality comes from women ( i )  bearing children too early or too la te 
in th e ir  reproductive live s , ( i i ) too frequently or a t in s u ffic ie n tly  spaced in te rva ls . I f  
women were able to control the ir fe r t i l i ty ^  in order not to have children at unwanted times in 
periods of th e ir l i f e  when pregnancy is  in im ical to th e ir  health, the incidence o f maternal 
m orta lity and morbidity would drop. Improved standards o f women’s education, both in  general 
and in particu lar regarding women's reproductive health, would reinforce the understanding of 
how to protect and improve one's reproductive health, and would accelerate the decline of 
maternal m orta lity and chronic m orbidities. Accordingly, the macroethical demands o f respect 
fo r autonomy, beneficence and jus tice  would coincide. The value of justice would he served 
not only regarding women themselves, pa rticu la rly  those who have trad ition a lly  been vulnerable 
by v irtue  of the ir growing age, or dependent status in  th e ir  communities, but also regarding 
the children dependent on such women, and fam ilies also dependent on the services o f such 
women, lik e  mothers, wives, daughters and grand-daughters.
Keywords : Macroethics, e th ica l princip les, societies of gynaecologists and o b s te tr i­
cians, reproductive health
In tro d u c tio n
Transcending the claims to ethical care that individual patients may 
properly make on the ir doctors are the claims that communities and nations 
may make on the professional societies of gynaecologists and obstetricians 
that practice among them. Individual practitioners who behave e th ica lly
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towards each patient may nevertheless be co lle c tive ly  in breach of wider 
e th ica l duties to communities i f  their services are inequitably available to 
members of wider populations of potential patients among whom the physicians 
l iv e  and earn the ir live lihood. For instance, where particular specialists 
conscientiously serve the patients they accept, but decline to accept those 
w ith family income a given leve l, or who exceed a given parity or age, or 
who are under the scrutiny of th ird  parties (such as parents), the profes­
s ional societies of which such practitioners are members w il l  be in default 
of meeting the eth ica l claims that properly may be made on them.
The ethical duties to ethical care that individual patients may 
properly make on th e ir doctors are the claims that communities and nations 
may make on the professional societies of gynaecologists and obstetricians 
tha t practice among them. Individual p ractitioners who behave e th ica lly  
towards each patient may nevertheless be co llec tive ly  in breach of wider 
e th ica l duties to communities i f  the ir services are inequitably available to 
members of wider populations of potential patients among whom the physicians 
liv e  and earn the ir live lihood. For instance, where particular specialists 
conscientiously serve the patients they accept, but decline to accept those 
w ith  family income a given leve l, or those who exceed a given parity  or age, 
or who are under the scrutiny of third parties (such as parents) the profes­
sional societies of which such practitioners are members w il l  be in default 
of meeting the eth ica l claims that properly may be made on them.
The ethical duties to individuals are known as microethics, and are 
generally distinguishable from macroethics the ethical duties to communi­
t ie s .  Microethics apply in  relations between individuals, such as patients 
and physicians, while macroethics addresses relations between co llective 
agents such as government departments or population groups and individuals. 
Macroethics accordingly raises questions of services made available by 
governments and of ind iv idua ls ' rights aris ing by virtue of membership of a 
so c ia lly  c lassifiable category of persons. Such categories may be drawn by 
reference to inherent physiological features such as gender and e thn ic ity , 
while others may be constructed, such as of handicap by reference to a 
spec ific  function, e.g. childbearing and status, such as being unmarried.
There is  an inherent tension between micro- and macroethics, between 
the individual and the common good. There are no easy answers to resolve 
th is  tension. The purpose of th is paper is  to explain some of the macro- 
e th ica l challenges that face societies of gynaecologists and obstetricians
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around the world in order to find an appropriate balance in the context of 
the ir communities between micro- and macroethical responsib ilities.
BIOETHICAL PRINCIPLES
Three central bioethical principles, derived from the frequently 
invoked Belmont Report /11 /, may be applied to access to reproductive health 
services at the macroethical level of analysis. These three principles are 
respect to persons, beneficence and justice.
Respect to  Persons
The princip le  of respect to persons has at least two components, v iz . 
autonomy, and protection of persons incapable of autonomy. Autonomy at the 
microethical level is  reinforced by ensuring that voluntary and informed 
consent is  obtained .before a patient is  treated. Disrespect of autonomy 
occurs when an individual chooses a method of family planning, not having 
been informed of its  fa ilu re  rate, and i t  fa i ls  and unwanted pregnancy 
results. The ethical responsib ility at the programmatic level of Societies 
might be to ensure that accurate information on fa ilu re  rates of the range 
of family planning methods is  made widely available. For example, the rates 
of contraceptive fa ilu re  range from 2% of women using the p i l l  with fa ilu re  
during the f i r s t  12 months of use to 10% to 16% for the use of condom, 
diaphragm, and rhythm method and 26% for the use of spermicides /6 / .  More­
over, information on how fa ilu re  rates vary by groups also needs to be made 
available. For example, the likelihood of contraceptive fa ilu re  generally 
declines as individuals get older /4 /. Fact sheets on fa ilu re  rates might be 
developed and printed by Societies for d is tribu tion  by the ir members and 
family-planning c lin ics .
Ensuring respect fo r autonomy can be disputable. Marriage is  generally 
not a condition of personal autonomy. Some health or family planning c lin ics  
make marriage a condition of d istribution of family-planning services. 
Accordingly, the offer of means both of b irth  control and b irth  promotion to 
individuals not as individuals but only as partners in marriage can be said 
to offend the princip le of autonomy. Moreover, the law in many ju risd ic tions  
provides for elimination of discrimination on grounds, among others, of
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m arita l status. Accordingly, the eth ica l princip le of respect fo r the 
reproductive preferences of autonomous people should prevail, without regard 
to m arita l status.
Reinforcing respect fo r autonomy is  the princip le that autonomy should 
be at the maximum degree. Societies should ensure adolescents not be generi- 
c a lly  c lassified as incapable of autonomy, but be assessed on a case-by-case 
basis with regard to functioning independently in the ir communities.
The second component of respect fo r persons is  protection of the 
vulnerable. Vulnerability can be c lassified by reference to a variety of 
c r i te r ia ,  such as capacity fo r autonomous decision-making. T rad itiona lly , 
the p rinc ip le  of protection of the vulnerable has been applied to mentally 
handicapped persons to ensure that the ir reproductive autonomy is  not 
v io la ted  by, for example, contraceptive s te r iliz a tio n . Societies can also 
c la s s ify  vulnerable groups by reference to r isk  factors, such as high risk  
of unintended pregnancy. The sheer number of unintended pregnancies among 
adolescents suggests that th is  age group is  vulnerable and in need of pro­
tec tion  against unintended pregnancies, abortions, and sexually transmitted 
diseases. In the United States, for example, "1031000 teenagers became preg­
nant and of these 31 000 were younger than 15. The pregnancy outcomes in ­
cluded 477 710 live  b irths  and 412 617 induced abortions, the remainder were 
s t i l lb i r th s  /2 /. On a world scale, yearly 15 m illion teenagers give b irth  
80% of them in the developing countries /5 /.
Given the vu lnerab ility  of th is  h igh-risk group, Societies might use­
fu l ly  play a leadership ro le  in developing strategies to prevent premature 
pregnancy and childbearing. Such strategies include: 1) developing respon­
s ib le  sexual behaviour, including abstinence among g ir ls  and boys /9 / ;  2) 
e ffe c tive  use of contraception by g ir ls  and boys /14/; 3) use of abortion 
to prevent untimely and irresponsible parenting /13/; 4) prevention of 
morbidity and mortality among young women and premature b irths  through 
adequate prenatal and follow-up care of mothers /12/; 5) encouragement and 
support for responsible parenting among both parents /1 / and 6) sex or 
fam ily l i f e  education /7 /.
Beneficence
This principle goes beyond the negative medical ethic "Do No Harm", 
by imposing a positive duty to do good, i f  necessary by in it ia t in g  action 
tha t w i l l  advance the welfare of individuals and communities. The ethical
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princip le  of beneficence is  sometimes expressed as the princip le of u t i l i t y  
or of u tilita rian ism  /8 /. U t i l i ty  requires that actions be taken that prove 
useful rather than useless or dysfunctional. The concept of u tilita ria n ism , 
often expressed as an obligation to seek the greatest happiness of the 
greatest number, re flec ts  a major philosophical trad ition  of that name.
The macroethical duty of beneficence is  not only to seek good, but 
also to actually do good. An eth ica l duty exists to monitor the effects of 
well-meaning polic ies to see whether they achieve the good they intend or 
whether they are unsuccessful or do actual harm in the ir consequences. 
A programme to assess the incidence and causes of in fe r t i l i t y  would not be 
su ffic ien t to meet the ethical duty of beneficence; i t  would have to be 
followed by services to prevent and trea t in fe r t i l i t y .  Moreover, the 
princip le  of beneficence compels proponents of reproductive health programme 
to build into th e ir programme a capacity for continuous self-evaluation les t 
a programme designed to do good may inadvertently do harm to vulnerable 
individuals and to the community its e lf .
Ju stic e
The most obvious ethical issue implicated in  the princip le of justice  
is  that of access to health services. Macroethically, justice requires 
s im ilar treatment fo r sim ila rly situated groups. I t  may require, fo r in ­
stance, that each group co llective ly  receives an identical a llocation of 
resources, and be iden tica lly  taxed or otherwise burdened. I t  may also mean, 
however, that each group receives services proportionate to i ts  needs, and 
contribute proportionately from th e ir means. Variants of application of the 
princip le  of jus tice  include equal entitlements fo r groups of equal social 
merit or worth, and that groups be rewarded proportionately to the contribu­
tion  they make to society.
Underlying doctrine on co llective  justice  is  a need to iden tify  
appropriate c o lle c tiv it ie s  of persons. Beyond obvious c o lle c tiv it ie s  iden­
t i f ie d  by sex, race, re lig ion , ethnic or national orig in and, fo r instance, 
age, c o lle c tiv it ie s  may be established by reference to other objective 
c r ite r ia . The in fe r t i le  of a community are iden tified  by a reference to a 
de fin ition  of in f e r t i l i t y  that may be derived from medical, social or, for 
instance, demographic sources. Those so found to be in fe r t i le  may seek 
c lin ic a l care, but the collective interests of an in fe r t i le  population w il l
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require preventive services, therapeutic services, access to assisted 
reproduction and access to alternative legal poss ib ilit ie s , such as adop­
tio n , to rear children in  th e ir fam ilies.
The righ t not to be victimized by discrimination on account of the 
common feature may find  expression in legal as well as macroethical prac­
t ic e . The ethic of jus tice  that condemns discrimination on grounds of sex 
would require that both women and men have equal access to family planning. 
As a resu lt, family planning services that do not provide services fo r men 
would vio late the princ ip le  of jus tice . S im ilarly women who are denied 
access to family planning services because of a requirement that thely f i r s t  
obtain the ir husbands' authorization would not meet the princip le of justice 
i f  husbands enjoy autonomous access.
In addition to the eth ic of sexual nondiscrimination there is  a widely 
recognized princip le in international and national human righ ts codes of 
nondiscrimination on grounds of handicap or d is a b ility . In the same way that 
health services are available to assist reproductively functional people to 
achieve the ir reproductive goals, services may be claimed by the in fe r t i le ;  
not simply c lin ic a l services to overcome the ir d isa b ility  i f  possible, but 
also to services that o ffe r alternative options to being equipped for 
natural reproduction.
ETHICAL ALLOCATION IN PRIVATIZED AND SOCIALIZED SYSTEMS
The growing se n s itiv ity  to bioethical issues and concerns that devel­
oped in  the 1960s and 1970s was conditioned essentially by technological 
developments. The development of machines, drugs and vaccines affecting the 
health of patient populations and the delivery of health services to 
communities was recognized to have a social as well as c lin ic a l dimension. 
More recently, however, b ioethical concerns are being driven by economic 
scarc ity . To the question of who gets health care is  being added the ques­
tio n  of who pays, and who bears the sacrifice  of foregoing care in order to 
make scarce resources available to others. The d istribution  of inadequate 
resources to unlimited demands is  a central issue in the science of eco­
nomics, and increasingly the question of who should pay for services is  
being related to the question of who benefits from them.
The professional duty to allocate scarce resources equitably, in ­
cluding lim ited resources of time, space, beds and equipment, is  pa rticu la r­
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ly  demanding where professionals operate under legally created and protected 
monopolies. While claiming to serve the public interest in the provision of 
specialist services through appropriately trained and conscientious prac­
titio n e rs , professional licensing agencies define who may undertake profes­
sional services, and may function with the effect of precluding from 
practice alternative sources of services that potential patients would find 
satisfactory. Preservation of excellence of services to patients may be at 
the cost of convenient and affordable access to services. Accordingly, 
licensing authorities and professional societies of medical specialists 
committed to the provision of good-quality health care must take into 
account not only standards of c lin ic a l care but also standards of availab i­
l i t y  of, and access to, services.
Countries respond to issues of the cost, benefit and d is trib u tio n  of 
services d iffe re n tly . Socialized health-care systems are conditioned by the 
be lie f that i t  is  the society at large that benefits from an improved health 
care among its  members, and that i t  is  again the society at large that 
should pay the costs. Services are distributed according to medically 
determined need, and are funded according to economically determined means, 
economic policies aimed at preventive misuse of public health resources and 
rewards fo r economic use. Private health care systems make services ava il­
able for those who wish to receive them and have the means to pay fo r them. 
Some participants in societies with such systems who lack personal means 
such as private insurance and lack provision of services through a th ird  
party pay or such as an employer or specialist public service (fo r instance 
for m ilita ry  veterans) may forego services they wish to receive which are 
medically indicated for them.
Both socialized and privatized health care systems present macro- 
ethical challenges to societies of gynaecologists and obstetricians. In the 
analogy of the medical lifeboa t, privatized systems show some people safely 
aboard, but others struggling fo r admission and at risk  of drowning before 
help comes. In socialized systems, everyone is  aboard, but provisions may 
be low and some in the lifeboa t may perish. In both systems therefore 
c r it ic a l questions of allocation arise, in privatized systems to make some 
level of service available to the otherwise unserved, and in socialized 
systems to make an equitable level of service available to claimants who in 
princip le rank as equal.
Socialized systems face the question of which of the governing prin­
ciples should determine the allocation of public resources. The goal of
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awarding p rio rity  to the more sick over the less sick may seem equitable in 
tha t in  matches resources to needs. In terms of effectiveness of use of 
resources, however, th is  may be dysfunctional, in  that resources are a llo ­
cated to those less lik e ly  to recover and resume lives  as productive members 
of society. As a re su lt, resources are denied to those more lik e ly  to 
recover u n til the ir conditions and prognoses deteriorate to the point where 
they jo in  the more sick who w il l  be less lik e ly  to recover. Resources may 
accordingly be allocated to serve the outcome of maximum recovery, but at 
the sacrifice  of more seriously i l l  patients who may be afforded comfort 
measures but minimal medical care.
Another basis of resource allocation in socialized systems is  to 
p r io r it iz e  less costly treatments ever more costly, and to embloy resources 
in  preventive rather than curative programmes. The result may be to invest 
in  high-cost technologies, sparingly and to use specialists to plan and 
execute mass educations and tra in ing programmes, d i f f ic u l t  to achieve where 
the levels of lite racy  are low. Indeed, promotion of lite racy may be con­
sidered a proper charge on the health budget e ither to fa c ilita te  individual 
se lf-he lp  of to tra in  aux ilia ry  health professionals to deliver basic ser­
vices throughout the population.
The allocation of resources according to the principle of achieving 
maximum reduction of health risk  factors includes both preventive and 
curative aspects of health care. The princip le depends, of course, on r e l i ­
able identifica tion  of the factors constituting risks to the relevant health 
status (fo r instance, a ffecting  reproductive health) of target populations, 
and in i t ia l  allocation of resources might be devoted to th is  end. Epidemio­
lo g ica l studies might be required, reinforced perhaps by acquisition of 
anecdotal case studies, from health professionals and self-report studies, 
from patients who would be subject to in terpretation by professionals in 
appropriate disciplines and specialists in cultures of study populations.
I t  may be anticipated that a major part of resources devoted to risk  
reduction would be given to programmes of preventive care, including educa­
tio n  through appropriately communicated information and explanation, and 
removal of physical and, for instance, iatrogenic and even nosocomial 
sources of risk. In addition, however, resources might have to be given to 
the cure of medical disorders which caused or preconditioned secondary risk  
to the health of affected patients. For instance, the cure of venereal 
disease should both reduce the spread of in fection and protect the affected 
patient against the r is k  o f consequent in fe r t i l i t y .
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Privatized health systems raise the question of whether the scarce 
resource of professional time should be given to meeting patients' wishes to 
indulge themselves with costly treatments unnecessary for th e ir basic 
health care and that are unrelated to r is k  factors and to obtaining and 
using costly equipment the beneficia l e ffects of which are unproven or in 
the context of communal health standards marginal.
An equally pressing, often more pressing, question is  how members of a 
medical specialty can render services to those who cannot pay. An equi­
librium  may arise i f  practitioners supply services to fee paying patients 
and therapy obtain resources to subsidize services to those who need them 
but cannot pay. Professional societies may, fo r instance, make i t  a condi­
tion of membership that members render a proportion of the ir time and 
fa c i l i t ie s  available to meet the needs of indigent patients. S im ilarly , 
private hospitals or c lin ics  may give a proportion of the ir services and 
fa c i l i t ie s  to needy patients unable to pay fo r them. Such services may be 
considered to be given as charity rather than in fulfilm ent of professional 
macroethical duties, but microethics require that the autonomy of patients 
be given maximum respect, and that patients' d ignity never be compromised.
A re s tric tio n  of privatized health systems is  that in themselves they 
do not equip health professionals (pa rticu la rly  when paid on a fee -fo r- 
service basis) to undertake preventive communal health care, although in ­
dividual preventive care may be undertaken. Under such systems, however, 
governments may be w illing  to support preventive health programmes as part 
of public health care or as a co n tribu tio n ,- fo r instance, to maintaining 
employment, educational, and maternal and ch ild  health standards.
Experience indicates that many health systems are neither purely 
socialized nor purely privatized. Socialized systems often accomodate 
private-practice-supplying additional or competing services fo r patients 
who wish to use them and can afford to with privatized systems often in ­
clude public provision of services fo r such populations as the needy e lderly 
and the deprived young. Accordingly, the macroethical challenges associated 
with socialized and privatized systems may both be faced in mixed systems, 
and the interaction of, and balance between, socialized and privatized 
elements of a mixed system may generate macroethical problems of th e ir own. 
For instance, private beds in public fa c i l i t ie s  may subsidize the rich  and 
diminish resources available fo r those who depend on public provision, and 
inaequate public provision of services may be protected or concealed where 
people of modest means feel compelled to s tra in  the ir resources to purchase
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services in the private sector rather than incur delays in access to public 
fa c i l i t ie s .
An additonal problem, experienced by ind iv idual physicians but a f­
fecting  public investment in health services, is  whether they are w illin g  
and able to prescribe treatments for ind ividual patients according to the ir 
a v a ila b ility , or whether they w ill prescribe unavailable resources and 
require patients to press the p o lit ic a l system to increase the supply of 
resources. Physicians may conceal macroallocation judgements whithin in ­
d ividual prescriptions and prognoses, maintaining the status quo of perhaps 
inadequate public provision of resources, or prescribe and make prognoses 
without regard to public provision of services, thereby forcing some pa­
tie n ts  into the private sector or provoking medical professional co n flic t 
w ith the government.
REPRODUCTIVE HEALTH CARE
The preconditions to macroethical planning and pursuit of repro­
ductive health care are the development and the maintenance of epidemiolo­
g ica l and related information relevant to the reproductive health status and 
r is k  factors of a target population. The sponsorship of studies that ge­
nerate such information might be the responsib ility  of governments, but 
a lternative sources of support and leadership might be available through 
universities, university-based medical centres and independent hospitals, 
and c lin ics . The la t te r  may be unable to support more than modest studies of 
the population w ith in th e ir  own catchment areas. Societies of gynaecologists 
and obstetricians could o ffe r encouragement and leadership at many levels, 
fo r instance to press fo r and fa c ilita te  national or regional studies, to 
recommend hospital-based and clinic-based studies by the ir members, and 
collaboration by hospitals and/or c lin ics  w ith in a region pooling th e ir 
data, and, for instance, providing standardized means and expert assistance 
tha t may be applied to the task of completing relevant epidemiological and 
associated studies.
Many factors contribute to maternal m orta lity  and chronic morbidity. 
Some factors combine w ith others to compound the r is k  of death or d is a b ility  
faced by pregnant women. Obstetric, health service and reproductive factors 
may be isolated and treated in sequence fo r purposes of presentation, but in 
practice such factors my interact, coincide, or arise from common orig ins.
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Moreover, these factors are only the medical factors and do not necessarily 
include social factors, such as low-status of women, that can compound the 
medical r isk  factors, leading to higher rates of maternal m orta lity and 
morbidity.
O b s te tr ic  Facto rs
Maternal death and in ju ries  are usually divided into three categories:
( i )  "d irect" obstetric deaths and in ju ries  — those resulting from complica­
tions of pregnancy, delivery or the ir management; ( jj j)  "ind irect" obstetric 
deaths and in ju ries — those due to other medical factors that were aggra­
vated by pregnancy, fo r example, heart disease or anaemia; and ( i i i ) un­
related deaths and in ju ries  — fortu itous deaths and in ju ries suffered by a 
woman while pregnant, fo r example, from accidents.
The major causes of d irect obstetric deaths and in ju ries, p a rticu la rly  
in the developing world, are haemorrhage, in fection and toxaemia (pregnancy- 
induced hypertension or high blood pressure of other o rig in . Other causes of 
obstetric death and in ju ry  include insk illed  abortion, obstructed labour 
due, in part, to a deformed pelvis which can arise from chronic malnutri­
tion , and a ruptured uterus. Some of these factors w il l contribute, more 
than others, to maternal m ortality and morbidity.
Responses to these factors that may be undertaken by Societies include 
advancing the means to iden tify  h igh-risk pregnancies and to reduce the rate 
of associating complications. Societies might develop programmes to educate 
the ir members in these areas and also to warn women and couples of indica­
tions of high risk  and of the physical and life -s ty le  changes they might 
pursue that would reduce the r is k . S im ilarly, the iden tifica tion  of medical 
factors that make pregnancy contraindicated or that are aggravated by 
pregnancy might be undertaken, and identified  factors might form the basis 
of professional and popular education programmes. In addition, practitioners 
of other medical specia lities might be offered means of education on the 
harmful effects of the ir studied pathology on pregnancy, and of pregnancy 
on the pathology in which they specialize. Moreover, Societies might in s t i­
tute tra in ing programmes to make treatment methods least damaging to the 
physical and mental health of the women popular.
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H ealth  S ervice F acto rs
Health services can be deficient in  many respects. They can be un­
available or deficient in  certain areas of a country. Women can lack access 
to services for a variety of reasons, including structural problems such as 
lack of roads or legal or cu ltural problems, such as the requirement of 
husbands' prior authorizations for d is tribu tion  of contraceptive services to 
th e ir  wiwes. Health personnel can be inadequately trained or lack necessary 
supplies and equipment to provide adequate services. Particularly in  devel­
oped countries, fear of l ia b i l i t y  to malpractice suits may cause gyna­
ecologists and obstetricians to reduce th e ir obstetric practice and lim it  
themselves to the rendering of gynaecological services.
Societies might take leadership in it ia t iv e s  to assess the health 
service factors that are most d irectly  related to excessively high rates of 
maternal mortality and morbidity, and advocate necessary changes to reduce 
the r is k  factors associated with inadequate health services.
Regarding reduction of obstetric services due to fears of lit ig a t io n ,  
fo r  instance, Societies might provide expert witnesses to assist courts to 
render just decision. Moreover, Societies might participate in legal and 
ju d ic ia l education programmes showing that advanced electronic monitoring 
techniques would not reduce the risk  of maternal mortality or morbidity or 
of s t i l lb i r th  or neonatal in ju ry , and that the prevailing standards of pro­
fessional practice do not require employment of theoretically, or expensive­
ly  available high-technology-based care. Societies might establish that not 
everything that might be used must be used in  order to satisfy legal and/or 
e th ica l standards, and that macroethically the excellent should not become 
an enemy of the good or adequate, or an enemy of wide access to sound care. 
That is , societies need to ensure that standards are developed fo r the 
health of the ir patients, not simply in order to defend the ir members in 
court.
Reproductive F acto rs
I t  is well known that the risks of morbidity and mortality associated 
w ith pregnancy are greater for women in the following categories:
+ women less than 18 years of age,
+ women 35 years or older,
+ women whose la s t b irths occurred in  the preceding 24 months,
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+ women with lim ited access to reproductive health services, such as 
those who liv e  in ru ra l areas, and
+ women with unwanted pregnancies lia b le  to end in unskilled abortion.
Societies might assess which categories of women in the ir countries 
and regions of the ir countries are at greatest risk  of maternal m orta lity 
and morbidity due to these conditions, and in s titu te  professional and popu­
la r programmes to reduce the number of h igh-risk pregnancies and, fo r in ­
stance, to advocate the introduction of programmes in areas where services 
are unavailable or inadequately available.
Conclusion
The above are only some examples of the ways in which societies of 
gynaecologists and obstetricians might begin to face macroethical chal­
lenges. The potentia l of Medical Societies as professional groups to u t i l is e  
the ir positions of influence on improving reproductive health in the ir 
countries is  s ign ifican t. Medical societies can lead the way by proactively 
using the ir professional positions to explain and direct what programmes 
would maximile the reproductive health of th e ir communities, rather than 
only be reactively responding to misconceived governmental and other in i t ia ­
tives. Medical Societies might ask themselves what more they can do to 
advocate and fa c ilita te  reform in services, laws and, for instance, cu ltu ra l 
or re lig ious practices that would reduce the risks associated with obstet­
r ics , health service and reproductive factors that prejudice reproductive 
health.
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CI R C U L A T I ON
CLINICAL UTILITY OF QUANTITATIVE ASSESSMENT OF LIVER HAEMODYNAMICS 
IN  CIRRHOSIS PROVIDED BY DYNAMIC HEPATOSCINTIGRAPHY
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Interre lationsh ips between quantitative assessment of portal (%Qp) and a r te r ia l (%Qa) 
components of hepatic blood supply obtained by dynamic hepatoscintigraphy, and c lin ic a l 
variables characterizing the severity of liv e r  c irrhos is  and portal hypertension were studied 
in  25 c ir rh o tic  patients. The variables, c lin ic a l s ta te , size of oesophageal varices, ascites 
accumulation, sonographic stigmata of porta l hypertension, l iv e r  mass and elim ination rate of 
lidocaine and antipyrine were studied. The %Qa rose in  proportion to the severity o f liv e r  
in ju ry  estimated from the Child-Turcotte and McCormick grading scores. The mean %Qa fo r pa­
tien ts  with Child A c irrhos is  was s ig n ifica n tly  higher than that fo r 8 healthy subjects 
(34.8^7.9% vs 18 .1^4 .0 ; P <  0.01). The %Qp values showed relationship with the size o f eso­
phageal varices, provided discriminatory data with respect to the asc itic  f lu id  accumulation 
and the development of intraabdominal co lla te ra l c ircu la tio n . The liv e r  mass had no impact on 
hepatic dual blood supply pattern, but was linked with the rate of antipyrine clearance. 
Neither antipyrine clearance nor lidocaine elim ination rate corresponded to a lte ra tions  of 
hepatic d ia l blood supply. The %Qp showed a negative corre lation with the in i t ia l  h a lf - l i fe  of 
lidocaine, which was referred to lowered hepatic uptake of the drug. I t  is  concluded tha t the 
quantitative assessment of %Qp and %Qa re fle c t the advancement of portal hypertension better 
than liv e r  function fa ilu re  does.
Keywords : Hepatoscintigraphy dynamic, l iv e r  c irrhos is , porta l hypertension, drug
metabolizing capacity
In tro d u c tio n
Hepatic blood flow is  of importance fo r the function of the liv e r ;  i t  
may have pathophysiological as well as clinical-pharmacological implica­
tions. The sinusoidal hepatic blood is  a mixture of hepatic a r te r ia l and
O ffp rin t requests should be sent to : Marek Hartleb, 40-752 Katowice, u l.  Medyków 14,
Poland
Akadémiai Kiadó, Budapest
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p o rta l venous blood. About two-thirds of the blood is  normally supplied by 
the porta l vein while in  cirrhosis the hepatic artery is  the predominant 
source of blood supply /19 /. The c irrh o tic  pattern of hepatic dual blood 
supply is  attributed to augmented vascular resistance within regenerative 
nodules, increased hepatic artery flow and, ch ie fly , to decreased porta l 
in flow  referred to portal-systemic co lla tera ls /11/.
The quantitative assessment of a rte r ia l/p o rta l contribution to to ta l 
hepatic blood flow (HBF) can be obtained by an analysis of f i r s t  pass flow 
studies through the liv e r  using radionuclides which are not trapped by th is  
organ on its  f i r s t  pass 64/. This method was shown to be reproducible and 
to  correlate well to the c lin ic a l state and splanchnic vascular abnormali­
t ie s  /18, 21/. Furthermore, the dynamic intravenous hepatoscintigraphy 
appeared to be a valuable tool in diagnosing portal thrombosis /18/ or 
qua lify ing  patients to shunt surgery /1 /. Nevertheless, the c lin ic a l impor­
tance of determining the po rta l/a rte ria l HBF has received scant attention.
In chronic liv e r  in ju ry , a continuous loss of functional in te g rity  and 
reduction of parenchymal mass is  closely associated with vascular recon­
s truc tion  within and beyond the liv e r. Hence, in  the present study we in ­
vestigated the relationships between haemodynamic parameters derived from 
dynamic hepatoscintigraphy and c lin ica l parameters characterizing the liv e r  
function and portal hypertension.
P a tie n ts  and Methods
The present study was approved by the local Research Ethical Committee.
We have studied 8 healthy male subjects and 25 patients (14 males, 11 females), aged 
between 28 and 70 years, su ffe ring  from liv e r c irrh os is  o f various aetiology, 7 a lcoholic, 
12 posthepatitic , 2 primary b i l ia r y  and 4 cryptogenic c irrhos is . The diagnosis of c irrhos is  
was h is to lo g ica lly  confirmed in  14 cases, the remainder were c lin ic a lly  and biochemically 
evident. The c lin ic a l state o f c irrhos is  was assessed by the combined c lin ic a l and laboratory 
c r i te r ia  of the Child-Turcotte /6 /  and the McCormick /17 / c lass ifica tions.
Radionuclide study
For radionuclide angiography, patients were positioned supine beneath the gamma camera 
Toshiba, GCA 202 interfaced to the d ig ita l computer Trinary HC-3200, including in  the f ie ld  of 
view o f heart, abdominal aorta, l iv e r ,  spleen and kidneys. The patients were allowed to relax 
fo r  15 min prior to scintigraphy. Sodium phytate (IEAiR Swieck, Poland) labelled with 10 mCi 
(370 MBq) of -^Tc pertechnetate was injected through a polyethylene catheter in to  the le f t  
an tecub ita l vein as a 1 ml bolus, followed immediately by 20 ml of saline in order to ensure 
rap id  tra n s it of the radionuclide in to  the heart.
LIVER HAEMODYNAMICS IN  CIRRHOSIS 19
cou n ts
Fig. 1. Handling tim e /a c tiv ity  curves drawn fo r l iv e r ,  spleen and abdominal aorta regions of 
in te res t. Double-head arrows mean the beginning points o f a r te r ia l and venous in flu x  to the 
liv e r .  Solid squares mean the time intervals of hepatic curve taken to calculations
Images were acquired in to  a 64*64 matrix at rate of 1 s image fo r 80 s. Computer 
acquisition was commenced with the onset of the in je c tio n . Time-activity flow curves were 
generated over the r ig h t hepatic lobe, excluding i t s  medial and in fe rio r part, and over the 
abdominal aorta, spleen and r ig h t kidney. Original curves were smoothed and divided by the 
number of pixels of i t s  own region of in terest. Hepatic curves were analyzed in a r te r ia l and 
porta l compartments, each of 6 s duration (Fig. 1). The onset of the a rte ria l hepatic inflow 
was defined as the f i r s t  point on the hepatic curve following 25% peak rad ioac tiv ity  over the 
abdominal aorta. The onset of the portal venous in flow  was set at the peak of the splenic 
curve, or in the kidney curve, i f  the splenic peak was blurred (5 cases). Percentage rates of 
a r te r ia l (%Qa) and porta l (%Qp) flow to the l iv e r  were calculated according to Sarper /20 /.
%Qa = ka/(ka + kp)*100 
%Qp = 100 -  %Qa,
where ka and kp are respective constant rates of a r te r ia l and portal segments of hepatic time- 
a c it iv ity  flow curve f i t te d  with linear function.
The liv e r  mass was estimated from the r ig h t la te ra l hepatic area measured by computer 
according to Eikman's formula /8 / .
The dynamic hepatoscintigraphy was tested fo r interobserver error i . e . ,  a second 
observer unaware of the c lin ic a l data extracted a l l  measurements independently. The coe ffic ien t 
o f variation for the %Qa measurement was 7%. The rep roduc ib ility  of the method expressed as 
re la tive  difference between two successive %Qa measurements performed in the same subject (4 
healthy probands) 7 days apart ranged from 4.5% to 12.4%.
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C lin ic a l studies
A l l  patients with l iv e r  c irrhos is  were examined by both sonography and oesophagogastro- 
scopy. Oesophageal varices were graded according to c la ss ifica tio n  set by the Terminology 
Committee o f the World Society of Digestive Endoscopy-OMED, depending on the degree of pro tru­
sion o f the varix in to  the esophageal lumen and noted 0 fo r  none present to grade IV fo r the 
most severe /16 /. C rite ria  fo r the diagnosis of variceal bleeding was preexisting haematemesis 
or melaena in patients with varices without other potentia l sources of blood loss.
Sonography examination of the portal vein and i t s  related structures was carried out 
using a re a l time sonography equipment -Sigma 20, with a linea r transducer of 3.5 MHz frequen­
cy. Patients were fasted overnight and the following measurements were taken during suspended 
in s p ira tio n : the largest diameter o f the portal vein, and the transverse and long itud ina l 
diameters o f spleen. Scanning fo r co lla te ra ls  around the spleen, pancreas, stomach, and g a ll­
bladder, and along the splenic and porta l vein (cavernous transformation) was made. For pur­
poses o f th is  investigation a po rta l hypertension score was developed and designated the 
"Sonoscore". One point was scored fo r each of the fo llow ing: (a) portal vein la rger than 
1.3 cm, (b) splenomegaly (the upper lim its  fo r longitudina l and transverse diameters were 12.8 
and 4.0 cm), (c) clear presence of abdominal co lla te ra ls  in  at least one vascular bed. In case 
o f the sonographic image being obscured by asc itic  f lu id ,  the examination was performed a fte r 
peritonea l puncture. The degree o f ascites was graded from 0 to 3+; 1+ indicates sonography 
detection o f liq u id  exclusively, 2+ means c lin ic a lly  detectable ascites with protrusion o f the 
um bilicu lus, 3+: tense ascites.
Pharmacokinetic studies
Patients received a single 1000 mg dose of antipyrine (Phenazone, Sigma) o ra lly  in  the 
fas tin g  sta te. A venous sample of 5 ml was obtained in a heparinized tube 24 h a fte r antipyrine 
ingestion. Antipyrine concentration was measured by gas chromatography /12 /. The s im p lified  
one sample antipyrine clearance (С1д) was calculated from /7 / .
C1A = [ In  (d/Vd) -  In c [ ] / t 24xVd,
where d is  the dose of antipyrine given and c is  the antipyrine concentration at a s ingle time 
o f sampling ^ 24). The volume of d is tribu tion  (Vd) was estimated on the basis of body weight, 
he ight, age and sex /3 /.
Eleven patients were given lidocaine (Xylocaine 2%, Astra) intravenously in  a dose of 
50 mg. Venous blood was drawn from the antecubital vein through a polyethylene catheter 5, 15, 
30, 60, 120 and 240 min a fte r the administration o f lidocaine. Serum lidocaine content was 
assayed by gas chromatography /1 4 /. Lidocaine concentration-time data were plotted on semi- 
logarithm ic computer display graph fo r each subject. The elimination rate constants fo r  the 
i n i t i a l  phase (k) and terminal phase (jb) were calculated by means of least squares regression 
using the data points ly ing on the in i t ia l  and terminal s tra igh t-line  portions of the graph. 
The area under the curve (AUC) was calculated from time zero to the las t sample time whereas 
h a lf - l iv e s  (T2) fo r both phases were calculated by d iv id ing  In 2 by к and ß, respectively. The 
data are presented as mean +_ S.D. The поп-matched two sample Mann-Whitney tes t and linear 
regression were used in the s ta t is t ic a l analysis.
Results
Figure 2 shows the %Qa results as a function of the patient's c lin ic a l 
s ta te . The %Qa results fo r healthy subjects ranged from 12.8% to 23.3% and 
were s ign ifican tly  lower than the %Qa fo r mild (grade A) c irrho tics
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Fig. 2, A rte r ia l contribution to hepatic blood supply in  healthy controls and c irrh o tic s , 
subgrouped according to the C h ild -Iu rcotte  grading score
• i . Oa
Fig. 3. Relationship between c lin ic a l evaluation of c irrh os is  by McCormick grading score and 
a r te r ia l contribution to hepatic blood supply
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(18.1 +_ 4.0 vs 34.8^7.9% ; P <L 0.01). The patients with severe c irrhos is  
(grade B+C) presented s ig n ifican tly  lower %Qa ( t  = 2.78; P< 0.02) then those 
with mild cirrhosis. The measurements did not provide sign ificant separation 
between grade В and C (56.9+_17.2% vs 58.5^16.7%). Figure 3 correlates %Qa 
resu lts  with c irrh o tic  gradings according to McCormick, including in  con­
tra s t to the Child-Turcotte c lass ifica tion  porta l hypertension stigmata lik e  
oesophageal varices, splenomegaly, co lla te ra l abdominal veins and hydro- 
thorax. The comparison of %Qp due to ascites accumulation and "Sonoscore" 
re su lt is  presented in  Tables I  and I I .
The mean %Qp resu lts subgrouped by the endoscopical degree of oeso­
phageal varices are depicted in Fig. 4a. The %Qp for patients with absent or
Table I
Portal venous contribution to HBF (mean ±5 .D .) 
subqrouped accordino to the degree of ascites accumulation
Ascites3 n %Qp
— 10 59.2 + 12.9
9 44.0 + 19.5
+++ 6 39.3 + 15.1*
3 fo r symbol see "Patients and Methods" 
n = number of patients
^ s ig n if ic a n tly  lower than fo r patients 
without ascites ( t  = 2.24; P <  0.05)
Table I I
Portal venous contribution to HBF (mean itS .0 .) 
subqrouped on the basis of "Sonoscore" result
Sonoscore3 n %Qp
1 6 67.0 + 10.6
2 7 59.3 + 9.8
3 12 33.9 + 11.2"
3 Sonoscore c r ite r ia  see "Patients and Methods" 
n = number of patients
* s ig n if ic a n tly  lower than fo r Sonoscore 1 
( t  = 3.18; P <  0.01) and Sonoscore 2 
( t  = 3.21; P< 0.01) groups
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Fig- 4, Portal venous contribution to hepatic blood supply as a function o f; (a) endoscopical 
grade of esophageal varices and (b) occurrence of gastro in testina l bleeding (mean + S.D.)
I-degree varices was 66.8 +_ 9.0%; i t  was found to be s ign ifican tly  higher 
than the %Qp in groups of patients with larger varices. The comparison of 
%Qp between bleeders and nonbleeders is  shown in Fig. 4b.
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F in . 5, Relationship between lidocaine half-time (T2) in  the in i t ia l  phase of systemic elimina­
tion and the a r te r ia l contribution to hepatic blood supply
A n t i p y r i n e  c l e a  r a n с e  ( m l / m in  )
Fig. 6. Relationship between antipyrine clearance and calculated mass of the l iv e r
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The liv e r mass ranged from 0.80 to 2.46 kg (mean value: 1.76j^0.42 kg) 
and showed no relationship with blood-flow estimates. The mean in i t ia l  and 
terminal-phase T2 of lidocaine elimination were 15 .1^3 .8  min and 215.7 _+ 
+_ 135.8 min, respectively. Terminal-phase T2 of lidocaine elimination did 
not correspond to quantitative haemodynamic parameters, whereas in i t ia l -  
phase T2 of lidocaine showed positive correlation with %Qa (Fig. 5). Anti- 
pyrine clearance ranged from 7.8 ml min to 37.8 ml min (mean value was 
18.7^6 .4  ml min ) and was related to the liv e r  mass (Fig. 6) but did not 
correlate with quantitative haemodynamic estimates (r  = 0.10, P У  0.05).
Discussion
I t  may be assumed from our study that the dynamic hepatoscintigraphy 
based upon measurement of the slopes of the hepatic flow curve provides 
certain d iffe ren tia tion  between healthy subjects and advanced c irrho tics . 
We confirm that the contribution made by the hepatic artery is  considerably 
increased in severe forms of liv e r cirrhosis (grades В and C), whereas in 
grade A patients the porta l vein is  the predominant source of hepatic blood 
supply. Nevertheless, not a l l  patients with h is to log ica lly  proven cirrhosis 
showed a 30% elevation of the a rte ria l component. This finding indicates 
that blood flow alterations may not occur in the early stage of th is  disease 
and precludes dynamic hepatoscintigraphy from being a diagnostic test in 
liv e r  cirrhosis.
Apart from ascites, the Child-Turcotte c lass ifica tion  does not include 
the c r ite r ia  of portal hypertension. By contrast, among the nine c r ite r ia  of 
McCormick c lass ifica tion  five  are d irectly  attached to haemodynamic sequelae 
of portal hypertension. Most of the %Qa measurements exhibited clear corre­
la tion  with McCormick score, however there were four values being far beyond 
95% confidence lim its  of linear regression giving rise  to a suggestion that 
in some s t i l l  undefined conditions the c lin ic a l advancement of portal hyper­
tension is  not followed by para lle l a rte ria liza tion  of hepatic blood supply. 
More detailed studies of th is  problem are warranted.
Both c lassifica tions of severity of liv e r  in ju ry  derive from general 
c lin ic a l experience and are recommendable for prognostic purposes. Hitherto, 
the re la tive  p o rta l/a rte r ia l pattern may be viewed as a single c lin ic a l 
estimate of prognostic significance. In accord, the ascites accumulation 
which was recognized an independent prognostic factor /2 / correlated well 
with the portal contribution to HBF.
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The porta l/a rte ria l HBF is  clearly associated with unremittingly high 
po rta l pressure. The prevalence of extrahepatic co lla tera ls was evaluated by 
combined sonography and oesophageal endoscopy examinations. The size of 
oesophageal varices was c learly  related with the magnitude of %Qp. Further­
more, the lowest %Qp values were found in c irrho tics  with a h istory of 
varicea l bleeding. This finding is  in agreement with the evidence that large 
varices remain the most lik e ly  to bleed /5 /. Varices do not constitute the 
major route within co lla te ra l c ircu la tion , however they represent an in d i­
cator of generalized development of portal-systemic c irc u it .  S im ilarly , the 
%Qp values effective ly subdivided the patients according to extrahepatic 
co lla te ra ls  detected by sonography. The patients with apparent porta l hyper­
tensive markers had the lowest %Qp, which on the average was the ha lf of the 
%Qp found in patients with mild or absent co lla tera ls. This findings points 
out tha t only large-size vascular channels, constituting s ign ifican t path­
ways in to systemic c ircu la tion  are visualized in routine sonography.
C irrhotic liv e r may be shrunken, normal sized or enlarged, hence, the 
to ta l cross area of intrahepatic vasculature can d iffe r  from patient to 
pa tien t. The influence of hepatic volume on early survival time a fte r shunt 
surgery had been stressed /15 /. In the current study the liv e r  mass e s ti­
mated from la tera l hepatic scan image showed no relationship with liv e r 
haemodynamics. This finding seems surprising as liv e r  volume in c irrhosis 
is  also determined by the extent of fib ros is  which promotes an increase in 
intrahepatic vascular resistance.
The live r plays the principal role in disposition of drugs and ha lf- 
liv e s  of these are generally prolonged in c irrhosis. The drug elimination 
capacity by the liv e r  cannot be predicted on the basis of known laboratory 
tes ts . We attempted to ascertain whether a loss of hepatic vascular in te g r i­
ty  is  linked to a s ign ifican t impairment of hepatic drug elim ination. In a 
former study /9 / we found that propranolol b ioava iîab ility  changed inversely 
to porta l contribution to HBF. Now, we have studied elimination rates of two 
drugs extensively cleared by the liv e r , prototypes of low and high extracted 
compounds /13/, respectively.
Antipyrine clearance was related with the liv e r mass, but not with the 
Child-Turcotte score and hepatic dual blood supply. S im ilarly, lidocaine 
elim ination rate did not correspond to the measurements of p o rta l/a rte r ia l 
HBF. I t  cannot be answered on the basis of the present data whether lid o ­
caine elimination followed the changes in to ta l HBF, however i t  has recently 
been shown /10/ that in  la te  c irrhosis the magnitude of HBF is  of l i t t l e
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importance to systemic lidocaine clearance. Generally, i t  should be rather 
assumed that in cirrhosis the hepatic metabolizing capacity, and not vas­
cular derangements is  the ra te -lim iting  factor to clearance rates of both 
drug categories.
Surprisingly, the %Qp corresponded to the h a lf- l ife  of the in i t ia l  
elim ination curve of lidocaine. This time in terva l ranging in our study from 
8.3 to 21.6 min, ch ie fly re flec ts  compartmental d is tribution , although the 
calculated volume of d is tribu tion  was unrelated to %Qp (data not shown). The 
liv e r  may be considered a large compartmental space in lidocaine d is tr ib u ­
tion, access to which depends on the effic iency of hepatic extraction. On the 
other hand, i t  is known that in c irrhosis hepatic uptake of drugs may be 
affected by sinusoidal cap illa riza tion  /22 /. So, i t  is  tempting to postulate 
a linkage between the a rte r ia l blood supply and the efficiency of lidocaine 
hepatic extraction.
Up to now, there is  no direct method measuring portal venous and hepa­
t ic  a rte r ia l blood flow separately. Dynamic hepatoscintigraphy permits the 
quantitative separation of the portal from the a rte ria l blood supply at the 
hepatic leve l. The results obtained by th is  method reflected the c lin ic a l 
state of patients with liv e r  cirrhosis corresponding well to c lin ic a l 
c lassifica tions of the severity of liv e r  in ju ry , and, in particu la r, giving 
a considerable insight in to the haemodynamic consequences of porta l hyper­
tension. In contrast, p o rta l/a rte r ia l HBF assessment was not sensitive 
enought to diagnose liv e r  cirrhosis and did not allow the evaluation of 
hepatic drug metabolizing capacity.
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DIPYRIDAMOLE THALLIUM-201 SCINTIGRAPHY IN  PATIENTS 
WITH ARTERIOSCLEROSIS OBLITERANS.
INCREASED ACCURACY IN IDENTIFYING CARDIAC RISK
L. BAJNOK1 , J.  VARGA1 , B. KOZLOVSZKY2 ,
T. FÜLÖP J r . 3 , A. MOHÁCSI3
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Forty-eight preselected patients (pts) with arteriosclerosis obliterans were inves­
tigated by dipyridamole thallium  scintigraphy (DTS). No corre lation was found between the 
d is tribu tion  of positive or negative exercise ECG testing (ExECG) and isotopic risk-scores 
(P >  0.1 in the chi-square te s t) . We assessed cardiac ischaemia in 12 pts with in su ffic ie n t 
ExECG. Although only 2 pts had documented previous myocardial in fa rc tion , 20 pts exhibited 
irrevers ib le  perfusion defect. S ilen t reversible or irreve rs ib le  ischaemia was id en tified  
in 12 pts (25%). Seven pts would not have been diagnosed to have coronary artery disease (CAD) 
even by ExECG. In conclusion, DTS was found very useful in  these cases. We support a stepwise 
cardiac r is k  s tra t if ic a tio n  before major vascular surgery.
Keywords: A rteriosclerosis obliterans, coronary artery disease, cardiac r is k  s t r a t i f i ­
cation, dipyridamole thallium  scintigraphy, exercise stress ECG testing
In tro d u c tio n
The cardiac r isk  of peripheral vascular surgery is  increased because 
of the high incidence of ischaemic heart disease in  th is  patient population 
/9 /. Besides, the clamp of the aorta elevates the afterload that can cause 
an extreme burden on the heart. The release of compression usually results
Abbreviations: AMI: Acute myocardial in fa rc tion , CAD: Coronary artery disease,
ExECG: Exercise stress ECG testing, DTS: dipyridamole thallium  scintigraphy, G: grade, 
PD: perfusion defect, Pts: patients, Rd: red is tribu tion , Tl-201: Thallium-201 chloride
O ffprin t requests should be sent to : L. Bajnok, H-4012 Debrecen, Nagyerdei k r t .  98, 
P.0. Box: 19.
Akadémiai Kiadó, Budapest
30 L . ВАЛОК e t  a l .
in  a drop of blood pressure /2 /. There are two poss ib ilities  to decrease the 
r is k  of perioperative cardiac events (unstable angina, heart fa ilu re , myo­
card ia l infarction, sudden death): ( i )  previous coronary revascularization 
i f  necessary, ( i i ) and/or invasive haemodynamic monitoring during the 
vascular operation /6 / .
Therefore, the diagnosis of ischaemic heart disease is  an important 
task of the preoperative medical consultant /10 /. However, the diagnosis is  
made d if f ic u lt  by the poor exercise tolerance of these patients (pts) /5 /. 
Angina occurs less frequently than s ign ifican t coronary stenoses, and the 
physical stress ECG (ExECG) is  of less diagnostic value. For th is  reason, 
Hertzer et a l. suggested routine coronarography before lower limb vascular 
surgery /9 /. Recently dipyridamole Thallium-201 scintigaphy (DTS) seems to 
be a reliable heart screening test to establish the re la tive  operative 
r is k  /3, 16/.
In this study, we made e ffo rts  to obtain additional information from 
DTS beside ExECG.
P a tie n ts  and Methods
Forty-eight patients (p ts ) (40 men and 8 women) were studied. Mean age: 55.6 +_ 8.5 
(40—77) years. A ll of the pts had documented peripheral occlusive arteriosclerosis. The pts 
were examined by an experienced vascular surgeon and a card io log ist. Among others, leg Doppler 
index measurements, rest ECG and in 44 cases multistep graded, moderate bicycle exercise ECG 
tes tin g  (ExECG) were performed. The ExECG was considered to be (1) positive i f  1 or more mm of 
ST segment (downsloping or f la t )  depression or elevation was induced; (2) inconclusive i f  the 
exercise was stopped due to claudication at a lower leve l than target heart ra te , and no 
conclusive ECG finding culd be seen; (3) negative ( i f  neither of these c r ite r ia  were fu lf i l le d ) .
For the radionuclide studies pts were chosen mainly on the basis of c lin ic a l and ECG 
find ings: those with angina and/or positive or inconclusive ExECG were preferred. The s c in ti­
graphy was carried out a fte r taking informed consent, generally in fasting sta te. We infused 
0.56 mg/kg dipyridamole (Persantine; Thomae GmbH) over 4 minutes. Serious complication occurred 
in  one occasion, in the form o f trans ito ry  symptomatic drop of blood pressure.
After 3 min delay 65 MBq Tl-201 chloride was administered intravenously. Within ten min 
a 3-view acquisition had begun (LAO, A, L-70) on a gamma camera (Gamma MB 9200) equipped with 
an all-purpose, paralle l-hole collim ator. Besides X-ray f ilm , В min-pictures were obtained on 
a computer (DIAG), too. We took red is tribu tion  pictures a fte r 3 h in rest.
Images were interpreted by two observers unaware of c lin ic a l and ECG data. Visual 
analysis, modified in te rpo la tive  background subtraction, d ig ita l display, circumferential 
p ro f i le  curve generation and comparison with normal range were made. We considered an investi­
gation to be positive fo r perfusion defect (PD) i f  at least 18 degrees of the p ro file  curve were 
under the normal range (mean value +_ 2 S.O.). We assorted the red istribu tion (Rd) as complete, 
p a r t ia l or reverse ( i f  the PD appeared or was more conspicuous on the rest images). We used a 
four-grade (G) score to characterize the severity of PDs: 0: no PD; I :  fixed PD; I I :  reversible 
PD in  one region; I I I :  m ultip le  PDs ( in  two or more coronary te rr ito r ie s  with Rd in  at least 
one o f them).
For s ta tis tic a l analysis the chi-square tests were applied.
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Fig. 1. A typ ica l example of a high r isk  (G I I I )  scintigraphy: septal and in fe ro-apica l 
reversible perfusion defects (PD) in  LAO view (F ig. 1A). In fe rio r wall fixed PD in  anterio r 
view (Fig. 18). (Beside the d ig ita l display, the corresponding circumferential and washout 
curves with normal ranges can also be seen)
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Results
The d istribution  of the outcomes of DTS was the following: negative in 
12 cases, G I ,  G I I ,  and G I I I  in 14, 11 and 11 pts, respectively (F ig. 1).
We compared these results with c lin ic a l and ExECG data. In three 
independence analyses DTS grade O -III were set against (1) c lin ic a l va ri­
ables (presence or absence of angina and/or rest ECG abnormality); (2) the 
to ta l;  and (3) the unequivocal ExECG results (n = 44 and 33, respectively). 
In Table I  the former two respects; (1; 2) were compared with DTSr in  s
Table I
D istribution of the results of two stress tests: The correlation 
between dipyridamole thallium scintigraphy and exercise ECG, 
depending on c lin ic a l variables (angina/rest ECG)
Angina/Rest ECG
-
+
Exercise ECG 
+
-  +
?*
+
Dipyridamole 0 1 0 3 2 3 0
thallium I 2 0 2 3 2 5
scintigraphy I I 1 2 1 4 0 1
grades I I I 1 2 2 4 0 1
n = 44 P >  0.05 and 0.1 in  the chi--square test
(see in  text)
x: Inconclusive testing 
Grade 0: No perfusion defect (PD) 
I :  Fixed PD 
I I :  Reversible PD 
I I I :  M ultip le  PDs
Table I I
Correlation between dipyridamole thallium 
scintigraphy and unequivocal exercise ECG
Exercise ECG
Dipyridamole 0 1 5
tha llium I 2 5
scintigraphy I I 4 5
grades I I I 3 7
n = 32 P > 0.10
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combined way, while in  Table I I  the la tte r one (those pts with unequivocally 
positive or negative ExECGs). (From the second paralle l the 12 pts with 
inconclusive ExECG were excluded.) No s ign ifican t correlation was found 
between the severity of ischaemia assessed by scintigraphy and other (1; 2; 
3) available parameters (P >0.05; 0.1; 0.1, respectively).
We regarded a positive DTS as having c lin ic a l consequences i f  there 
was (1) PD after negative (5 pts) or inconclusive (7 pts) ExECG, or (2) a 
high risk  pattern a fte r a positive ExECG. So the isotope study offered 
special information in more than 50% of the pts (the 25 cases underlined in 
Table I ) .  Besides s ign ifican t PD, in 16 of these 25 pts we found Rd, too. 
Reversible or irrevers ib le  s ilen t ischaemia was detected in 12 pts (25%).
Twenty-five pts showed persistent PD (20 pts had fixed, irreve rs ib le  
PD, with or without Rd in another te r r ito ry , and 5 pts had p a rtia l Rd or 
"worsening" PD). The other c lin ic a l variables of these pts can be seen in 
Fig. 2: only s lig h tly  more than half of these pts had ever experienced 
angina, and only 1 suffered from a documented AMI. (The other post-in fa rc­
tion patient did not have a fixed PD.) Only one of the 11 angina-free pts 
had characteristic rest ECG abnormalities. In addition, 5 of them had nega­
tive  or inconclusive ExECG.
Discussion
Dipyridamole is  a potent coronary d ila ta to r with acceptable side 
effects even during intravenous administration. I t  can be used fo r cardiac 
stress testing in case of pts with low exercise tolerance. I f  the e ffec t of 
the drug is  investigated with Thallium-201 isotope, the maximal reserve 
capacity of perfusion of the d ifferent coronary branches can be compared 
d ire c tly , and the se ns itiv ity  for s ign ifican t stenosis is  the highest among 
the noninvasive tests.
By the re ve rs ib ility  of PDs myocardial ischaemia can usually be 
d ifferentia ted from in farction which is  manifested in a fixed decrease of 
a c tiv ity  of a coronary te rr ito ry .
In order to diminish the coronary complication rate of peripheral 
vascular surgery, i t  is  important to id e n tify  high-risk patients before the 
planned procedure. DTS is  a method suitable fo r th is  purpose. Boucher et a l. 
/3 / found postoperative cardiac events in 50% when reversible PD existed. 
However, there is  no general consensus regarding the prognosis of fixed,
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irreve rs ib le  PDs /13 /. McEnroe et a l. /14/ claimed that the operative r isk  
is  s ign ifican tly  higher in  these cases as compared to negative studies, 
while Boucher et a l. could not find more frequent coronary events in  these 
cases.
Some authors /1 , 12/ showed a higher accuracy of DTS when applied 
semiquantitative evaluation. We used a four grade score to characterize the 
severity of myocardial ischaemia (from normal through intermediate r is k  of 
single te rr ito ry  PD with or without Rd to the multiple PDs).
Opposing to other c lin ic a l s ituations /4, 8, 11/, the outstanding 
superio rity  of myocardial scintigraphy in  r is k  s tra tifica tio n  of peripheral 
vascular pts was questioned by some authors /7 , 15/, as the combined, m u lti- 
step diagnostic approach resulted in more accurate assessment. We used a 
s im ila r stepwise algorithm in th is  work to optimize the cost/benefit ra tio , 
and to decrease the probab ility  of false positive results. This meant that 
pts with positive or inconclusive ExECG were preferred (but not exclusively 
chosen) in the recruitement. Although negative scintigraphic results were 
less frequent than in  a general population with peripheral vascular disease, 
we could compare the ra tio s  of positive/negative ExECGs in the d iffe ren t 
r is k  categories. There was no significant difference in the c lin ic a l and 
ExECG parameters between the low, intermediate and high risk groups defined 
by DTS (P >  0.1). Of the two stress testings, ExECG and DTS, the la t te r
angi na 
(13)
? ExECG : i nconclusive exercise ECG 
pos. ExECG : positive exercise 
neg. ExECG : negative exercise
F ig . 2, The c lin ic a l and ECG variables of patients w ith persistent PDs (n = 25 patients)
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Exercise ECG
Fig. 3. A possible algorithm fo r cardiac investigation and treatment 
before and during major vascular surgery
proved to be more accurate in almost a l l  c lin ic a l situations. We also found 
DTS more re liab le  in  the special indication we studied. Seven of 36 pts with 
positive scintigraphy were not suspected to have ischaemic heart disease by 
c lin ic a l and ExECG findings. Although only two patients had had AMI, we found 
irreversib le  ischaemia in at least one coronary region in 20 pts. This fact, 
even i f  we are aware of the inevitable false positive rate of OTS, and 
despite the preselected population, may highlight the great prevalence of 
ischaemic heart disease and, with special importance, i t s  s ile n t form among 
these patients. We think that the rest ECG alone is  clearly in su ffic ien t for 
the risk  assessment before peripheral vascular surgery.
Taking into account the cost/benefit ra tio , we suggest a diagnostic 
flowchart for preoperative medical consultation before planned vascular 
surgery (Fig. 3). The f i r s t  step is  an attempt to perform an ExECG that is 
rarely de fin ite ly  negative in these cases. So we think that the DTS is  neces-
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sary in  the majority of cases and the most jeopardized patients can be se­
lected, fo r whom coronary revascularization may o ffe r the most beneficial 
e ffe c t before leg a rte r ia l surgery.
There are lim ita tions  of th is  study. The bias in  the inclusion c r ite ­
r ia  we mentioned above makes our claims partly  lim ited to th is  special popu­
la tio n . As in our patients with coronary artery disease coronarography had 
not been performed merely because of planned vascular surgery, we could not 
ca lculate the sens itiv ity  and spec ific ity  of these tests exactly. On the 
other hand, as not a l l  the patients included in  th is  work underwent peri­
pheral vascular surgery, we could not make a correlation between isotopic 
r is k  categories and operative complication ra tios.
A c k n o w le d g e m e n t . We g re a tfu lly  thank M. Emri, Mrs. Z. Kari, and Mrs. I .  Porcsin 
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THE EFFECT OF SULPHONYLUREA THERAPY ON THE OUTCOME OF 
CORONARY HEART DISEASES IN  DIABETIC PATIENTS
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J.  SIMON, Z.  ARANYI ,  G. B ALLA G I - P 0 R 0 A N Y
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(Received: Запиагу 2, 1992)
A retrospective study was performed on 1040 diabetic patients. The survival time of 
those treated with f i r s t  generation sulphonylureas (n = 227) was considerably (P<  ^0.001) shorter 
a fte r the f i r s t  attack o f angina pectoris (5 +Д years, mean +_ S.E.) or acute myocardial in ­
farction ( 6 ^ 1  years) than of those (9 ^ 1  years) on glibenclamide treatment (n = 144), with 
regime alone ( n =282) or treated with insu lin  (n=387). The systo lic  blood pressure of patients 
with f i r s t  generation sulphonylureas (166^1/91^1 mmHg) proved to be higher (P <1 0.01) than 
those treated with glibenclamide (15 9^1 /91 ^1  mmHg) or being on regime alone (155 +_ 1 /89^1 
imHg) or on insu lin  (156 +_ 1/89 +Д mmHg) treatments. Serum sodium level was found to be lower 
(P <  0.05) in  patients treated with any kind of sulphonylureas (138^1 mmol/1) than in  the 
other patients (143^1 mmol/1). During an observation period, 576 of patients died, 412 o f them 
due to cardiovascular or renal fa ilu res . Among the diabetic subjects suffering from coronary 
heart disease no difference could be detected in  r isk  factors except for higher systo lic  blood 
pressure. The shorter survival time of patients treated w ith first-generation sulphonylureas 
might be explained by the arryhthmogenic a c tiv ity  of firs t-genera tion sulphonylureas. Improve­
ment in therapy, metabolic and cardiovascular a lterations during the survey can not be respon­
sib le for the shorter survival time of patients treated with f i r s t  generation-sulphonylureas.
Keywords : Coronary heart diseases, survival time, hypoglycaemic sulphonylurea compounds 
diabetics
In tro d u c tio n
Since insulin  was discovered cardiac and vascular complications have 
become the most common causes of diabetes m orta lity /23/. According to the 
conventional theory th is  may be explained by severe arteriosclerosis of 
diabetic vessels. Epidemiologic studies involving large populations rea lly
O ffp rin t requests should be sent to : G. Pogátsa, National In s titu te  of Cardiology, 
H-1450 Budapest, P.0. Box 9-88, Hungary
Akadémiai Kiadó, Budapest
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demonstrated a higher frequency of macroangiopathy in diabetic vs me- 
ta b o lic a lly  healthy individuals /7 /. On the other hand, autopsies /14, 17, 
21, 29, 31, 34, 35/ drew attention to the fact that most of the diabetic 
cardiac disorders could not be explained simply by microangiopathy. Further, 
a discrepancy was demonstrated by coronarography in diabetic subjects 
su ffe ring  from angina pectoris between vascular narrowing and the in tensity 
of pain /29/. However, m orta lity due to coronary heart disease is  known to 
be twofold in diabetes than in  metabolically healthy states /13, 36, 37/.
First-generation sulphonylurea compounds enhanced cumulative cardio­
vascular mortality /38/ and ventricular arrhythmias /27/ in human beings, 
ca rd io tox ic ity  of cardiac glycosides /4, 27/ and ischaemic arrhythmias /5 / 
in  animals. Glibenclamide affected ventricular arrhythmias of diabetic 
patients /19, 27/, experimentally induced arrhythmias /4, 5, 27/ as well as 
haemodynamic /3, 26/ and electrocardiac parameters /6, 28/ oppositely. The 
cardiac effects of antid iabetic sulphonylurea drugs might be also involved, 
therefore, in the more severe outcome of coronary heart disease. To approach 
th is  question, we analyzed the relationship between the type of antidiabetic 
medication and the outcome of coronary heart disease in the Diabetic Out­
patien t C linic of our In s titu te .
Patients and Methods
In a retrospective study 1040 diabetic patients (481 men, 559 women) were followed in 
the Diabetic Outpatient C lin ic  o f our Ins titu te  between November 1, 1967 and A p ril 30, 1991, 
282 (163 male and 119 female) patients were contro lled only by regime, 227 (105 male, 122 
female) were treated with f i r s t  generation sulphonylurea compounds in the following d is tr ibu ­
t io n :  93 (44 male, 49 female) were on carbutamide (Bucarban; Chinoin, Budapest); 95 (46 male, 
49 female) on tolbutamide (Oterben; Chinoin); 39 (15 male, 24 female) on chlorpropamide 
(Diabinese; P fizer); and 2 (1 male, 1 female) on g lic laz ide  (Diamicron; Servier) therapies. 
While with the second-generation sulphonylurea compound, glibenclamide (Euglucon, Hoechst t i l l  
1975; Gilemal, Chinoin from 1975 on) 144 (58 male, 86 female) patients were treated, and 387 
subjects (155 male, 232 female) were on insu lin  therapy (Novo-Nordisk products). Ihe therapy 
was p ra c tica lly  homogeneous in  each groups: i t  occurred only in 6% (13 cases) and 7% (10 cases) 
o f patients that firs t-genera tion  sulphonylureas and glibenclamide, respectively was sub­
s titu te d  fo r insu lin . The percentile proportion of subjects treated with first-genera tion 
sulphonylurea compounds or glibenclamide were not changed between 1967 and 1991. No differences 
existed between the d iffe re n t kinds of sulphonylurea compounds during the therapy (12^1 years). 
In s u lin  was applied for 16^1 years and diet only fo r 7+Д years.
The drop out of patients was an average o f 6%; 1% (2 patients) on first-genera tion 
sulphonylurea, 2% (3 patients) on glibenclamide therapies, 9% (25 patients) on d ie t only and 
9% (35 patients) on insu lin  stopped presenting.
The alcohol consumption did not exceed 300 ml s p ir its  or 1.5 l i t r e  wine weekly except 
two patients.
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The diabetic subjects were controlled on the average meanly once a month (most 
frequently weekly, ra re ly  annually). On these occasions postprandial blood glucose /32/ values, 
or recently blood glucose p ro file  (method of Petrányi e t a l.  /25/ or glucometer) as well as 
glucose /32/ and acetone /30/ excretions of urine collected over 24 hours were measured. Other 
blood parameters, lik e  serum creatinine /15 /, u ric  acid /10, 11/, cholesterol /1 , 8 /, t r i ­
glycerides /20 /, sodium /24 /, potassium /24 /, from 1980 on HDL-cholesterol /22 / and from 1981 
EbAlc /12/ levels were determined at least annually.
Patients were asked about the history of las t period and dietary management at every 
v is i t .  At the same time physical examination, measurement o f body weight and that o f blood 
pressure in both supine and standing positions, were performed. ECG, fundus, and neurological 
examinations, and chest x-ray were performed at least annually.
S ta tis tic a l evaluation of data was carried out on an IBM-АТ personal computer. Data 
input was performed by the modified Lotus Database (Lotus Development Corporation, 1985) 
programme. The results have been evaluated s ta t is t ic a lly  by analysis of variance (ANOVA) and 
ch i-tes t by a modified version of Systat (Version 3.0, 1985) programme. The mean values +_S.E. 
are given.
Results
During the observation period of 23 years 576 patients (265 men, 311 
women) died of cardiac (n = 260), peripheral a rte r ia l (n = 17), cerebro­
vascular (n = 105), renal (n = 22), gastrointestinal (n = 16), haematological 
(n = 9), cancerous (n = 76), and other (n = 38) diseases; 15 died a fte r an 
accident and 10 committed suicide. Protocols of autopsies being only spo­
rad ically available were not evaluated. The d istribution  of cardiac and 
other causes of death was dissim ilar in the d iffe re n tly  treated groups. In 
diabetic subjects treated with the f i r s t  generation of sulphonylurea com­
pounds the cause of death was cardiac in 66% (150 cases) and vascular or 
renal in 9% (20 cases). In diabetic patients treated with regime alone the 
death was cardiac in  13% (37 cases) and vascular or renal in 9% (25 cases), 
in  those treated, with insu lin  i t  was cardiac in 14% (54 cases) and vascular 
or renal in 18% (70 cases).
Both the duration of observation (8 _+ 1 years) and the age (at the 
beginning of observation 55 _+ 1 years) were the same in the d iffe ren tly  
treated groups. Only the insulin-treated subjects were somewhat younger 
(52 1 years). The duration of diabetes was shorter in the group on diet 
only (4 _+1 years) and longer in those treated with insulin (10+^1 years), 
compared with the others (8+^1 years).
Angina pectoris occurred in 46 diabetic subjects on first-generation 
sulphonylurea therapy, in  52 cases treated with glibenclamide, in  94 in - 
sulinized patients, and in 52 diabetic subjects on regime alone. In the last 
three groups the survival time of patients suffering from angina pectoris
42 G . POGATSA e t  a l .
did not d iffe r  s ig n ifican tly , whereas i t  shortened (P <. 0.001) under the 
influence of first-generation sulphonylurea therapy considerably (Table I ) .  
The onset of angina pectoris occurred p ractica lly  at a sim ilar age and a fte r 
a s im ila r duration of diabetes in  the patients treated with first-generation 
sulphonylureas or glibenclamide (Table I ) .  S ignificant a lterations (P<0.05) 
in  these variables could be found only in the groups treated with insu lin  
and tha t kept on regime alone (Table I ) .
Acute myocardial in fa rc tion  occurred in 45 diabetics treated with 
firs t-genera tion  sulphonylureas, in 28 treated with glibenclamide, in  46 
insu lin ized  and in 28 d ie te tized patients. Survival of diabetic patients on 
firs t-genera tion  sulphonylurea proved to be markedly (P < 0.001) shorter 
than in  the other groups (Table I ) .  Acute myocardial lesion was observed at 
a s im ila r age and after a s im ila r duration of diabetes in subjects treated 
w ith the first-generation of sulphonylurea compounds or glibenclamide 
(Table I ) .  Similarly to angina pectoris, duration of diabetes and age at 
f i r s t  acute myocardial in fa rc tion  were found dissim ilar (P <  0.05) only in 
the groups treated with in su lin  or regime alone (Table I ) .
At the beginning of the observation, data fo r the diabetic subjects 
su ffe ring  from angina pectoris or myocardial in farction did not d iffe r  
notably among the patients treated with d iffe ren t antidiabetic drugs con­
cerning history, physical status, x-гау-, and ECG-results. However, the 
incidence of arrhythmias in  patients with angina pectoris (20-25%) or myo­
ca rd ia l infarction (23-30%) was higher during first-generation sulphonylurea 
therapy than during other treatments (0-14%). Explanation for th is  pheno­
menon may be the fact tha t 186 of the 227 patients on first-generation 
sulphonylurea compounds were already treated with such compounds before 
th e ir  entry in the present study. At the beginning of the observation, 
severity  of angina pectoris did not d iffe r  markedly among d iffe re n tly  
treated groups as estimated by frequency of anginal attacks (weekly 11 +_ 1 
attacks) as well as by the consumption of n itroglycerin  p i l ls  (weekly 8 _+ 1 
p i l l s ) .  In subjects suffe ring  from myocardial in farction, frequency of 
anginal attacks was considerably (P < 0.5) higher in the glibenclamide 
treated group (56%) than in  the group treated with first-generation sulpho­
nylurea compounds (35%). Accordingly, differences in  cardiac state following 
acute myocardial in fa rc tion  could not explain the shorter survival of pa­
t ie n ts  on first-generation sulphonylurea medication. During the survey, 
d iabe tic  patients did not show d ifferent impairment of cardiac state (car­
diac enlargement, dyskinesis of ventricular wall, deterioration in ECG
T a b le  I
Common d a ta  f o r  d ia b e t ic  p a t ie n t s  s u f f e r in g  and th o s e  n o t s u f f e r in g  from  c o ro n a ry  h e a r t  d is e a s e
Kind of 
therapy
Survival 
a fte r f i r s t  
cardiac 
attack 
yr
Age
at f i r s t  
cardiac 
attack 
yr
Duration
of
diabetes
yr
Duration
of
observation
yr
Cigarettes 
per day
Body
mass
index
kg/m^
Blood pressure 
systo lic  d ias to lic  
in supine position
mmHg mmHg
Number
of
patients
n
Data fo r diabetic patients suffering from angina pectoris
D: 10 + 1 59 + 1 9 + 1 7 + 1 6 + 1 27.6 + 1.1 157 + 3 92 + 2 52
1-Su: 6 + 1 62 + 1 15 + 1 9 + 1 5 + 1 28.5 + 1.2 171 + 3 93 + 2 46
2-Su: 9 + 1 61 + 1 15 + 1 9 + 1 6 + 2 26.1 + 1.3 160 + 3 88 + 1 52
I : 10 + 1 57 + 1 21 + 1 П  + ! 6 + 1 26.8 + 1.1 162 + 2 90 + 1 94
Data fo r diabetic patients suffering from acute myocardial in fa rction
D: 10 + 1 63 + 1 9 + 1 6 + 1 6 + 2 28.3 + 1.3 155 + 3 88 + 2 28
1-Su: 6 + 1 61 + 1 16 + 1 10 + 1 4 + 1 29.0 + 2.4 166 + 2 91 + 1 45
2-Su: 10 + 1 61 + 2 15 + 1 8 + 1 8 + 2 25.2 + 1.4 154 + 3 86 + 1 28
I : 10 + 1 57 + 1 20 + 1 8 + 1 5 + 1 26.3 + 1.1 162 + 3 90 + 1 46
Data fo r diabetic patients without any signs of coronary heart disease
D: — — 10 + 1 8 + 1 5 + 1 27.7 + 1.2 154 + 2 89 + 1 208
1-Su: — — 14 + 1 9 + 1 3 + 1 28.0 + 1.0 164 + 2 91 + 1 161
2-Su: — — 14 + 1 8 + 1 5 + 1 27.0 + 1.2 158 + 2 91 + 1 128
I : - - 17 + 1 8 + 1 6 + 1. 26.1 + 1.4 155 + 2 88 + 1 211
2 S.E. 2 2 2 2 2 2.6 5 2
Legend :
0 = diabetic patients treated with regime alone,
1- Su = diabetic patients treated with first-generation sulfonylurea compounds,
2- Su = diabetic patients treated with a second-generation sulfonylurea, glibenclamide,
1 = diabetic patients treated with insu lin ,
2 S.E. = twice value of S.E.
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signs) in the various treatment-groups except the appearance of an apico- 
basal discrepancy in the lungs (P <  0.05) between the groups of patients 
treated with first-generation sulphonylurea compounds (2%) or with gliben- 
clamide (24%) following acute myocardial in fa rc tion . Supraventricular (30 
and 4%, respectively) and ventricular (23 and 0%, respectively) ectopic 
beats occurred at an elevated frequency (P < 0.05) following acute myocar­
d ia l in farction in group of patients treated with f i r s t  generation sulpho­
nylurea compounds. I t  was only the insulinized group (Table I I )  in  which 
parameters of carbohydrate metabolism were found to be considerably (blood 
glycated haemoglobin: P <£. 0.05; blood glucose: P < 0.05; glucose excretion:
P <  0.05) higher both in  patients suffering from angina pectoris and those 
with myocardial in fa rc tion . The level of serum trig lyceride  was found to be 
higher (P <  0.05) in diabetic subjects treated with glibenclamide, while 
tha t of HDL-cholesterol (P •<£ 0.05) in those on first-generation sulphonyl­
urea therapy (Table I I ) .
As to cardiovascular r isk  factors, overweight at the f i r s t  v is i t  on
2
the body mass index value 27.4+:0.2 kg/m did not d iffe r  notably among the 
investigated groups and did not change considerably during the observation 
period (Table I I I ) .  S im ilarly , the tobacco smoking habits did not altered 
during the survey (Table I I I ) .  Systolic blood pressure in patients treated 
w ith f i r s t  generation-sulphonylureas was markedly (P<i 0.05) higher compared 
with those either on glibenclamide, or on regime alone both at the beginning 
or la te r on (Table I I I ) .  In th is  respect we should remember that 186 from the 
227 patients were already treated with first-generation sulphonylurea com­
pounds before joined the present survey.
Diabetic re tino- and nephropathies occurred more often in  fa ta l 
cases than in survivors, however, the incidence of diabetic retinopathy 
considerably increased in the survivors during the observation period 
(Table IV).
During follow-up of the diabetic patients blood glucose (P < 0.001) and 
glycated haemoglobin (P <  0.001) levels as well as glucose excretion 
(P <£ 0.001) decreased considerably (Table I I ) .  These parameters showed the 
lowest level in the group treated with regime alone, while the highest one 
in that on insulin  therapy (Table I I I ) .  The levels of serum creatinine 
(P < 0.001) and uric  acid (P<f0.01), glycated haemoglobin (P<0.01) and sys­
to l ic  blood pressure in  supine position (P< 0.001) were found to be higher in 
patients who died during the survey period than in  the survivors (Table IV). 
The serum sodium level was found to be considerably lower (P-dO.Ol) in a l l
T a b le  I I
M e ta b o lic  d a ta  f o r  d ia b e t ic  p a t ie n t s  s u f f e r in g  o r  n o t s u f f e r in g  from  c o ro n ary  h e a r t  d is e a s e
Kind of 
therapy creatinine uric
acid
7*
S e r u m
trig lyceride
nM
HDL-
cholesterol
nM
cholesterol
nM
B i o
glycated
haemoglobin
%
о d
glucose
nM
glucose
excretion
mmol/day
Number
of
patients
n
Data fo r diabetic patients suffering from angina pectoris
D: 102 + 3 362 + 9 2.28 + 0.14 1.35 + 0.09 6.3 + 0.1 5.94 + 0.22 7.05 + 0.20 6 + 3 52
1-Su: 95 + 1 343 + 14 2.03 + 0.25 1.44 + 0.13 6.5 + 0.2 7.04 + 0.36 7.76 + 0.20 17 + 5 46
2-Su: 105 + 4 350 + 11 2.89 + 0.29 0.96 + 0.08 6.4 + 0.2 6.68 + 0.24 8.11 + 0.21 13 + 4 52
I : 104 + 4 348 + 10 2.12 + 0.17 1.31 + 0.09 6.6 + 0.1 7.82 + 0.22 8.91 + 0.27 48 + 7 94
Oata fo r diabetic patients suffering from acute myocardial in fa rction
□ : 109 + 5 358 + 10 2.27 + 0.23 1.17 + 0.09 6.2 + 0.1 5.58 + 0.19 6.38 + 0.19 1 + 1 28
1-Su: 97 + 1 333 + 10 1.81 + 0.16 1.66 + 0.09 6.5 + 0.1 6.79 + 0.23 7.69 + 0.16 13 + 3 45
2-Su: 108 + 6 376 + 12 2.49 + 0.22 0.75 + 0.08 6.4 + 0.3 6.75 + 0.20 7.52 + 0.11 7 + 2 28
I : 110 + 5 353 + 11 1.95 + 0.11 0.97 + 0.09 6.7 + 0.1 8.03 + 0.28 8.58 + 0.28 49 + 8 46
Data for diabetic patients without any sign of coronary heart disease
0: 95 + 1 367 + 6 1.88 + 0.08 1.67 + 0.07 8.6 + 2.3 5.79 + 0.11 7.05 + 0.08 3 + 1 208
1-Su: 103 + 3 358 + 7 1.64 + 0.10 1.78 + 0.10 6.5 + 0.1 7.57 + 0.23 8.01 + 0.11 21 + 3 161
2-Su: 99 + 3 347 + 7 2.11 + 0.12 1.51 + 0.07 6.1 + 0.1 6.65 + 0.16 8.30 + 0.19 13 + 3 128
I : 99 + 3 348 + 6 1.90 + 0.10 2.20 + 0.71 6.5 + 0.1 7.91 + 0.19 8.88 + 0.16 51 + 4 211
2 S.E. 7 21 0.39 0.31 0.8 0.46 0.43 9
Legend: see in  the footnote of Table I .
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Table I I I
Data for the diabetic patients treated with d iffe re n t types of antidiabetic drugs
Body
mass
index
kg/rn^
sodium
nM
S e
trig lyceride
rrM
r u m
HDL-
cholesterol
nfl
cholesterol
nM
B i o
HbAlc
0,
о d
glucose
nM
Urine
glucose
excretion
mmol/day
Cigarettes 
per day
A rte ria l blood 
pressure
systo lic  d ias to lic  
in supine position 
mmHg mmHg
Number
of
patients
n
Patients treated with carbutamide
B: 27.2 + 0.4 141 + 1 1.53 + 0.11 1.69 + 0.11 6.8 + 0.1 9.69 + 0.37 9.60 + 0.19 82 + 10 5 + 1 163 + 2 91 + 1 93
E: 27.0 + 0.5 138 + 1 1.71 + 0.09 1.58 + 0.10 6.6 + 0.1 7.81 + 0.28 8.17 + 0-12 26 + 4 5 + 1 165 + 2 92 + 1 83
Patients treated with chlorpropamide
B: 27.5 + 0.7 140 + 1 1.30 + 0.22 1.56 + 0.17 6.2 + 0.2 8.14 + 0.60 9.64 + 0.33 92 + 19 2 + 1 169 + 4 90 + 2 39
E: 27.3 + 0.B 136 + 1 1.39 + 0.25 1.53 + 0.15 6.1 + 0.2 7.19 + 0.33 7.88 + 0.16 18 + 4 1 + 1 172 ±  4 91 + 2 39
Patients treated with glicazide
B: 26.5 + 0.9 139 + 1 1.40 + 0.12 1.87 + 0.06 5.8 + 2.1 8.94 + 0.25 8.87 + 1.56 23 + 9 1 + 1 160 + 10 87 + 2 2
E: 26.7 + 0.8 134 + 1 1.47 + 0.11 1.8B + 0.05 5.7 + 1.8 7.61 + 0.16 7.26 + 0.95 1 + 1 1 + 1 180 ±  10 88 + 3 2
Patients treated with tolbutamide
B: 27.5 + 0.5 141 + 1 1.57 + 0.16 1.90 + 0.10 6.5 + 0.1 7.32 + 0.29 8.37 + 0.28 34 + 8 5 + 1 161 + 3 87 + 2 95
E: 27.6 + 0.6 138 + 1 1.96 + 0.17 1.78 i  0.09 6.5 + 0.1 6.53 + 0.17 7.40 + 0.11 5 + 2 4 + 1 164 + 3 90 + 2 88
Patients treated with glibenclamide
B: 27.8 + 0.6 141 + 1 1.94 + 0.10 1.32 + 0.26 6.3 + 0.1 7.21 + 0.15 9.40 + 0.19 48 + 6 7 + 1 156 + 1 87 + 1 144
E: 27.9 + 0.5 13B + 1 2.37 + 0.11 1.23 + 0.05 6.3 +_ 0.1 6.68 + 0.12 8.09 + 0.12 12 + 2 6 + 1 158 + 2 89 + 1 231
Patients treated with regime alone
B: 27.8 + 0.4 143 + 1 1.74 + 0.07 1.60 + 0.05 6.3 + 0.1 6.24 + 0.11 7.47 + 0.12 15 + 3 6 + 1 154 + 1 90 + 1 282
E: 27.2 + 0.5 143 + 1 2.03 + 0.07 1.53 + 0.05 6.6 + 0.4 5.80 + 0.09 6.97 + 0.07 3 + 1 5 + 1 155 + 1 89 + 1 257
Patients treated with insu lin
B: 26.5 + 0.4 143 + 1 1.80 + 0.08 1.40 + 0.05 6.7 + 0.1 8.58 + 0.17 10.29 + 0.17 115 + 7 7 + 1 156 + 1 89 + 1 387
E: 26.В + 0.5 143 + 1 1.97 + 0.07 1.69 + 0.37 6.6 + 0.1 7.91 + 0.13 8.83 + 0.12 50 + 3 6 + 1 158 + 1 89 + 1 352
2 S.E. 2 0.34 0.31 0.6 0.47 0.34 7 2 7 3
Legend: see in Table I .  Begin (B) or end (E) of follow-up.
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T a b le  IV
D ata  o f  d ia b e t ic  p a t ie n t s  c o n tr o l le d  in  th e  o u t p a t ie n t  c l i n i c
S e r u m
creatinine
pM
uric
acid
pM
trig lyceride
nM
97 + 1 355 + 3 1.77 + 0.05
100 + 1 354 + 3 2.04 + 0.05
9 1 + 1 345 + 5 1.85 + 0.07
93 + 1 346 + 4 2.05 + 0.07
101 + 2 364 + 5 1.66 + 0.07
105 + 2 361 + 4 2.02 + 0.07
2 S.E. 11 0.18
B l o o d Urine Cigarettes Blood pressure Alterations of
HdA^ c glucose glucose systo lic d iasto lic fundus kidney
excretion in supine position
\  им mmol/day per day mmHg mmHg % 4
Data of a l l  diabetic patients (n = 1040)
At the f i r s t  presenting in the outpatient c lin ic
7.50 +0.10 9 .18+0.10 66 + 4 6 + 1 158 + 1 90 + 1 19 34
During the observation in the outpatient c lin ic
6.85 +0.08 8.04+0.06 23 + !  5 t  1 158 + 1 90 + 1 23 36
Data fo r the diabetic survivors (n = 464)
At the f i r s t  presenting in the outpatient c lin ic
7.31 +0.14 9 .14+0.16 6 5 + 6  7 + 1 151 + 1 89 + 1 13 26
During the observation in the outpatient c lin ic
6.72 +0.11 8.17+0.11 2 8 + 3  5 + 1 151 + 1 89 + 1 21 30
Data 'fo r fa ta l cases of diabetes (n = 576)
At the f i r s t  presenting in the outpatient c lin ic
7.75 +0.14 9.22+0.11 67 + 5 5 + 1 164 + 1 90 + 1 23 40
During the observation in the outpatient c lin ic
7.02 +0.11 7 .94+0.07 1 9 + 2  5 + 1 164 1 90 + 1 24 41
0.31 0.29 10 2 3 2 - -
Legend: see in Table I .
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diabetics treated with sulphonylureas than in  those kept on insu lin  or d ie t 
(Table I I I ) .  Serum potassium level showed no group difference.
I t  is  possible that the development in  the f ie ld  of the therapy of 
coronary heart diseases, hypertension, coronary care and concomitant d is­
eases may be responsible for the differences in  the outcome of coronary 
heart disease between the groups treated with first-generation sulphonylurea 
compounds or glibenclamide and the other groups. For th is reason, the obser­
vation period of 24 years was divided in to  four parts, and cardiac e ffec t of 
antid iabetic  drugs was compared in each period. The survival time of dia­
betic  subjects with angina pectoris or myocardial infarction on f irs t-g e ­
neration sulphonylurea therapy showed shorter survival time and an elevated 
sys to lic  blood pressure in  each period. The incidence of concomitant d is­
eases showed no notable group difference. Therefore i t  seems unlike ly that 
therapeutical progression would considerably influence the survival time of 
patients with acute myocardial in farction or angina pectoris.
Among the patients without any signs fo r coronary heart disease 119 
were treated with first-generation sulphonylureas, 899 with glibenclamide, 
83 with insu lin , while 161 patients were kept only on regime. Variables of 
cardiac and metabolic states showed a s im ila r d istribution in these groups 
both at the beginning and during the observation period (Tables I  and I I ) .
Discussion
Almost a ll of the diabetic patients followed-up at the Outpatient 
C lin ic  of our In s titu te  showed some manifestations of heart and vascular 
complications of diabetes mellitus. This fact could serve as an explanation 
fo r the more than 55% of death in our d iabetic patients during the 24 years 
of observation.
Furthermore the higher mortality of the diabetic patients with acute 
myocardial in farction in  coronary care units is  attributed to the more fre ­
quent onset of cardiogenic shock and that of fa ta l arrhythmias, compared 
with a metabolically healthy population /18 /. The present work makes another 
explanation possible. Arrhythmogenic e ffect of first-generation hypoglycemic 
sulphonylureas /3—6, 26—28/ is  namely supposed to be responsible fo r the 
higher m ortality rate in  coronary heart disease since, with the exception of 
higher systolic blood pressure, no difference was detected re la ting  metab­
o lic  or risk  factors among the investigated groups.
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In a previous report /33/ systolic blood pressure remained unaltered, 
but d iasto lic  blood pressure was diminished in  a group, in which tolbutamide 
was administered to patients with impaired glucose tolerance and the drug 
prevented manifest diabetes from processing. On the other hand, tolbutamide 
was described by Wales /36/ as a drug increasing systolic blood pressure. 
Furthermore, various sulphonylurea compounds influence blood pressure in 
experimental animals d iffe ren tly . These data refer to a group-specific 
property of sulphonylureas (based on chemical structure) responsible for 
the ir divergent e ffect on blood pressure /2 , 3, 26/. The present work con­
tributes further support to th is  hypothesis.
In contrast to Laube and Krausch /19 /, we did not find a decreased 
HDL-cholesterol level in the diabetic subjects treated with sulphonylureas. 
I t  should be noted that the cited work does not give any reference to the 
applied sulphonylurea compounds. Additionally, sim ilar findings could be 
made by th is  experiment with no difference between the sulphonylurea genera­
tions. Furthermore i t  is  worth mentioning that the investigated patient 
groups d if fe r  neither in serum potassium level nor saluretic therapy.
The results of the present observation suggest that glibenclamide 
should be preferred to the first-generation sulphonylurea compounds, espe­
c ia lly  in the case of manifest coronary heart disease (or i f  i t s  r is k  is  
existing), when satisfactory metabolic control cannot be achieved with 
regime alone and sulphonylurea treatment becomes necessary in type-2 (non- 
insulin-dependent) diabetes.
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EXPERIENCES WITH FUNCTIONAL INSULIN SUBSTITUTION:
A FOLLOW-UP STUDY ON CONTROL AND PATIENT COMPLIANCE
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Functional insu lin  substitu tion , an insulin regimen made up of two da ily  in jec tions of 
intermediate-acting insu lin  and prandial boluses of regular in su lin , was to be introduced in  49 
type 1 diabetic patients, as previous regimens consisting o f two or three da ily  in jec tions 
proved to be in e ffic ie n t due to the patients li fe s ty le  or inherent metabolic la b i l i t y .  Forty- 
fiv e  patients were treated w ith human insulin in jected by NovoPen. In 38 cases therapy was 
changed in the frame o f a one-week, small-group, inpa tien t, structured educational course. 
A fter a mean 14 months o f follow-up metabolic status improved in 33 cases while there was 
further derangement in 16. Eighteen patients were practis ing true functional therapy, i.e .  doing 
blood glucose tests before each in jection . Further 22 diabetics were try ing to achieve better 
metabolic control through 2-3 da ily  blood glucose tes ts  and insulin dose corrections. The 
metabolic status was not affected by the frequency of blood glucose testing, rather by ra is ing 
of the da ily dose o f short acting insulin in  conjunction w ith the switch in therapy acting 
bene fic ia lly . A ll patients insisted on using NovoPen fu rthe r on.
Keywords : Diabetes m e llitus , functional in su lin  substitution, small-group diabetic 
education, blood glucose s e lf- te s tin g
In tro d u c tio n
In Europe, the concept and methodology of functional insu lin  substitu­
tion  were f i r s t  developed by Waldhäusl and Howorka /5, 6, 10, 21/. The main 
point of th is  method is  the separation of basal and prandial insu lin  doses. 
Actually, i t  is  a version of in tensified, fractiona l insulin therapy. The 
la tte r  became popular in  the mid 80s. Functional insulin therapy has two
O ffprin t requests should be sent to : j .  Fövényi, H-1441 Budapest, P.0. Box 76, Péterfy 
S. u. 8-20.
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essentia l characteristics distinguishing i t  from other arts of in tens ified  
in s u lin  treatment. 1. The diabetic patient does a lte r the treatment not only 
according to general conditions (menses, illne ss , etc.) influencing the 
d a ily  insu lin  need. Besides in jecting basal intermediate-acting insu lin  
twice d a ily , the doses of short-acting prandial insu lin  are adjusted on each 
occasion according to the current blood glucose level (measured by the pa­
t ie n t ) ,  the carbohydrate content of the planned meal, the glucose need of 
the forthcoming physical a c tiv it ie s , etc. Moreover, the patient has to re­
spond promptly to any deviation of the blood glucose level from the set 
ta rge t range (correction). By these means the life s ty le  of these patients 
is  libe ra lized  to some extent: meals can be omitted or taken at any time and 
the carbohydrate content of the meals need not be preset. 2. A ll these 
advantages can only be achieved i f  the patient checks the blood glucose 
leve l at least four times a day. This is  inevitable as the patient must 
in je c t short-acting insu lin  before each princ ipa l meal and the dose should 
be calculated according to the current blood glucose level /10/. The usage 
of pen devices makes frequent insulin  in jections easier, resu lting in  a 
switch to human insu lin .
High motivation and diabetes knowledge level of the patient are the 
preconditions for any kind of in tensified insu lin  therapy. The most effec­
t iv e  way of teaching diabetic patients is  group teaching /2 /. According to 
the technique of Waldhäusl and Howorka the completion of a diabetes course 
is  an essential introduction to functional therapy /10/ as well. The cor­
recting  and prandial in su lin  doses could not be defined exactly but some 
more or less personal algorithms could be computed based on studies in 
physiology /20/ and some patient parameters. These algorithms were published 
in  a tabular form /10, 21/ and provide substantial help when in it ia t in g  the 
functiona l treatment of a given patient.
This open, uncontrolled study looked at the advantages of the func­
tio n a l insu lin  treatment of b r i t t le  diabetics and at the factors determining 
therapeutic success or fa ilu re .
Patients and Methods
Forty-nine type 1 (insulin-dependent) patients (17 males, 32 females) were included in 
the study (Table I ) .  Their age a t the time of switching to functional treatment was 29.6+^1.9 
years (mean S.E.). Duration o f diabetes was 13.2+_1.3 years.
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Fig. 1. Regression of HbAlc measured during functional insu lin  therapy on the short-acting 
insu lin  dose (a) administered during conventional therapy and on the previous to ta l da ily
insu lin  dose (b)
S h o rt-  ac tin g  insulin (IU /d a y )
D aily insulin dose (IU )
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Fig. 2. Regression of HbAlc measured during functional insu lin  therapy on the HbAlc measured
during conventional therapy
Functional insu lin  therapy was in itia te d  because two or three times da ily  insu lin  
administration regimens (Actrapid MC/Monotard MC) proved not to be satisfactory amid the pa­
t ie n ts . Eighteen patients enjoyed excellent metabolic contro l (HbAlc <  7%) even before changing 
to  functional therapy. These patients had been consulting our team for years and did not choose 
functiona l therapy because o f bad control but in the hope of a more lib e ra l l i fe s ty le .  The 
remaining 2/3 of the patients switched to functional therapy mainly because of metabolic prob­
lems. Forty-five diabetics started functional therapy using NovoPen I  and NovoPen I I  to  in jec t 
Actrapid HM and Protaphane HM, respectively. Four patients injected Actrapid MC and Monotard MC 
by no-dead-space disposable syringes. Basal insu lin  was injected in  two nearly equivalent doses 
(2 X 25% of the da ily dose) in  the morning and at bedtime /8 , 12, 14, 21/. The obligatory 
morning Actrapid dose, the prandial Actrapid doses to be injected fo r each 10 grams of carbo­
hydrate and the correcting Actrapid doses were set according to the tables of Waldhäusl and 
Howorka /10, 21/ and pa rtly  based on practical experiences.
Thirty-eight patients learn t functional in su lin  therapy in  the frame o f five-day, 
in pa tien t, small-group, structured courses, the others were instructed ind iv idua lly .
Patients were seen at months 3, 6 and 12 a fte r being switched to functional therapy and 
a t least yearly thereafter. However, patients were ty p ic a lly  seen more frequently, at any time 
they needed. In th is  report only the results of the f i r s t  and last v is i t  are shown, thus the 
follow-up period was 14^2.0 months.
Overall glucose contro l was checked by HbAlc determination (BioRad HPLC method, normally 
4-6%). Diabetic diary keeping and the monthly number o f blood glucose self-determinations were 
the measure of patient motivation and compliance. This report focuses on the relationships 
between therapy (in su lin  doses), metabolic contro l and patient compliance. Several other
HbA1c du r ing  conventional th e ra p y  (°/o)
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No. of 
patients
m Increased /no change 0  Decreased
Fig. 3, The changes in control and insu lin  dosage a fte r the switch in therapy
parameters were also checked (complications, frequency of hypoglycaemias, e tc .) but these are 
not detailed here.
S ta tis tica l analysis was done using conventional methods (Chi^-test, Student's jt- te s t, 
simple and multivariate analysis of variance, simple and multiptle regression analysis). 
Results were given as mean +^S.E.
Results
The changes of short-acting and intermediate-acting insulin doses are 
detailed in Table I .  The to ta l daily insu lin  dose did not change but, ac­
cording to the type of therapy /16/, the da ily  dose of the short-acting in ­
su lin  increased for 33 patients while the daily dose of the intermediate- 
acting insulin decreased fo r 42.
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Table I
Patient m aterial, average insulin doses and changes in insulin dosage 
during functional treatment
Patients (mean +_ S.E.)
n = 49 17 men and 32 women
Age: 29.6 + 1 .9  yrs
Duration of diabetes: 13.4 +_ 1.3 yrs
38 patients completed a diabetes course
Average insu lin  doses (IU/dav)
Before 
functional 
mean +_ S.E.
Short acting 15.2 + 1.4
Intermediate acting 29.7 +_1.6
Total 45.0 + 2.0
During
in su lin  treatment
mean +_ S.E.
20.4 + 0.7 p <: 0.01
22.6 + 1 .1 P < 0.001
43.0 + 1.6 P = 0.17
Changes in insu lin  dosage during functional treatment
Increased
Short-acting insu lin  dose 33 patients
Intermediate acting in su lin  dose 7 patients
Decreased/did not change 
16 patients 
42 patients
Significant decrease of the HbAlc levels was found (Table I I ) .
Nine patients checked the ir blood glucose 60 times a month or less 
frequently. Twenty-two diabetics checked i t  60 to 120 times and 18 patients 
did 120 tests or more (Table I I I ) .  Thus, patient cooperation was fa r from 
being satisfactory as only the last group tested properly. Group teaching 
proved to be an e ff ic ie n t way of motivating patients. The monthly number of
Table I I
HbAlc levels during conventional and functional insulin treatment
T h e г a p у
HbAlc Ccntrol Conventional Functional
7% > (normoglycaemia) 18 patients 20 patients
74 < <= 84 (acceptable) 6 patients 17 patients
8% < <=  104 (poor) 16 patients 8 patients
104 < (bad) 9 patients 4 patients
HbAlc mean *_ S.E. (4) 8.2 + 0.3 7.5 + 0.2 P <  0.05
Increase Decrease During functional treatment
HbAlc 16 patients 33 patients
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Table I I I
Monthly number o f blood glucose se lf-te s ts  during 
functional treatment
Tests/month 60 > 61-119 120 <
No. of patients 9 22 18
Diabetes course Completed Not completed
No. of patients 
Blood glucose 
tests/month (mean +_ S.E.) 
P
38
104 +5.3
<0.05
11
83.7 + 10.1
blood glucose tests was 104.0 j+ 5.3 in the case of those who completed the 
course while the others did only 83.7 j+10.1 tests a month (P < 0.05). Other 
factors (age, duration of diabetes, duration of functional insulin tre a t­
ment, sex, previous insu lin  regimen, age at diagnosis) showed no s ign ificant 
difference.
Looking for determinants of control, insu lin  dose changes were ana­
lysed by insulin types using ANOVA. Analysing the rise  and/or lowering of 
short-acting and/or intermediate-acting insulin doses due to the switch in 
therapy, we found that the HbAlc of those patients whose intermediate-acting 
insu lin  doses were .not decreased during functional therapy was much higher 
on the long run than the HbAlc of the others (9.0 _+ 1.1 vs 7.2 +_ 0.2%, 
P< 0.05).
Significant linear correlation was found on simple regression analysis 
between the HbAlc measured while on functional therapy and the previously 
administered dose of the short-acting insu lin , the whole previous daily in ­
sulin need (r  = 0.56, P< 0.001, г = 0.30, PCC.01, Fig. 1) and the HbAlc values 
measured during conventional therapy (r  = 0.4, P< 0.01, Fig. 2), respectively. 
Only the previous short-acting insulin dose proved to be sign ificant in a 
multiple regression model. Several other variables (age, duration of dia­
betes, duration of functional treatment, the dosage of intermediate-acting 
insulins during conventional and functional treatment, the amount of short- 
acting insulin administered during functional treatment and the monthly 
number of blood glucose tests) also fa iled to influence the HBAlc change.
Addressing the same question from a d iffe ren t point of view the param­
eters df the patients fa llin g  into d ifferent HbAlc classes were analysed 
(ANOVA and Chi -te s t, Table IV). I t  was found that the patients whose con-
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Table IV
Insu lin  dosage changes according to HbAlc classes.
Prediction o f expectable metabolic contro l based on the changes in therapy
Functional treatment Conventional treatment Changes in  short-acting 
insu lin  dosage after 
switching to functional 
therapy :
increase/decrease or no 
change
HbAlc (%) No. of 
patients
Daily insu lin  dose (IU) 
Short-acting Total 
mean^S.E. mean+^S-E.
7%> 20 11.2 + 1.5 39.0 + 2.8 17/3
7% <6 < 8% 17 16.3 + 2.1 48.9 + 3.5 12/5
8%< <10% 8 26.0 + 4.9 55.2 + 5.4 2/6
10% < 4 15.3 + 2.6 44.0 + 2.5 2/2
t r o l  was worse, even during functional treatment, injected higher doses of 
short-acting insu lin  on conventional therapy (F = 5.2, P <  0.01) and had a 
higher daily insu lin  need (F = 3.3, P = 0.03). The trend of the short-acting 
insu lin  dosage seemed to influence contro l. The d is tribu tion  of patients 
among the HbAlc classes was roughly equal i f  the ir short-acting insu lin  dose 
was decreased or was not changed during functional treatment. On the contra­
ry , i f  the short-acting insulin dose was raised the HbAlc f e l l  in  the lower
О
classes (Chi = 14.5, P <  0.01 with correction). There was no s ign ifican t 
difference among the patients of the four HbAlc classes in any other respect 
(age, sex, duration of diabetes, duration of functional treatment, in i t ia l  
dose of intermediate-acting insu lin , insu lin  dosage during functional tre a t­
ment, number of monthly blood glucose tests, completion of a diabetes 
course, daily number of insulin  in jections on conventional therapy).
A decrease of the daily insu lin  dose in conjunction with the switch of 
therapy led to worse control (Chi^ = 4,8, P< 0.05, Fig. 3). This means that 
the better d is tribu tion  of the daily insu lin  dose does not necessarily im­
prove the patien t's control.
Discussion
The patients studied were partly  b r i t t le  diabetics and pa rtly  had to 
switch to functional treatment because of an irregular life s ty le .  Thus, the 
study yielded a rather peculiar material. Moreover, no control group could 
be formed as i t  seemed to be unethical to treat these fa ir ly  young patients,
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who in several cases were suffering from lata complications, using methods 
that previously turned out to be ine ffective. This would also mean that with 
respect to the lite ra tu re  /5, 6, 7, 15, 18/ we did not consider the method 
to be experimental.
The patien t's  control changed fo r the better by the end of the roughly 
one year follow-up period. This is  certa in ly a s ign ificant achievement, 
especially in  lig h t of the above patient characteristics. The background of 
th is  change was analysed based on a lim ited number of parameters. The number 
of patient re ferra ls , for example, was omitted for technical reasons. 
According to the personal experiences gained abroad we supposed that the 
potential inherent benefits of the treatment method w il l  outweigh the draw­
backs and thus blood sugar self-determination w il l  not pose any problem. 
I t  is  noteworthy that while in  many publications on other forms of intensive 
and "in tens ified " insulin treatment the authors go into deta ils on the ne­
cessary frequency of blood glucose se lf-tests  to achieve best results, the 
true practice of the ir patients is  barely documented in the "Results" sec­
tion /1 , 3, 7, 11, 13, 14, 16, 18, 19/. I f  accurate data are available /4, 
15, 17, 22/, the frequency of blood glucose tests is  usually only satisfying 
in the case of pregnant diabetics. Only 36.7% of our diabetics checked the ir 
blood glucose sa tis fa c to rily . Another 45% did at least two tests a day. One 
of the major obstacles was the pain they experienced. The bulky Hungarian 
made D-Cont glucose meter operating p ractica lly  only in conjunction with an 
AC/DC adapter was also perceived as an obstacle. The patients are to be 
praised fo r doing so many tests in  spite of th is  condition. A large selec­
tion of automated finger pricking devices has become available recently. 
A new, t in y  piece of the new generation of the D-Cont glucose meter family 
can also be purchased at a bargain price. In the lig h t of the multivariate 
analysis group education is  an e ffective  form of patient motivation. I t  is  
interesting that several factors, previously thought to be most important, 
did not influence the HbAlc at a l l ,  e.g. blood glucose self-determination 
(as experienced by /15/) and completion of a diabetes course. Patients un­
doubtedly experienced an improvement in the ir quality of l i f e .  This was 
attributed mainly to the more fle x ib le  method of insu lin  therapy and to the 
NovoPen in jec tion  system (and to the decrease in the number of hypoglycae- 
mias, not analysed in th is  report). In summary, the blood glucose control of 
2/3 of our patients already uncontrollable with conventional methods, im­
proved s ig n ifica n tly . No s ign ifican t differences in age, sex and type 
d is tribu tion , insulin doses, e tc ., was found between the group practising
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true functional therapy and the patients who checked the ir blood glucose 
less frequently. Five of the 16 patients whose metabolic status changed for 
the worse checked the ir blood glucose sa tis fa c to rily , while 11 did not. In 
these cases a switch to the previous insulin  regimen would not be the solu­
tion  as the patients would not tolerate the fixed regimen. S tr ic t  follow up 
is  planned to amend contro l.
Main determinants of control were the ra tios of previous and current 
insu lin  doses. I t  was found that the control achievable by functiona l in­
su lin  therapy was in s ign ifican t inverse relationship with the d a ily  insulin 
need, the short-acting insu lin  dose and the HbAlc during conventional in ­
su lin  treatment. Thus, the higher these parameters the less successful the 
therapeutic switch is  l ik e ly  to be. More precise analysis stressed the sig­
nificance of the short-acting insulin dosage. This means tha t i f  a given 
patient has received most of the insulin in  short-acting form during conven­
tiona l therapy, the increase in the number of insulin in jections on func­
tiona l therapy is  not enough to achieve better control, the amount of the 
short-acting insulin should be increased as well. On the other hand, no 
further deterioration of control can be foreseen on the basis of the in i t ia l  
insu lin  dosage. However, an increasing HbAlc value is more l ik e ly  to be 
found on functional in su lin  therapy i f  the orig ina l insulin  dose has not 
been changed or had been lowered. Increasing the dose of the intermediate- 
acting insulin  is , of course, not beneficent.
Although both control and quality of l i f e  improved during the follow­
up period i t  is  not possible to assess the true value of functiona l insulin 
therapy due to the mentioned problems. I t  must be noted, that while during 
the f i r s t  period patients had to be persuaded to accept the theraputic 
switch, la te r other patients applied for the change themselves a fte r having 
been informed on the benefits by the diabetics on functional therapy. 
Neither did anybody want to switch back to conventional therapy nor did the 
NovoPen users want the syringes they used formerly. In spite of our previous 
expectations the use of the method should be studied in a contro lled , ran­
domized pattern with special regard to the selection of the proper patients 
and possible forms of th e ir  motivation on the long run.
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LDL MOLECULAR SIZE AS RISK FACTOR 
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Sera of 65 fasting human subjects — 32 patients with coronary artery disease (CAD) 
aged 42-80 years and 33 healthy individuals — were tested for determination of nine l ip id -  
related laboratory parameters, including protein-enriched LDL (low density lipoprote in  choles­
te ro l (LDL apo B) which is  proportional to the amount of cholesterol per LDL p a rtic le . Three of 
the investigated parameters: protein-enriched LDL, HDL cholesterol and apo В leve l d iffe red 
s ig n if ic a n tly  in the two groups (corrected P <; 0.001, P< 0.009 and P< 0.009, respective ly). 
Discriminant analysis revealed that protein-enriched LDL, LDL cholesterol, apo В and fasting 
tr ig lyce rid e  levels, but not HDL cholesterol, were the major discrim inating factors fo r CAD in 
th is  study.
Pearson corre lation coeffic ients were calculated to describe the association between 
th is  size-related parameter and those which in both groups seem to be most strongly associated 
w ith i t :  apo B/A-I ra tio  ( i ) ,  trig lyce ride  ( i i )  and LDL/HDL ra tio  ( i i i ) .  The analysis was done 
separately in the two groups. In the patients w ith CAD the influence of these three parameters 
were less decisive in the determination of the protein-enriched LDL than in the contro ls (co rr. 
co e ff.: ( i )  -0.155 vs -0.358; ( i i )  -0.624 vs -0.791; ( i i i )  -0163 vs -0.471). In healthy 
volunteers the size-reducing e ffect of the same parameters was more profound, and at high 
values of LDL/HDL ra tio , apo B/apo A-I ra t io  and trig lyceride  no d is tinc tio n  in LDL pa rtic le  
size can be made anly longer between CAD patients and controls. Thus the improvement o f the 
atherogenic p ro file  does not seem to resu lt in  the reduction of r is k  fo r CAD in  terms of LDL 
size and composition.
Keywords: LDL, molecular size, r is k  fac to r, coronary artery disease, apolipopro- 
te in  B, A-I
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Introduction
Research on cardiovascular risk factors is  amply ju s tif ie d  by the 
importance of coronary artery disease (CAD) as the most common and highly 
le tha l manifestation of atherosclerosis. There is  evidence to suggest that 
apart from to ta l or even LDL cholesterol content, the apo В concentration in 
the LDL fraction is  another very important factor in the estimation of 
susceptib ility  to CAD /4 , 22, 26/. The apo В level in LDL is  involved in the 
term "protein-enriched LDL", a designation applied to a quantity defined as 
LDL cholesterol/LDL apo В /29/.
I f  i t  is assumed that cholesterol constitutes about 50% of LDL par­
t ic le s  and an additional 20% represents protein — which, unlike lip id s , is  
not subjects to any kind of exchange /10, 19/ — then the amount of chol­
esterol in a pa rtic le  is  proportional to the partic le  size. Since each LDL 
partic le  bears only one apo В molecule on i t s  surface /19/, the LDL-C/LDL 
apo В ratio  is proportional to the cholesterol content of an individual LDL 
partic le . Thus, LDL molecular size is  mainly governed by its  cholesterol 
content. The smaller a LDL molecule usually the higher is  i t s  density as a 
resu lt of the increased proportion of the higher density of apo В molecule 
/10, 20, 31/.
I t  seems lik e ly  tha t the progress of atherosclerosis is  influenced by 
the size of low density lipoprotein (LDL) partic les in the blood. A plau­
s ib le  explanation of such an association /9 / may be the fact that small 
partic les penetrate the a rte r ia l wall more readily than larger ones /14/. 
There is  also a difference in the binding capacity of LDLs to a rte r ia l 
proteoglycans in terms of molecular weight and partic le  size /32/.
In individuals with premature coronary heart disease LDL particles are 
smaller and of higher density than those in normal subjects /9, 14/. These 
observations are consistent with those of Sniderman et a l. /26/ and Teng et 
a l. /30/, who reported a decreased LDL cholesterol/LDL apo В ra tio  in th is  
disease. There is  a suggestion that th is  decreased ra tio  may be the result 
of the increase of an LDL subfraction with small re la tive  cholesterol 
content and partic le  size /16, 17/.
One of recent controversies started with the introduction and study of 
protein-enriched LDL as one of the risk factors in CAD. While its  importance 
in  th is  respect is  generally agreed, there is  argument that i t  cannot be 
regarded as an independent risk factor, and implication that HDL cholesterol 
appears to be the best indicator for CAD /29/. In the present study we
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attempted to determine which ones of the studied lip id -re la ted  parameters 
display s ign ifican tly  d ifferent values in the CAD patients' group, and also 
to estimate that as a consequence of the ir interaction, which one of the 
routinely — thus frequently — measured parameters is  in close corre la tion 
with the one of the best predictive value in th is  disease. These associa­
tions are described in deta il and a comparison between the investigated 
groups is  made to assess the ir difference in extent and character.
Subjects and Methods
Patients and controls
Blood samples were taken a fte r overnight fasting (a t least 14 h) from 65 subjects of 
whom 32 were patients with myocardial in fa rc tion  (27 males and 5 females) from Newfoundland. 
Ihey were treated and taken regular medical care at the Department of Cardiology of the General 
Hospital in  St. Bohn's. Ihe ir average age, 56.5 years, ranged from 42 to 80. Three o f the pa­
tie n ts  were steady smoker, 21 of them qu itted smoking during recovery and eight had never 
smoked. Four patients were on treatment fo r  diabetes m ellitus and 6 received antihypertensive 
medication consisting of beta-blocker and Ca-channel blocker (propranolol and verapamil). The 
diagnosis of myocardial in farction was based on symptoms, ECG findings as well as enzyme 
changes (CPK, SGOT or LDH). Among the drugs prescribed upon discharge from hospital there was 
no cholesterol lowering agent. The patien ts, however, were instructed to keep a h igh -fib re  
cholesterol-poor d ie t.
Thirty-three healthy individuals (22 males and 11 females) vo lun ta rily  gave blood 
sample fo r the study as controls. Their age ranged from 17 to 78 years with a mean o f 53.2 
years.
The blood was drawn into a 10 ml vacutainer container with a 15% solution of EDTA a n t i­
coagulant. The plasma was freshly separated a fte r centrifugation at 1500 g fo r 30 min a t room 
temperature.
At the f i r s t  step the samples were tested fo r plasma apo В and A-I concentration by 
using an imnunoturbidimetric assay k i t  (Isolab Inc.) /25 /. An enzymatic trig lyce ride  assay was 
also performed (Boehringer Mannheim) /18 /.
Apo В and A-I determination
0.1 ml of plasma was diluted w ith 0.5 ml of an aqueous solution containing 0.3% Tween, 
0.3% NaCl and 0.1% sodium azide. For apo В determination 0.1 ml, fo r apo A-I 0.02 ml o f the 
d ilu ted sample was added to a labelled disposable p lastic  cuvette equipped with cap (ava ilab le  
from Isolab: code ID-8200) and containing 1 ml of reaction buffer (PBS of pH = 7.4, 3% PEG-6000 
and 0.1% sodium azide). After 0.1 ml o f goat antiserum was added the cuvettes were capped and 
gently shaken. The incubation time at room temperature was 30 min. Light absorbance was tested 
by using a spectrophotometer at 340 nm. Turb id ity is  linear with apolipoprotein concentration 
up to 200 mg/dl. Calibrators are supplied with the k i t  in  the form of lyophilized human plasma 
with sodium azide as preservative. They are standardized against the CDC-IUIS reference pool 
fo r serum apolipoproteins /7 /.
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Triglyceride assay
The enzymatic tr ig ly c e r id e  assay was applied fo r  the 8M/Hitachi Systems 704/705. The 
assay u tilizes  EDTA plasma samples. The f i r s t  step was an enzymatic hydrolysis by lipase. The 
hydrolysis produced g lyce ro l, which was measured as described by Pinter et a l.  /21 /. The 
substrate mixture consisted o f 10 ml of phosphoenolpyruvate (3.5 mol/1), 0.25 ml of ATP 
(75 mmol/1), 1 ml of NADH (2.5 mg/ml), 0.1 ml pyruvate kinase (2 mg/ml) in  2.2 mol/1 ammonium 
su lfa te  aqueous solution and 0.1 ml of la c tic  dehydrogenase (0.5 mg/ml) in 2.2 mol/1 ammonium 
su lfa te  solution. L ight absorbance was measured spectrophotometrically at 340 nm.
Separation of lipoprote in  frac tions  by a ff in ity  chromatography
In order to separate the plasma beta-lipoprotein and alpha-lipoprotein (HDL) fractions, 
the plasma was applied to  a heparin-agarose chromatographic column supplied with LDL-Direct 
Plus k i t  (Isolab Inc .) /6 / .
This procedure is  based on the princip le o f a f f in i t y  chromatography. The beta-lipo- 
proteins, the term includes those exhibiting beta or pre-beta electrophoretic m ob ility , bind 
to  the column s p e c if ic a lly . The binding is  mediated by apolipoprotein E and В at near-physio- 
lo g ic a l pH and ionic strength. However, at higher s a lt  concentration the bound lipoproteins 
(mainly LDL and less IDL and VLDL) are to be desorbed /1 3 /. Alpha-lipoproteins pass through 
the column together w ith  several other serum pro te ins, th is  fraction contains HDL(2) and 
HDL(3).
The advantage o f th is  separation method here was i t s  s im p lic ity  in comparison with 
ana lytica l u ltracen trifuga tion , on the one hand, and th a t the fractions could readily be used 
fo r further assays w ithout interference from e a r lie r  applied reagents, on the other. Quan­
t ita t iv e  comparison between the two medtods is  given by Bentzen et a l.  /6 / .
In the eluted beta-lipoprote in  fractions, which mostly contain LDL, less amount of IDL 
and VLDL partic les, the apo В level and cholesterol concentration were measured. Since the 
blood was taken a fte r fa s tin g , the amount of chylomicrons can be ignored. The method fo r apo В 
determination in the beta e lu tion  fraction was the same as the one referred to : immuno- 
turb id im etric assay.
Cholesterol assay
The to ta l plasma cholesterol as well as the cholesterol in  e lution fractions was 
measured by a m odification o f the method described by A lla in  et a l. /1 / .  The assay procedure 
requires enzyme reagent (1.6 mmol/1 4-aminoantipyrine, 5560 U /l peroxidase and 400 U/l cho­
le s te ro l oxidase in phosphate buffer of pH = 6.7) and activa tor (40 mmol/1 phenol in aqueous 
so lu tion). Incubation period 20 min at room temperature. Light absorbance was measured with 
spectrophotometer at 505 nm.
The obtained values o f apo В and cholesterol leve ls  in the beta elution fraction  were 
applied to estimation o f the LDL cholesterol/apo В ra t io .  The determined values of apo В and 
A -I levels in the unfractionated plasma, on the other hand, were used fo r calculating the 
apo B/apo A-I ra tio .
S ta tis tic a l methods
Difference between patients and control was tested fo r significance by using Student's 
ta te s t. In order to describe the studied associations we calculated Pearson correlation 
coeffic ien ts for s ta t is t ic a l evaluation. A stepwise discrim inant analysis was carried out to 
f in d  a set of variables (laboratory tests) which, as discriminant functions, can be used to 
achieve a maximal segregation o f CAD patients and con tro ls . The stepwise analysis also e s t i­
mates the order of importance o f these variables in  terms of th e ir discrim inative power. The 
computer programme autom atica lly stops when the addition of new data does not resu lt in  a 
higher segregation ra te than the indicated one.
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Results
Serum lip id s  in patients and controls
The results of the apolipoprotein (B and A -I), trig lyceride  and cho­
leste ro l determinations in the investigated blood samples are shown in 
Table I .
Table I
Serum lip id s  and lipoproteins in coronary artery disease patients 
and normal subjects
Parameters CAD patients n = 32
Controls 
n = 33
Significance 
leve l (corr.P)
Apo В (mg/dl) 88.3 (19.7) 71.7 (15.6) P <  0.009
Apo A-I (mg/dl) 99.6 (17.2) 96.3 (20.8) ns
Apo B/A-I 0.917 (0.254) 0.768 (0.197) ns
lo t.ch o l. (mmol/1) 5.03 (0.87) 5.13 (0.97) ns
LDL. chol. (mmol/1) 3.44 (0.76) 3.76 (0.91) ns
HDL chol. (mmol/1) 0.92 (0.31) 1.22 (0.39) P< 0.009
LDL-C/LDL apo В 0.0508 (0.007) 0.0573 (0.006) P <  0.001
T rig lyc. (mmol/1) 1.77 (0.97) 1.53 (0.66) ns
LDL/HDL chol. 4.17 (1.67) 3.28 (0.95) ns
A ll values are mean + S.D., ns: non s ig n ifica n t
The size-related protein-enriched LDL, which is proportional to the 
cholesterol content of an individual LDL practic le , and HOL cholesterol were 
found to be s ign ifican tly  decreased in CAD patients (corrected PC 0.001 and 
P< 0.009, respectively) (Table I ) .  We also experienced an elevated apolipo­
protein В concentration in the patients' group (corrected Pc 0.0C9) despite 
th e ir moderately reduced LDL cholesterol leve l, which might be due in  part 
to a cholesterol-poor d iet, for the patients have already been on treatment 
for several months.
The apo A-I level was about the same in  CAD patients as in  the con­
tro ls  — thus i t  was not considered to be an important risk  factor, though 
Yano et a l. /33/ found i t  otherwise. The rest of the parameters — apo B/A-I, 
trig lyce ride  and LDL/HDL cholesterol, on the other hand, showed a somewhat 
elevated value, never reaching the lim it  of significance.
The elevated serum trig lyce ride  level in patients was thought to be 
responsible for the observed higher apo В concentration, but a fte r closer
70 L . KOZMA e t  a l .
Table I I
Discriminant analysis in 65 subjects w ith the diseased state 
as grouping variable
Step Function Parameter Equivalent F Significance: P<
1. add apo В 11.411 0.0017
2. add LDL-C 12.061 0.0001
3. add trig lyceride 14.879 0.00001
4. add LDL-C/LDL apo В 13.300 0.00001
Percent of cases correc tly  classified: 90.57%
scrutiny i t  was revealed that apo В level was higher in CAD than in controls 
in cases with p ra c tica lly  the same trig lyce ride  levels.
In order to estimate the discrim inative power of these parameters for 
CAD we applied a discriminant analysis to the experimental data. When a l l  
the variables were included in the analysis, the best segregation of pa­
tie n ts  and controls based on laboratory data was achieved after step 4, by 
introducing the data of protein-enriched LDL (LDL-C/LDL apo B) (Table I I ) .
The parameters which are not shown in Table I I ,  although were included 
at the s tart, — including HDL-C — were not necessary to achieve the maximal 
segregation of patients and controls. Since the addition of these data could 
not have made a better d istinction possible between the two groups, the 
predictive value of these missing parameters is  less than of those in Table 
I I .  This also suggests that the s ign ifican t association between HDL-C and 
CAD may be only secondary to the connection between HDL-C and apo В or 
LDL-C/LDL apo B, data also showing strong association with CAD.
Table I I I
Correlation coefficients between lip id -re la te d  parameters 
in coronary artery disease and normal control
Investigated
parameter
Associated
parameters
Correlation
Patients
coeffic ien ts
Controls
Protein-enriched LDL Triglyceride -0.6242 -0.7906
HDL cholest. 0.4409 0.3757
apo B/A-I -0.1551+ -0.3577
LDL/HDL cholest. -0.1626+ -0.4713
P< 0.05
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We then focused our attention on the parameter of the most s ig n if i­
cantly decreased value: protein-enriched LDL. Calculating the Pearson 
correlation coefficients in each of the two groups, the results are sum­
marized in Table I I I .
Protein-enriched LDL: d ifferent patterns of variation in CAD
In patients with CAD the size-related protein-enriched LDL exhibits 
the best correlations with trig lyce ride , HDL, LDL/HDL ra tio  and apo B/A-I 
ra tio , in a decreasing order (Table I I I )  while in the control group, these 
associations are a ll stronger, except for that of HDL with protein-enriched 
LDL. An association between these lipid-associated parameters is  not rea lly  
unexpected, but i t  is  questionable whether there are differences in  the 
extent and re la tive  prominence of these associations between patients and 
controls.
LDL-C/LDL apo В in both groups is  decreasing with trig lyce ride  con­
centration but there is  an obvious difference in the correlation c o e ffi­
cients. The re la tive  cholesterol content of LDL and consequently i t s  size, 
though smaller in CAD, does not depend so much on trig lyceride level as in 
controls, the decrease is  less pronounced.
The second parameter associated with protein-enriched LDL is  HDL 
cholesterol — which by its e lf  showed a s ign ifican t association with the 
disease. The correlation between these two risk  factors makes i t  even more 
d if f ic u l t  to t e l l  whether th is association of HDL with CAD is  a primary one 
or only secondary to that of LDL-C/LDL apo 8.
In our study, with lim ited number of patients though, i t  is  suggested 
that the association of CAD with HDL is  only secondary as shown by the 
result of the discriminant analysis (Table I I ) .  HDL level, s ig n ifican tly  
reduced as i t  is  in CAD patients, did not belong to the variables of most 
discrim inative power, between diseased and controls.
The correlation coefficients featuring the two remaining parameters, 
LDL-C/HDL-C and apo B/A-I ra tios, with protein-enriched LOL are very s im ilar 
to, and consistent with, the strong correlation between the two ra tios  (not 
shown here). In the control population LDL-C/LDL apo В values are higher for 
most cases and fo r both parameters. I t  is  worth mentioning that protein- 
enriched LDL is  much more dependent on both ra tios in the control group than 
in patients. This is  clearly shown by the Pearson correlation coeffic ien ts, 
being twofold in controls (Table I I I ) .
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Discussion
S ign ificantly  low levels of protein-enriched LDL and HDL cholesterol 
were found in CAD patients, confirming lite ra ry  data /16, 26, 30/. A l­
though, based on our unpublished data, there is  a s ligh t association between 
protein-enriched LDL and age, in th is  study the different mean age in our 
groups is  to account for only one-seventh of the standard deviation fo r 
LDL-C/LDL apo В in the patients. Normal levels of LDL-C were detected, 
associated with a disproportionate increase in  apo В as has already been 
reported in CAD and is  thought to contribute to the acceleration of athero­
sclerosis /4, 22, 26/.
I t  is  worth mentioning that the LDL-Direct Plus k it  we used fo r the 
iso la tion  of the beta-lipoprotein fraction cannot distinguish between VLDL, 
IDL and LDL, though LDL certainly represents the majority of the partic les. 
In spite of th is  p i t fa l l ,  the determined LDL-C/apo В ratios were s t i l l  
acceptable for a s ta t is t ic a l evaluation, because IDL-C/apo В values are 
approximately the same /12, 24/ and VLDL, on which no similar data have yet 
been available, constitutes only 7-8% of the partic les in the beta fraction . 
Therefore, the presence of IDL and VLDL is  thought not to have a profound 
e ffec t on the associations outlined here.
The conventional method for LDL-C calculation (LDL-C = Tot.C — HDL-C — 
tr ig ly c ./5 )  was not applicable here e ither, because VLDL-C was not to be 
subtracted when VLDL-аро В was measured.
Although the separation of LDL by ultracentrifugation could have been 
a more exact approach, the procedure we used is  rapid, more convenient to 
perform and as such, i t  has a better chance to become daily routine for 
screening to detect disease susceptib ility  fo r CAD.
In a discriminant analysis we found apo B, LDL-C, trig lyce ride  and 
protein-enriched LDL to be the best discrim inative variable of a l l  the 
studied serum lip id s , as reported also by Barbir et a l. /5 /. The 90.57% 
segregation of cases required the involvement of these parameters, but no 
HDL cholesterol came into play in the analysis in spite of i ts  s ign ifican t 
difference in the Student's _t-test between the two investigated groups. In 
our opinion — unlike the conclusion of Swinksls et a l. /29/ — the size- 
related protein-enriched LDL has more discrim inative power fo r CAD than 
does HDL.
There is  no doubt about the existence of a correlation between pro­
tein-enriched LDL and HDL cholesterol but the f i r s t  seems to be a risk
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factor to CAD more important than the la tte r . Steiner et al. /28/ also 
rejected an association between CAD and HDL cholesterol by using stepwise 
log is tic  regression analysis. They claimed, however, that CAD showed a 
strong association with smoking and intermediate-density lipoprotein apo B. 
Since we only included serum lip id s  in the analysis therefore smoking was 
omitted and because the antibody we used in the immunoturbidimetric assay 
cannot distinguish between IDL and LDL apo В we can not be more spec ific  
here. However, there are indications that apo B/C ratios in IDL closely 
approximate those in  LDL /12, 24/. Among serum lip id  parameters the t r i ­
glyceride level showed the strongest association with protein-enriched LDL 
/11, 15, 23/. A plausible explanation for the fact lie s  in the action of the 
concentration-dependent trig lyceride:cholesteryl ester exchange prote in , 
whereby LDL and IDL particles become enriched in trig lyceride and lose 
cholesteryl ester /10/. The size reduction is  probably the consequence of 
continuing lipase action on trig lyceride . Although th is  correlation was 
sign ificant in both groups a like , trig lyceride  level did not seem to e ffe c t 
the cholesterol depletion of the LDL particles in  the patients as much as i t  
did in controls.
Amos et a l. /2 / reported that results of segregation analysis were 
consistent with major gene determination of apo В and HDL-C levels, the 
HDL-C to apo A-I ra tio , the LDL-C to apo В ra tio  and a measure of re la tive  
content of cholesterol in HDL-C and LDL-C. I f  such gene(s) predisposing to 
CAD does exist then i t  would certa in ly set lim its  to the influerce on LDL 
size of environmental factors lik e  trig lyceride  leve l in blood, which may be 
an explantation fo r the reduced trig lyceride  dependency. One of the possible 
assumptions may be that as a resu lt of th is  gene e ffect the ac tiv ity  of the 
mentioned lip id  exchange protein is  altered in  CAD /27/. Nevertheless, 
hypertriglyceridaemia is  an important risk  factor fo r CAD as recently con­
firmed by Barbir et a l. /5 /, using a discriminant function analysis. In th is  
work LDL apo В was the second most important discriminant variable, sug­
gesting an, at least partly, independent way of action of these two para­
meters in conferring susceptib ility  to CAD.
As with trig lyce ride , sim ilar conclusions were drawn with regard to 
LDL/HDL cholesterol and apo B/A-I ratios. The LDL-C/LDL apo В ra tio  in  the 
patients did not vary with these parameters considerably. In contrast to 
trig lyceride , these associations proved to be s ign ifican t in the contro l 
group alone.
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Earlier observations indicated that individuals with normal levels of 
to ta l and LDL cholesterol were s t i l l  at an increased risk  of CAD i f  the ir 
apo В level is  high (hyperapo В syndrome) /26 /. Our findings confirm th is  
and are in accordance also with the observation that apo В correlates with 
the disease better than LDL cholesterol does /4, 8/. Part of the higher risk  
in  these cases can apparently be a ttribu ted  to the smaller size of the LDL 
partic les .
The small re la tive  cholesterol content and particle size is  probably 
due to the predominance of LDL subclass pattern В in CAD, reportedly asso­
ciated with increased apo В and trig lyce rid e  levels and decreased HDL cho­
le s te ro l, recently claimed to be inherited as an autosomal t r a i t  /3 / .  Such a 
genetic determination might explain fo r the observation that factors of 
strong influence in  controls like  tr ig ly ce rid e  level or apolipoprotein B/A-I 
and LDL-C/HDL-C ra tios  do not seem to e ffe c t LDL molecular size or composi­
tio n  in CAD so much.
In the lig h t of our data i t  is  suggested that in patients w ith strong 
genetic predisposition any improvement in  atherogenic p ro file  characterized 
by LDL/HDL cholesterol and apo B/A-I ra tio s  must be regarded and interpreted 
more cautiously in  terms of its  real value in  reducing the r isk  represented 
by low LDL molecular size for CAD. To a less extent th is  also applies to 
serum trig lyceride leve l. Genetic predisposition is certain in  case of pa­
tie n ts  with multiple family cases. The presence of cardinal non-genetic and 
non-lip id  risk factors lik e  smoking, stress, e tc., may have s im ila r conse­
quences. However, i t  is  important to emphasize that overall r is k  fo r CAD as 
a m u ltifac to ria l disorder consists of several components, LDL molecular size 
being only one of them. Thus the e ffect o f the same parameters, of course, 
can be quite d iffe re n t on the overall r is k ,  the investigation of which is 
beyond the scope of th is  study.
Conclusion
According to our findings i t  seems lik e ly  that the cholesterol content 
and size of apo В bearing lipoprotein partic les  in the beta frac tion  are 
factors of major importance in coronary atherosclerosis. Unfavourable 
atherogenic p ro file  expressed as high LDL/HDL cholesterol as well as apo 
B/A-I ratios and high serum trig lyceride leve l are associated with small LDL 
molecular size, but in the possible presence of genetic predisposition
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and/or other major environmental risk  factors lik e  smoking, stress, etc. the 
risk  fo r CAD represented by low protein-enriched LDL may remain considerably 
high in spite of an improvement of the mentioned l ip id  parameters.
A c k n o w le d g e m e n t :  Authors thank Gabriella Nemes fo r the typing work.
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GENOTOXIC EFFECTS OF OCCUPATIONAL EXPOSURE IN  THE PERIPHERAL 
BLOOD LYMPHOCYTES OF PESTICIDE PREPARING WORKERS IN HUNGARY
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Venous blood samples of 240 donors including 33 in du s tria l and 60 h is to rica l controls 
were investigated in order to assess the genotoxic r isk  o f pesticide preparing workers manu­
facturing monochlorinated benzene in  Hungary. Mutation frequencies were determined in the 
hypoxanthine-(guanine)-phosphoribosyl transferase genes located on the X chromosome. DNA repair 
capacity was estimated following hydroxyurea treatment with subsequent UV irrad ia tion  of 
separated lymphocytes. Smoking as confounding factor of genotoxicity was also taken in to  con­
sideration. Mutation frequencies were increased among the workers exposed to monochlorinated 
benzene in corre lation with the duration of working time, compared to the contro ls. Mutation 
frequencies were lower than expected among non-smoker, long-exposed workers. Smoking i ts e l f  
proved to be an e ffec tive  confounding factor in the enhancement of point mutations in the case 
of long-exposed workers. Smoking, however, caused no s ign ifican t increase in  the mutation 
frequency among the controls, and did  not influence the DNA repair capacity o f any of the 
groups.
Keywords: Genotoxicity. lymphocyte, pesticide, HPRT-locus, DNA-repair
Abbreviations: HPRT = Hypoxanthine-(guanine)-phosphoribosyl transferase; LI = Labeling 
index; MAC = Maximum allowable concentration; MF = Mutation frequency (LI(PHA)); PBL = Peri­
pheral blood lymphocyte(s); PCA = Perchloric acid; PHA = Phytohaemagglutinin; PHA% = P ro life ra­
tiv e  response of ce lls  to PHA treatment; RC = De novo DNA synthesis, 'DNA repair capacity'; 
SCE = S ister chromatid exchange; SSB = DNA single-strand break; 6-TG = 6-thioguanine; 
UV = U ltrav io le t lig h t (approximately 250 nm) ; VF = Variation frequency of HPRT mutations
O ffprin t requests should be sent to : Ú. Major, Natl. Ins t. Occupât. H lth ., H-1450 Bu­
dapest, P.0. Box 22, Hungary
Akadémiai Kiadó, Budapest
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Introduction
The estimation of the genotoxic effects including the frequency of 
mutations (MF) and the repair capacity (RC) of the existing mutations 
aris ing  from occupational and/or environmental exposure, is  especially 
important at those populations which are known (or suspected) to be exposed 
to genotoxic hazards in working places. These are e.g. the workers of the 
chemical industry.
The problems are the detection, estimation and evaluation of the e f­
fects of long-lasting and low-level exposure to carcinogens and co-carcino- 
gens. The human population monitored by d ifferent b io logical markers in ­
cluding cytogenetical methods may help to solve these branching problems 
/10, 11/ and repeated examinations would show the tendencies of the followed 
cytogenetic a lterations. Although there are molecular and cytogenetical 
techniques in the human ris k  assessment /4, 19/, the dosimetry and the dose- 
response relationships are s t i l l  unsolved /3 /.
The detection of mutations in  the hypoxanthine-(guanine)-phospho- 
ribosy l transferase (HPRT) locus of the X chromosome is  a frequently used 
tes t system in the human r is k  assessment among other b io logical markers /10, 
12, 17/. As the HPRT locus is  located on the X chromosome in  humans, a 
single copy is  only active in  lymphocytes irrespectively of the donor's sex. 
However, any form-of the mutations is  su ffic ien t to the loss of HPRT pheno­
type, i.e . ,  the manifestation of the resistance to the cytotoxic purine 
analogue 6-thioguanine (É-TG) treatment /3 /. An autoradiographic assay has 
been developed by Strauss and A lbertin i /12/ in order to detect the mutant 
( i .e . ,  6-TG resistant) lymphocytes.
The estimation of the capacity of DNA excision repair induced by short 
wave u ltrav io le t lig h t (UV) irrad ia tion  by measuring the unscheduled DNA 
synthesis can also serve the assessment of the genotoxic effects of an 
exposure as DNA repair can eliminate the consequences partly  or to ta lly  /9 /. 
The measurement of unscheduled DNA synthesis requiring a re la tive ly  small 
amount of ce lls  is  simple and i t  is  a practical method to estimate the DNA 
repair capacity (RC).
In a previous publication Tompa compared the changes in MFs among 
cancer patients and industria l workers /15/. Although these studies gave 
significant results the disadvantages of the lack of the comparability of 
the results to other end points of the same sample were clear. Parallel 
estimations of d iffe ren t end points as e.g. MFs and RCs of the same sample
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may give a better understanding of the la te genotoxic effects of indus tria l 
hazards at working places.
The aim of our present study was to estimate the genotoxic e ffects  of 
the working environment in samples of peripheral blood lymphocytes (PBLs) of 
workers manufacturing the pesticide Lutid in of monochlorinated benzene. The 
comparabilitiy of two pa ra lle lly  determined end points may improve the 
confidence of the risk  assessment. Therefore, we have measured 6-TG re s is t­
ance of PBL (VF) /14/ and the unscheduled DNA synthesis a fte r 250 nm UV 
lig h t irrad ia tion  (RC) /1 /.  Data taken from the exposed groups of pesticide 
workers were compared to those of h is to r ica l and industria l control groups. 
Smoking as a confounding factor of genotoxicity /6, 16/, was also taken 
into consideration.
The genotoxic effects of chlorinated benzenes /18/ and some deriva­
tives were extensively studied in v itro  by Fishbein /5 /, and Gad-el-Karim et 
a l. /7 / who demonstrated that these benzene derivatives were tumour pro­
moters. Boutwell et a l. reported sim ilar conclusions in the ir early obser­
vation /2 /.
Materials and Methods
1. Separation of lymphocytes
Samples from 240 donors were taken by venipuncture and prepared immediately. The donors 
included 147 exposed workers, 33 industria l controls working at the same firm  but in a harm­
less environment and 60 h is to r ic a l controls. A ll the samples were taken and prepared in  the 
same way. Grouping 1 to 5 o f the donors by sex, age and smoking habit is  presented in  Table I .
Table I
D istribution of control and exposed donors by sex, age, and smoking habits
Groups n
Average age 
+ S.E. П
Men
%
Women 
n %
Smokers 
n %
Non-
n
-smokers
0,
1 H is to rica l control 60 39.1 + 1.6 10 16.7 50 83.3 28 46.7 32 53.3
2 Industria l control 33 36.1 + 1.5 24 72.7 9 27.3 20 60.6 13 39.4
3 Workers exposed for 
0 to 1 year
45 28.0 + 1.9 40 88.9 5 11.1 24 53.3 21 46.7
4 Workers exposed for 
1 to 10 years
41 30.0 i  1.9 25 61.0 16 39.0 19 46.3 22 53.7
5 Workers exposed for 
>  10 years 61 45.8 +2.6
46 75.4 15 24.6 38 62.3 23 37.7
Total 240 36.2 + 1.7 145 60.4 95 39.6 129 53.8 111 46.2
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Twenty ml of heparinized and again 20 ml of c itra ted blood samples were taken from each donor 
in  order to determine 6-TG resistance (VF) and the unscheduled DNA synthesis (RC), respective­
ly .  Lymphocytes were separated on a Ficoll-Hypaque density gradient as i t  was described 
elsewhere /15/.
2. Determination of 6-TG resistance
Lymphocytes separated from heparinized blood samples were washed twice in  Hanks' balanc­
ed saline buffer (Gibco). C ells were counted in Buerker's chamber then were adjusted to 10é 
ce lls /m l in RPMI-1640 cu ltu re medium (Gibco) supplemented with 30% fe ta l c a lf serum (Gibco) 
w ithout an tib io tics. Three groups of cultures were made in  tr ip lic a te s  of each donor. Untreated 
con tro l ce lls  of group a) were only cultured in  RPMI-1640 medium, ce lls  of group b) were 
stimulated with 0.1% (v /v) Phytohaemagglutinin-P (PHA. Difco) in culture medium, while in 
group c) the PHA stim ulation was supplemented with 10-4 M 6-thioguanine (6-TG, Sigma) tre a t­
ment. Cells were cultured in  glass centrifuge tubes and incubated fo r 24 h at 37 °C in  a 
humidified CO2 thermostat (Labor MIM, Hungary). Six hours before termination, c e lls  o f each 
cu ltu re  were labeled with 1 jjC i/m l (^H)-thymidine (Amersham).
3. Estimation of DNA repair capacity
Lymphocytes separated from citra ted peripheral blood samples were washed twice in  Hanks' 
balanced saline (Gibco), supplemented with 10% of 0.12 M c i t r ic  acid (Reanal, Budapest). A fter 
counting in a Buerker's chamber lymphocytes were adjusted to  3 x 106 cell/m l in  c itra ted  Hanks' 
balanced saline. Control (group a) remained untreated. The c e lls  of group b) were treated with 
40 p l/m l, 0.125 M hydroxyurea (HU, Reanal, Budapest). Those of group c) were treated with HU 
plus irradiated with 250 nm UV l ig h t  (10 s, 60 cm). A ll groups were made in duplicates in  Petri 
dishes. Cells were subsequently labeled with 5.0 jjC i/m l (^H)-thymidine (Amersham) and incubated 
fo r  60 min at 37 °C in  thermostat. DNA was pelleted by a three times repeated washing o f the 
labeled nuclei with 1 M perch loric  acid (PCA, Reanal) then hydrolysed by 0.5 M PCA (30 min, 
88 °C). After centrifuging a t 2000 G the supernatant was cooled down and 0.3 ml a liquot was 
transferred into 10 ml s c in t i l la t io n  cocktail containing toluene (Reanal), Triton-X-100 
(Reanal), 0.2% 2,5-diphenyl-oxasol (Reanal) and 0.05% 1,4-bis-2-(5-phenol-oxasolyl)benzene 
(Reanal). DNA contents were measured by photometry at 580 nm (Spekol, K. Zeiss, Jena). Scin- 
t illo m e try  was performed in  LKB 1211 RACK BETA sc in tillom eter /1 /.
4. Biometrical analysis
a) Calculation of VF
The a b ility  of c e lls  to  incorporate (^H)-thymidine was determined by autoradiography. 
2500 PHA stimulated ce lls  were counted in order to calculate the labeling index fo r PHA 
(LI(PHA)). In the TG-treated group (PHA + TG) the to ta l number of ce lls  placed on coverslips 
was counted in a Buerker's chamber before smears were prepared. MF is  identica l with the 
labe ling  index of the 6-TG treated ce lls , therefore MF = LI(PHA + TG). VF ( i .e . ,  varia tion  fre ­
quency of mutations) was calculated by the equation o f VF = LI(PHA + TG)/LI(PHA) /17 /. VF is  
d iffe re n t from MF for including the frequency of the lectin-stim ulated ce lls . The significance 
o f elevations in MFs and VFs were s ta t is t ic a lly  analysed using the поп-parametric Mann-Whitney 
te s t applied to the ranked measurement /20/. The selection o f workers both for exposed and non- 
exposed groups was performed randomly. Sex, age, and smoking habit were considered as con­
founding factors.
b) Estimation of RC
In order to estimate the RC values we computed the DNA content of the samples using the 
equation DNA(pg) = fc(st)xl00pg/£ (sample), where £(s t) is  the extinction of the 100 jjg/m l 0NA
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standard (DNA, Sigma) and £(sample) is  the extinction of the given sample. RC was estimated 
following the formula RC = (R-HU)/HU, where R is  the average dpm/DNA(pg) value o f the UV 
irradia ted and HU is  the average dpm/DNA(pg) value of the UV-plus-HU treated samples o f the 
donor /1 / .  S ta tis tic a l analysis was performed with the Student's t  tes t.
Results
The concentration of aromatic solvents in a ir samples of the studied 
working places measured regularly by the Safety Department of the firm  are 
summarized in Table I I  and are compared to the Hungarian MAC values. I t  is  
clear that the actual aromatic solvent concentrations exceed the correspond­
ing MAC values.
Table I I
A comparison of concentrations o f aromatic solvents in the a ir  samples 
of the working rooms to the Hungarian MAC values
Solvent
Concentration in a ir  samples 
(mg/rtr5)
Average +^S.E. Range
MAC values 
(mg/m-5) 
(Hungary)
Phenol concentration 
in urine (mg/L) 
mean +_ S.E.
Benzene 21.2 + 7.06 2.8 -  134.0 5.0 Control donors: 
n = 23 50.0 + 40.7
Exposed donors: 
n = 18 602.3 + 89.3
Monochlorbenzene 33.5 +_ 17.77 1.9 -  173.4 50.0
Chloroform 72.2 + 6.35 30.0 -  99.0 20.0
Methanol 39.1 + 5.78 16.0 -  80.0 50.0
Toluene 91.2+12.54 4 1 .0 -15 3 .0 100.0
The 147 exposed donors were examined fo r genotoxicology end points as 
well as for routine c lin ica l check up. Increased phenol excretion was found 
in the urines of 23 donors with a mean of 602 mg/L, which is  12 times as 
high as the expected (normal) level (c f. Table I I ) .  Eight of these 23 
donors had also qualitative alterations in blood smears although they had no 
s ign ificant differences in the ir genotoxicology tests when compared to non- 
exposed (phenol-free) control donors. Detailed results of the routine c l in i ­
cal check up w il l  be published la te r.
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P roliferative response o f lymphocytes to PHA treatment
Table I I I  summarizes the results of the genotoxicity test. Within each 
groups (groups 1 to 5) the pro liferative response of T-lymphocytes (PHA%) of 
smokers and of non-smokers to РИА stimulation did not d iffe r  s ig n ifican tly  
except group 2 ( in d u s tr ia l controls) where PHA% of smokers and of non- 
smokers were on the average of 21.2% and 13.8%, respectively (P < 0.01). In 
group 1 (h is to rica l control) the corresponding PHA% values were 19.5% and 
18.3%, respectively. The average PHA%s of the (exposed) groups 3, 4, and 5 
were 20.8%, 21.3%, and 18.3%, respectively.
Mutation frequencies
In group 1 the frequency of the mutant ce lls  (MF) according to the la ­
beling index (LI(PHA + TG) was on the average 0.57. The MF values were calcu­
lable I I I
Results obtained on the genotoxical end points o f the exposed and control groups of donors
PHA stimulation Mutation Variation DNA-repair
Groups n index (PHA%) frequencies (MF) frequencies (VF) capacity (RC)
mean + S.E. mean + S.E. mean + S.E. mean + S.E.
1 H isto rica l control 60 18.90 + 1.43 0.57 + 0.07 3.27 + 0.42 5.07 + 0.29
Smokers 28 18.32 + 1.46 0.54 + 0.10 3.31 + 0.63 5.89 + 0.11
Non-smokers 32 19.52 + 1.45 0.59 + 0.10 3.19 + 0.56 4.40 + 0.77
2 Industria l controls 33 18.32 + 2.19 1.83 + 0.32 10.00 + 1.74* 8.03 + 0.39
Smokers 20 21.20 + 1.74 2.19 + 0.49 10.80 + 2.42* 8.84 + 1.98
Non-smokers 13 13.81 + 1.83 1.31 + 0.36 8.83 + 2.45* 6.83 + 1.88
3 Workers exposed for 
0 to 1 year 45 20.77 + 1.30 3.75 + 1.17 16.41 + 3.21* 8.25 + 0.36
Smokers 24 21.45 + 1.68 1.81 + 2.06 12.80 + 2.44* 9.33 + 0.42
Non-smokers 21 19.99 + 2.00 4.61 + 1.51 20.43 + 6.30* 7.11 + 0.53
4 Workers exposed fo r 
1 to 10 years 41 21.31 + 1.66 3.13 + 0.58 25.01 + 9.11* 6.78 + 0.48
Smokers 19 19.04 + 2.57 3.12 + 0.75 32.33 + 16.38* 7.75 + 0.67
Non-smokers 22 19.83 + 2.06 4.67 + 1.58 20.86 + 6.56* 7.32 + 0.53
3 Workers exposed for 
>10  years 61 18.29 + 1.30 3.53 + 0.99 23.03 + 5.16* 7.89 + 0.35
Smokers 38 19.04 + 1.78 4.49 + 1.49 28.32 + 7.45* 8.35 + 0.43
Non-smokers 23 16.83 + 1.86 1.73 + 0.36 13.94 + 4.59* 6.90 + 0.53
*  S ign ifican tly  d iffe re n t from h is to rica l controls, P <i 0.01 (Mann—Whitney te s t).
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lated fo r 10  ^ ce lls . In the exposed groups 3, 4, and 5, MFs s lig h tly  in ­
creased, the average MFs were 3.8, 3.1, and 3.5, respectively. MF values fo r 
the smokers and non-smokers differed s ig n ifica n tly  in the exposed group 3 
(c f. Table I I I )  where MF of smokers proved to be identical with that of 
group 2, while in the case of the non-smokers, MFs were 3.5 times as high as 
that fo r the industria l control (4.6, and 1.3, respectively). The difference 
between MFs for smokers and non-smokers did not increase in group 4 (3.1, 
and 4.7, respectively). In group 5 the tendency, however, changed as MFs of 
the smokers proved to be s t i l l  increasing to 4.5, while in the case of the 
non-smokers of Group 5 the average MF f e l l  to the control level (MF = 1.7).
Figure 1 indicates the d istribution  of the variation frequencies (VFs) 
of the mutations in a point diagram. As there were no sign ificant d if fe r ­
ences between PHA%s for smokers and those fo r non-smokers of the exposed 
groups there were also no essential differences in the correspondig VFs. In
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Fig, 1. Point diagram of the VF values in  the examined groups of workers 
(VF values increase in  each exposed groups p a ra lle l to the length of exposure, c f . de ta ils  in
the te x t)
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contrast with the e ffe c t of smoking as a confounding factor, VFs of groups 1 
to 5 were on the average of 3.27, 10.0, 16.4, 25.0, and 23.0, respectively, 
showing s light increase according to the length of exposure.
H is to r ic a l Industria l 0 -1 yea r 1-10years >10 years 
n =60 n=33 n=45 n = 41 n =61
F ig . 2, Point diagram of the d is tr ib u tio n  of DNA repair capacity values in  the examined groups
of donors
(An increase of RCs in the in d u s tr ia l controls' group is  observable when compared to  the 
h is to r ic a l controls. Chemical exposure, however, did not produce a further increase o f RCs,
c f.  details in the te x t)
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□NA repair capacity
The las t column of Table I I I  demonstrates the results obtained from 
the DNA repair capacity tests. There were no s ign ifican t differences in  RCs 
between smokers (5.9) and non-smokers (4.4) of group 1. In group 2 only RCs 
of non-smokers (6.8) correspond to the controls (on the average 5.07) while 
smokers' RCs, however, were higher (8.8). A v ir tu a lly  sim ilar tendency of 
the smokers' and non-smokers' RCs was also found in the case of the exposed 
groups, but the differences were not s ign ifican t. The detailed RC data are 
demonstrated in the point diagram shown in Fig. 2.
Discussion
In the present study we examined 240 samples taken from donors of 60 
healthy (not exposed, h is to rica l contro l), 33 industria l control donors and 
of 147 employees of a firm  producing pesticides in Hungary. This la tte r  
exposed donors' group was divided into subgroups according to the duration 
of the exposure. The smoking and the non-smoking habits of a l l the donors 
were also taken into consideration as confounding factors of the genotoxi- 
c i ty .
The expected level of PHA% according to the controls was on the aver­
age 18.9%. In group 2 (indus tria l control) the non-smokers' PHA% values 
(13.8%) reduced s ign ifican tly  (P <  0.01) when compared to that of the 
smokers (21.2%). This finding is  exceptional and d if f ic u l t  to explain since 
no sim ilar difference is  v ir tu a lly  existing in the case of the exposed 
donors regardless of- the duration of exposure. PHA% is  indeed increasing 
according to the duration of the exposure as i t  is  in groups 3, and 4, but 
smoking does not seem to be an effective d iffe ren tia ting  factor. In the case 
of donors of group 5, who suffered from the longest exposure, the capacity 
of le c tin  stimulation of T lymphocytes s lig h tly  reduced and returned to the 
control level.
Examining the frequency of the mutant ce lls  we observed that the 
short-term exposure increased MFs, the medium exposure resulted in  no 
further increase, while long-term exposure over 10 years elevated again MF 
to a certain extent. In the case of non-smokers the short-term and medium 
exposure resulted in a s ign ifican t increase of MFs when compared to that of 
smokers of the same group. In long exposed donors, however, MFs fo r non­
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smokers fe l l  to the control level, while MFs fo r smokers of group 5 s t i l l  
increased. These suggest that smoking as a confounding factor enhances the 
genotoxic effects of the halogenated benzene derivatives in the case of a 
chronic exposure. This enhancing effect of smoking is , however, hidden when 
in  the case of an acute or sub-chronic exposure, an illusory  reduction of 
MFs occurs. The true background of th is  illu s io n  is  not clear but adaptive 
mechanisms as e.g. an increase of DNA repair capacity is  suggested. The ex­
haust of these adaptive mechanisms leads probably to the dramatic increase 
of MF in the case of the long-term exposed workers.
Stimulation (PHA%) is  an important factor of VF according to the 
mathematical formula of Strauss and A lb e rtin i /14/. As no s ign ifican t d if ­
ferences of PHA% values were found among the exposed smoker and non-smoker 
donors no s ign ifican t alterations were observed in the ir VFs. VF values in ­
crease paralle l to the PHA% according to the length of exposure and remain 
stable at a high leve l in  group 5. Chemical exposure depending upon the time 
increases the average variation frequencies of mutations. Figure 1 demon­
strates that there are subpopulations of the chemically exposed groups 
(groups 3, 4, and 5) with considerably high VF.
The average DNA repair capacity of the industria l controls (group 2) 
increased 1.38 times as compared to that of the h is to rica l control (group 1, 
in  Figure 2). No fu rthe r increase was observable in the exposed groups 
indicating that the influence of the chemical exposure is  not s ign ifican t. 
The working environment i ts e lf  regardless of the dominating exposing factor 
has a stimulatory e ffec t upon the RC. A tendency of RCs is  clear in Figure 2,
i . e . ,  chemical exposure increases RCs independently of i ts  lenght. Smoking, 
as i t  is  indicated in  Table I I I ,  trends to be a confounding factor in ­
creasing RCs s lig h tly  but not s ign ifican tly  in  a l l  cases.
These results seem to confirm our hypothesis /15/ suggesting that 
human T lymphocytes are able to accommodate to chemical affections by adap­
tiv e  mechanisms. Smoking its e lf  may give a permanent stimulatory effect 
helping the immune system in the development of adaptive responses. In non- 
smokers, such an adaptation to chemical exposures takes approximately 10 
years. However, chemical exposure induced lower MFs in smokers during the 
same period, but over 10 years of exposure MF showed a further increase. In 
contrast, VF do not increase permanently according to the duration of expo­
sure i t  remained stable in  the long-exposed group. As VF includes PHA% which 
had been decreased to the control level in  group 5, th is  s tab iliza tion  seems 
to be explainable by a reduced PHA stimulation of PBLs. Tompa observed the
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same tendency among uranium miners and aluminium plant workers (unpublished 
data).
The expression of the DNA damage as a mutation needs certain time 
/13/ depends upon the individual sens itiv ity , the actual p ro lifera tion  ra te , 
and DNA repair capacity of the target T lymphocytes. The repair processes 
can minimize or even eliminate mutations as consequences of DNA damage /9 / .  
Therefore donors with in tac t repair system have also less risk of persisting 
mutations at a given chemical exposure than those with decreased repair 
capacity.
Since the estimation of RC is an essential informative factor in  r is k  
assessment, i t  is  important to measure the amount of the primary DNA lesions 
e.g. single-strand breaks (SSB) /8 /, or DNA adducts. For th is purpose thete 
is  an urgent need for adequate and accurate methods in  population monitoring 
/10, 11/. In the case of occupational risk  assessment we also need fu rther 
information about other end points as chromosome aberrations re flec ting  to 
true mutational events, and SCE. In th is  prescreening we would have data 
about the very f i r s t  steps of DNA damage occurring as SSBs and SCEs fore ­
casting the conversion of DNA damage into mutation.
This proposed more complete panel can help in  amore accurate under­
standing of the genotoxic consequences of the occupatuonal and/or environ­
mental chemical exposure and can also help in  a correct occupational r is k  
assessment.
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IMMUNOLOGY
RELATIONSHIP OF SERUM ANTIHISTONE ANTIBODY LEVEL 
TO THE PATIENT'S AGE
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Department of C lin ica l Chemistry and * ls t  Department of Medicine, 
University Medical School, Pécs, Hungary
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The serum antihistone antibody (AHA) p o s it iv ity  of patients with various autoimmune 
diseases was compared with th e ir  positive reaction fo r  antinuclear factor, rheumatoid factor, 
lupus erythematosus factor, kryoglobulin, immunocomplex, C-reactive protein, to ta l prote in , 
gamma globulin, IgG and IgM. In non-drug-induced SLE cases the predictive value of the AHA test 
was not higher than that of the other tests. I t  was s tr ik in g  that in  42% of patients w ith non- 
autoimmune disease aged over 70 the AHA test was pos itive . Elevated IgM values were recorded in 
about 70% o f positive AHA samples.
Keywords: Antihistone antibody, autoimmune diseases, age, imnunoglobulins, myeloma
In tro d u c tio n
A special feature of autoimmune (AI) diseases is  an immune response 
characterized by the appearance of antibodies generated to antigens hardly 
demonstrable, i f  at a l l ,  in  healthy subject. The commonly known antigens are 
localized in in trace llu la r compartments and are highly conserved molecules 
such as DNA, histones and essential enzymes. Currently the view is  held that 
autoimmune diseases can be diagnosed, f i r s t  of a l l ,  by a variety of what are 
called "sets" of antinuclear autoantibodies (ANA) raised against the nu­
cleus, nucleolus or cytoplasmic antigens. These "sets" are either disease- 
specific (anti-native DNA; anti-SM: in SLE) or may be present in  several 
diseases, varying in prevalence (antihistone in SLE, in drug-induced lupus)
O ffp rin t requests should be sent to: K. lobst, H-7624 Pécs, Ifjúság u. 13, Hungary
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/1 , 5, 15/. Of the disease-specific "sets", the histone antigens were of 
special interest fo r us.
In our ea rlie r studies on the bio- and histochemistry of glycated 
histones /8, 11, 12/ we also reported that in  the liv e r  ce ll nuclei of pa­
tie n ts  who had died of diabetes mellitus the level of glycated histones was 
found s ligh tly  elevated — in contrast with healthy subjects, who showed no 
such elevation /9 /.
Therefore, in  collaboration with the Biotechnical Laboratory of the 
University of Pécs, we launched a programme to prepare an antiglycohistone 
antibody and to develop an ELISA test. These w i l l  be reported elsewhere. On 
the other hand, we have studied the incidence and prevalence of antihistone 
antibody (AHA) in autoimmune diseases /4, 15, 18, 25/. I t  was in the course 
of these studies that an increased AHA p o s itiv ity  of elderly subject, mainly 
in  those over 70 years of age, made its e lf  conspicuous. Our investigation 
in to  th is  problem is  presented here as a f i r s t  attempt.
Material and Method
We examined the serum AHA a c tiv ity  in patients treated fo r autoimmune diseases in  the 
1st Department of Medicine, Department of Dermatology and Department of Neurology o f the Uni­
v e rs ity  Medical School o f Pécs fo r years. The c lin ic a l diagnoses were lent support to by the 
resu lts  of routine measurement o f the antinuclear factor (ANf), rheumatoid factor (Rhf), lupus 
erythematosus factor (LE f), immunocomplex (IC), cryoglobulin (c ry ), C-reactive protein (CRP), 
to ta l protein, gamma g lobu lin  calculated from electrophoretic separation, determination of IgG 
and IgM by nephelometry in  61 patients with autoimmune disease and in 28 with nonautoimmune 
diseases, a l l  aged between 30 and 60-years: The currently accepted routine methods recommended 
by the IFCC were used throughout.
Furthermore, AHA examinations were conducted in  42 dermatological and neurological pa­
t ie n ts  aged less than 70, the diagnosis of autoimmune disease was established by various labo­
ra to ry  methods. The AHA a c t iv i ty  of 34 multiple myeloma (Ж ) patients was determined in  the 
course of the ir haematological treatment and regularly checked by us.
A separate group comprising a to ta l of 53 surg ica l, ophthalmological, orthopaedic, 
traumatological and nonsurgical patients aged over 70, admitted with non-immune diseases on the 
basis of the ir case h is to rie s  and c lin ic a l pictures, also had th e ir AHA determined.
Serum antihistone was determined with the semiquantitative ELISA k i t  of the firm  BI0LAB 
(Wavre, Belgium). The p rin c ip le  o f the test is  tha t the to ta l histone (H l, H2A, H2B, H3 and H4) 
adsorbed to the wall o f the w e ll forms a complex w ith the serum antihistone antibody, then the 
complex is  reacted w ith anti-IgM , IgG globulin, marked w ith peroxidase; then i t  is  solub ilized 
and the colour developed from the ABTS (azino-benzthiazoline sulphonate) peroxidase substrate 
is  measured at 405 nm. At evaluation, the 0D values of the negative and positive controls and 
+_ 2 S.D. of the healthy population were taken in to consideration.
Table I
The results of the various examinations of autoimmune (n = 61) and control (n - 28) patients
Diagnosis n ANF LEf RHf IC KRYO CRP IgG Icfl AHA TPR0T X glob
Autoimmune SLE 7 6/7 6/7 4/7 3/7 4/7 1/7 2/2 1/2 2/7 2/7 4/7
patients
Chronic active hepatitis 12 6/12 3/12 5/12 6/12 4/12 4/12 3/3 2/3 3/12 5/12 9/12
Raynaud's disease 16 3/16 2/16 0/16 2/16 1/16 0/16 0/6 1/6 3/16 0/16 5/16
Collagenosis 13 8/13 5/13 3/13 2/13 3/13 5/13 1/4 0/4 1/13 2/13 2/13
Rheumatic a r th r it is 10 7/10 1/10 7/10 10/10 6/10 7/10 0/4 2/4 2/10 0/10 2/5
Scleroderma 3 3/3 1/3 3/3 3/3 1/3 0/3 0/3 0/3 0/3
Total: 61
Control Asthma bronchiale 3
patients
Migraine 1
Polymyositis 4 ALL TESTS ARE NEGATIVE
Hepatic c irrhosis  4 2/4 2/4
Others 16
Total: 28
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Results
Table I  shows the results of the ten d iffe ren t tests widely used in 
the diagnosis of autoimmune diseases in addition to the AHA tes t. In spite 
of the low patient number within the ind iv idual autoimmune disease groups, 
none of them did a l l  the traditonal tests give positive resu lts. Tust the 
opposite was true. This also holds true of the AHA tests whose re lia b il i ty  
was occasionally in fe r io r  to the other tests used here or whose p o s itiv ity  
was, at the most, iden tica l with them. In 10 healthy controls of sim ilar 
age, the results of a l l  examinations were negative.
Table I I  presents the results of 42 patients aged between 40 and £5 
followed only by the AHA test and c lin ic a lly  diagnosed as affected with 
autoimmune disease. In Table I I I  the surprising result obtained fo r the 34 
MM patients is  indicated /20/. The rate of positive AHA values was essen­
t ia l ly  the same as in  Table I :  10% of the cases were positive in contrast 
with the 44% and 33% incidence of SM and SLE cases, respectively.
Table I I
Serum values o f autoimmune patients aged under 70 examined 
with the AHA test
Diagnosis n AHA-positive
SLE (ch ild ren) 3 1
Dermatological autoimmune patients 21 2
M ultiple sc le ros is 18 8
Total: 42 11
Table I I I
Results o f the AHA reaction in 34 m ultip le myeloma patients
n AHA-positive
M ultip le  myeloma 34 3
under 70 years 29 0
above 70 years 5 3
IgG type 24 2
IgA type 7 1
IgM type 3 0
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I t  was remarkable that the 3 positive samples (2 IgG, 1 IgA of the 
34 MM patients) were those of 5 MM patients aged over 70, while in  the 29 MM 
patients under 70 the results of the test were negative. This finding raised 
the idea of a possible relationship between the patients' age and serum AHA 
a c tiv ity .
According to the results in  Table IV, of the 55 patients over 70 
years of age treated for nonautoimmune diseases, 23 (42%) gave positive AHA 
reaction. Here, in addition to the 28 patients under 70 presented in  Table 
I ,  the 10 patients aged between 10 and 30 years also admitted with non­
autoimmune diseases whose sera showed no AHA a c tiv ity  served as negative 
controls.
Table IV
Results of the AHA examination of 55 patients 
aged over 70 treated fo r nonautoiinnune diseases
n AHA-positive
Internal medicine 38 17
Ophthalmology 2 1
Orthopaedics 6 2
Traumatology 4 1
Surgery 5 2
Total: 55 23
The serum to ta l protein, gamma globulin, IgG and IgM values of the 
AHA positive and AHA negative subjects aged under 70 years were compared. In 
to ta l protein (Fig. l /а) there was no difference between the two groups, in 
contrast with the more elevated value of gamma globulin in the AHA positive 
group (Fig. 1/b). The IgG value (Fig. 2/a) showed no appreciable deviation 
(33% and 38%). At the same time, the IgM concentration (Fig. 2/b) was 
elevated in about 70% of the AHA-positive cases, while in negative cases in 
only 37%.
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Fig. 1. Serum (a) to ta l protein and (b) gamma globulin concentration 
o f AHA positive and negative patients aged under 70
Fig. 2. (a) IgG and (b) IgM levels of AHA positive  and negative patients 
aged under 70 years
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Discussion
According to current views /23 /, with which the present authors agree, 
an immune response is  characteristic of each of the autoimmune diseases: on 
the one hand, a particular antibody is  recognizable in one disease and not 
in another; on the other hand, each of the autoimmune diseases can be 
characterized by a particular antibody p ro file . I t  is  largely these two 
t ra its  that enable the various autoimmune diseases to be easily d iffe ren ­
tia ted and diagnosed. H is to rica lly  the antibodies to DNA and histones were 
the f i r s t  to be w ritten of, then antibodies to nucleocytoplasmic nonhistone 
proteins and RNA complexes were iden tified  and characterized /16/.
Research on the d ifferent antibodies of great d iversity is  hampered, 
to a considerable degree, by thousands of in trace llu la r proteins, hardly 
iden tified , there may certainly be more effective antigens than the nucleic 
acids of conservative structure. Low immunogenicity applies also to core 
histones, in contrast with extranucleosomal histones, which give antiserum 
of high t i t r e  with Freund's adjuvant /16/. According to the lite ra tu re  /3 , 
22/, antibodies to ss-DNA (single-stranded DNA) and histones are of diag­
nostic importance, f i r s t  of a l l in drug-induced autoimmune diseases /7 , 17, 
19, 24/. In th is  respect our investigations have furnished no d irect data. 
On the one hand, no such patients were available for us, and on the other, 
we made neither anti-ss-DNA nor anti-ds-DNA (double stranded DNA) examina­
tions.
Our results (Table I)  show that p o s itiv ity  of the AHA test is  no mûre 
characteristic of our middle-aged autoimmune patients than are the other 
tests mentioned above /6, 21/. On the basis of th is , we believe that none of 
the disease groups studied by us is  characterized by an elevated AHA t i t r e .  
Occasionally, the explanation of th e ir p o s itiv ity  is  jus t as open as in  the 
case of the other tests. There is  no doubt that higher IgM values were found 
in a higher number of patients with elevated AHA t i t r e ,  while IgG showed no 
such difference. This observation is  in agreement with the data on immuno­
globulin putlished in cornection with to ta l histone and histone frac­
tions /10/.
Besides the communications on the diagnostics of AI diseases published 
to date, elevated AHA values in about 42% of AI negative patients over 70 
years may be regarded as a new observation. In accordance with th is , the IgM 
concentration of AHA positive patients was 70%.
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I t  was not the aim of the present study to re-examine the wide range 
of autoimmune diseases with the currently available methods, neither to 
assess the ir diagnostic value or to draw conclusions as to aetiology. Others 
had done th is  before us. Our earlier investigations into histones enabled 
the present p ilo t  study of the diagnostic value of AHA, on which only few 
lite ra ry  date are available. In the course of th is  study the AHA reaction 
turned out to be positive in about 42% of old subjects who showed no sign 
indicative of an autoimmune process. This observation also confirmed our 
view that the resu lts of tests used in the diagnosis of autoimmune diseases 
should be evaluated cautiously. The presence of an autoimmune disease should 
be only be established i f ,  in addition to the result of a combination of 
several antibodies, the patient's age has also been considered. A further 
piece of information may be expected from the AHA test, which, however, 
gives just as l i t t l e  information as the diagnostic procedures used so fa r. 
This opinion may be suprising i f  one considers that in SLE, the most 
thoroughly studied disease /22/, the pathogenetic importance of antibodies 
is  accepted. At the same time, i t  has not yet been c la rif ie d  whether the 
rest of autoantibodies exert the ir pathogenetic effect through immune com­
plexes or via other mechanisms. The question is  further complicated e.g. by 
the immunogenicity of HI histone being more or less evenly d istributed along 
the polypeptide chain. This enables specific  antibodies, corresponding to 
the d ifferent s truc tu ra l domains of the molecule, to be formed /2, 13/. 
These antibodies might some day play a ro le  in  the study of proteins ss well 
as chromatin and thus also in the diagnosis of the d iffe ren t autoimmune 
diseases.
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EFFECT OF VITAMIN E ON THE IWUNOREACTIVITY OF SPLEEN CELLS IN  
HYPERLIPIDAEMIC RATS
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Atherogenic ( l ip id - r ic h )  d ie t suppressed mitogen-induced lymphocyte blastogénie re ­
sponses in  ra ts . Supplementation with vitamin E completely abolished the suppressive e ffe c t of 
the d ie t. The atherogenic d ie t also decreased the tumour necrosis factor alpha (TNF-Ot.) a c t i­
v ity  produced by spleen macrophages, however, vitamin E supplementation fa iled  to abolish th is  
e ffec t. Oiet or supplementation had no measurable action on interleukin-1 (IL-1) production of 
macrophages.
Keywords: Vitamin E, hyperlipidaemia, immunoreactivity
In tro d u c tio n
The regulatory e ffect of hyperlipidaemia concerning ce llu la r immune 
functions is  well known: plasma lipoproteins in h ib it  mitogen-induced lympho­
cyte activation /6, 11, 16, 17, 20, 21, 24/. In a previous study /31 /, we 
have shown that l ip id  rich  diet markedly suppressed mitogen induced blasto- 
genesis; PHA and Con-A induced blast transformation of spleen ce lls  isolated 
from hyperlipidaemic rats was s ign ifican tly  decreased.
Vitamin E supplementation is  known to enhance humoral and cell-m ediat­
ed immunity and augment the efficiency of phagocytosis in laboratory ani­
mals, farm animals, and humans /34/. Therefore, there is  a considerable
O ffp rin t requests should be sent to : Rhenso González-Cabello, 1088 Budapest, Szentki­
rá ly i u. 46, Hungary
Akadémiai Kiadó, Budapest
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in te re s t of vitamin E therapy of diseases in  which free-radical reactions 
are involved /1, 2, 7, 12, 14, 18, 22, 36/. Vitamin E protects membranes 
from oxidative damages by interfering with free rad ica l-in itia ted  chain 
reactions of polyuns.aturated fa tty  acids /18 /. The pathogenic ro le  of free 
ra d ica l reactions and l ip id  peroxidation have already been described in 
hyperlipidemia /3, 4 /, as well as, in the deranged function of lymphocytes 
and monocytes /28, 32/. The effect of vitamin E on serum lip id s  and on 
lipoprote ins varies, but in most studies no significant changes were 
observed /9, 13, 15, 19, 27, 29, 30, 33, 35/.
In the present study the effects of vitamin E treatment were deter­
mined on cell-mediated immunoreactivity in  hyperlipidaemic rats.
M a te ria ls  and Methods
Experimental hyperlipldaemla
Young male Wistar albino rats weighing 150-200 g were used. Animals were divided into 
3 groups, each consisting o f 20 animals. The animals o f group I  were fed with normal LATI chow 
(Gödöllő, Hungary). The animals o f group I I  were fed w ith atherogenic d ie t consisting of 2.0% 
cho leste ro l, 20% sunflower o i l  and 0.5% cholic acid added to the control LATI chow. Animals of 
group I I I  were fed with the same lip id  rich  d ie t and treated with 8.56 mg/kg body weight 
v itam in E (НЕК-Pharma, GFR) fo r  9 days, mixed in to  the d ie t. The rats were k il le d  by decapita­
t io n  a t the 9th day /3 /.
Lymphocyte pro life ra tion  assay
Cells obtained from perfused ra t spleens were suspended in RPMI 1640 tissue culture 
medium (Gibco, USA) supplemented with 10% heat inactivated fe ta l ca lf serum (Phylaxia, Hunga­
r y ) ,  25 mM HEPES buffer (SERVA, GFR), 2 mM L-glutamine (Gibco, USA), 10 IU/ml p e n ic ill in ,  
100 pg/ml gentamicin and 7.5 pg/ml amphotericin B. 4 x  lO-’ spleen ce lls in 200 p i medium were 
placed in each flat-bottomed microplate wells (Greiner, GFR) using four pa ra lle l samples. 
Concanavalin A (Con-A, Pharmacia, Sweden), in doses o f 1, 5 and 10 p l/m l, was added to  the c e ll 
suspensions. Control cultures without lec tin  were included in each experiment. The plates were 
incubated at 37 °C in a humidified atmosphere with 5% CO2 fo r 72 h. The cultures were pulsed 
w ith  0.4 pCi ^H-thymidine (UVVR, Czechoslovakia) 24 h before termination. The c e lls  were har­
vested on f i l t e r  paper disks by an automated sample harvester (Skatron, Norway). Isotope deter­
minations were made in a liq u id  s c in tilla tio n  counter (Nuclear Chicago Isocap 300, USA). The 
re s u lts  were expressed in  cpm using the arithm etic mean of four replicate values /1 0 /.
Preparation of monocytes
Rat splenocytes were isolated as described above. Monocytes were separated by adherence 
to  p la s tic  surface. 10 x 106 ce lls /m l were seeded in  24-well tissue culture plates and allowed 
to  adhere for 2 h at 37 °C in  a humidified atmosphere containing 5% C02. Nonadherent c e lls  were 
removed by vigorous washing w ith  warm culture medium. The adherent ce lls  were harvested from 
the monolayer by scraping w ith a rubber policeman, then washed twice and f in a lly  resuspended in 
complete medium RPMI 1640 to a concentration of 1.5x10^ cells/m l /25/.
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Triggering IL-1 and TNF-ft, release
Monocytes (1.5 x 10  ^ cells/m l) were incubated in  the presence or absence o f 20 pg/ml 
lipopolysaccharide (LPS from E. c o li 0111:B4, Sigma, USA). A fter 24 h, ce ll-free  supernatants 
were harvested by centrifugation to remove ce llu la r debris and f i l t e r  s te rilized  using 0.22 (jm 
M illipore membrane f i l t e r .
Interleukin-1 assay
Interleukin-1 a c t iv ity  was assayed in the culture supernatants as described previously 
/25 /. B r ie fly , thymocytes from 5- to 7-week-old C3H/HeJ mice were prepared as sing le  c e ll 
suspensions and adjusted to the density 1.5 x 10  ^ c e lls /w e ll. They were cultured fo r  48 h at 
37 °C in  96 well flat-bottomed m icro tite r plates in the presence of 1 pg/ml Con A and test 
supernatant f lu id s . A fte r 48 h, the cultures were pulsed with ^H-thymidine. Thymidine incorpo­
ration was determined in a liq u id  s c in tilla tio n  counter. The results were expressed in  c.p.m. 
using the arithmetic mean of quadruplicate cultures. In the majority of experiments the super­
natants were diluted 1:8 p rio r to assay.
TNF-ас, assay
TNF-ft; a c t iv ity  was assayed as described elsewhere /26 /: TNF cytotoxic a c t iv i ty  was 
measured by the a b il i ty  of LPS-stimulated monocyte supernatants to cause detachment from the 
monolayer of ^H-thymidine labelled HEp-2 target c e lls . In b r ie f ,  HEp-2 target c e lls  were cu l­
tured in  Eagle's MEM enriched with 10% heat-inactivated fe ta l ca lf serum, 25 mmol/1 HEPES, 
2 mmol/1 L-glutamine and an tib io tics . A fter discarding detached, dead ce lls  with the super­
natant medium, HEp-2 ce lls  were resuspended with 0.5 ml o f 0.1% trypsin (Sigma, USA) in  medium 
TC 199, then washed twice. Resuspended HEp-2 target c e lls  (2 .5 x 103 ce lls /w ell) were placed in 
96-well f la t  bottom m icro tite r plates, then labelled with 0.4 pC i/well of t r it ia te d  thymidine. 
To each well test supernatant f lu id  was added and the cu ltu re plates were incubated fo r  24 h at 
37 °C in a 5% CO2 atmosphere. Target ce lls  incubated in  medium alone were included in  each 
experiment. A fter 24 h, the detached target ce lls  were removed. The remaining adherent ce lls  
were frozen at —20 °C. A fter thawing, the content of wells was sucked o ff  on to f i l t e r  mats 
with a c e ll harvester. Incorporated rad ioactiv ity  was determined by s c in ti lla tio n  counting. 
Results from six rep lica te  values were expressed, as mean c.p.m. The percentage of c y to to x ic ity  
was calculated taking the medium control as baseline /26 /.
Assays of serum lip id s
Sigma k its  were used fo r measuring serum lip id s ,  HDL-cholesterol, tr ig lyce rid es  and 
cholesterol.
S ta tis tic a l analysis was performed with Student's t_-test.
Results
Triglyceride levels of sera failed to change in groups I I  and I I I  as 
compared with those of controls (1.294^0.359 mmol/1). The to ta l cholesterol 
level of sera was s ign ifican tly  higher (4.3 fo ld) in hyperlipidaemic rats 
(7.970^2.57 mmol/1), but vitamin E treatment did not diminish the elevated 
level in th is  "short-term" experiment. The HDL-cholesterol leve l was
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Table I
The effect o f atherogenic d iet and vitamin E treatment on the lymphoblast 
transformation of ra t spleen ce lls  
(thymidine Incorporation, mean cpm ±  S.E., n = 20)
T reatment 
Group 0 1
Con A (p g /m l)  
5 10
I  Control 627 + 79 58324 + 8242 81181 + 7447 72061 + 6340
I I  Atherogenic 441 + 67 25738 + 5566 47928 + 7166 34996 + 6947
I I I  Atherogenic 616 + 76 56072 + 9007 83084 + 6070 73100 + 4198+ vitamin E
significance: P
Con A 1 pg/ml I  vs I I < 0.01
I  vs I I I n.s.
I I  vs I I I < 0.001
Con A 5 pg/ml I  vs I I < 0.01
I  vs I I I n.s.
I I  vs I I I < 0.001
Con A 10 pg/ml I  vs I I < 0.001
I  vs I I I n.s.
I I  vs I I I <  0.001
Table I I
E ffect of atherogenic diet on the TNF-alpha a c tiv ity  of ra t 
spleen macrophages (mean cy to tox ic ity  \  ± S .E ., n = 20)
Treatment
group Untreated LPS-treated
P*
I  Control -5.9 + 6 20.8 + 3.4 < 0.01
I I  Atherogenic -6.2 + 4.6 1.8 + 4.6 n.s.
I I I  Atherogenic 
+ vitamin E
-8.4 + 3.4 -5.1 + 4.7 n.s.
significance: P
untreated I VS I I n .s.**
I vs I I I n.s.
I I vs I I I n.s.
LPS-treated I vs I I <0.01
I vs I I I <0.001
I I vs I I I n.s.
^significance (untreated versus LPS-treated) 
**n .s .: not s ign ifican t
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Table I I I
Effect of atherogenic d ie t on the IL-1 a c t iv ity  of ra t spleen macrophages 
(thymidine incorporation, mean c.p.m. ±S .E .)
T reatment 
group (n) Untreated
LPS-treated P*
I  Control (13) 762 + 163 1938 + 209 <0.01
I I  Atherogenic (13) 1383 + 227 1864 + 155 n.s.
I I I  Atherogenic 
+ vitamin E (8)
742 + 85 1779 + 336 <0.01
significance: P
untreated I  vs I I <0.02
I  vs I I I n .s .**
I I  vs I I I < 0.05
LPS-treated I  vs I I n.s.
I  vs I I I n.s.
I I  vs I I I n.s.
*significance (untreated versus LPS-treated) 
**n .s .: not s ign ifican t
1.543 ^0.215 mmol/1 in control animal sera, and i t  was lower in hype rlip i- 
daemia (1.33^0.40). Vitamin E treatment was s im ila rly  ineffective.
The decrease of lymphocyte blast transformation of lymphocytes caused 
by l ip id  rich diet was abolished by vitamin E treatment (Table I ) .  Lipid 
rich  d ie t s ign ifican tly  decreased the LPS-induced TNF-a a c tiv ity  of mono­
cytes. Vitamin E treatment fa iled  to abolish the suppressed TNF-ос, a c tiv ity  
(Table I I ) .  As shown in Table I I I ,  the LPS-induced IL-1 a c tiv ity  of mono­
cytes was not changed by e ither the lip id  rich  d iet or the vitamin E tre a t­
ment .
Discussion
As shown earlie r /31 /, atherogenic d ie t resulted in a suppressed 
blastogénie response to plant mitogens. Vitamin E, added to the d ie t, com­
ple te ly  abolished the suppression. TNF-06 a c tiv ity  of spleen ce lls  was also 
decreased by the d ie t, however, vitamin E supplementation fa iled to abolish 
the suppressive e ffect. The d iet exerted no measurable e ffect upon LPS- 
induced IL-1 a c tiv ity  of spleen ce lls .
Since vitamin E supplementation fa iled  to a lte r serum lip id s ,  we 
suggest that i t s  effect should be exerted in d ire c tly . Vitamin E, as an a n ti­
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oxidant, protects the c e lls  of the immune system from peroxidative damage; 
possibly through a modulation of lipoxygenation of arachidonic acid, vitamin 
E a lte rs  ce ll membrane functions and c e ll-c e ll interactions /8, 34/. Short­
term vitamin E supplementation improves immune responsiveness in healthy 
e lderly  individuals; th is  effect appears to be mediated by a decrease in 
prostaglandins snd/or other lipid-peroxidations products /23/.
According to the protective effect upon immune reactiv ity  of vitamin 
E, a continuous d ie ta ry supplementation is  recommended, in particu la r in 
cholesterol rich d ie t, and possibly, in hypercholesterolaemic states.
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A study of hepa titis  В and D virus markers in  118 hepatitis  В virus seropositive 
patients suffering from h is to log ica lly  confirmed chronic liv e r  disease is  reported. The 
prevalence of hepatitis delta in fection amounted to 13.6%, whereas active hepa titis  de lta v irus 
rep lica tion  was proven in 6 of the cases. On the basis of these findings, conclusions — sim i­
la r  to  those published e a rlie r — are drawn about the ro le  of hepatitis delta v irus  in  the 
progression of chronic l iv e r  diseases. I t  is  suggested that HBsAg-IgM complex se ro po s itiv ity  in 
patients suffering from an ti-de lta  positive chronic liv e r  disease supports active h e pa titis  
delta v irus rep lica tion .
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Introduction
The delta agent (hepatitis  D virus) was f i r s t  described by Rizzetto et 
a l.  in 1977 /20/.
HDV infection may occur as coinfection and superinfection. The over­
whelming majority of chronic HDV hepatitises develop subsequent to a HDV 
superinfection. Chronic HDV infection causes serious liv e r in ju ry : infected 
patients often develop CAH or live r c irrhosis /2 , 4, 10, 11, 18, 22, 24—26/.
HDV infection occurs worldwide; i t s  prevalence in a population is  
determined by the number of HBsAg ca rrie rs . Anti-HD seropositiv ity in 
symptomless HBsAg ca rrie rs  greatly varies by country and continent. For 
example, i t  was claimed to amount to 20-30% in  Ita ly  and France, 10-20% in 
Sweden, Switzerland and North Africa, 0-5% in  the USA, England, Austria and 
Japan, and to exceed 60% in Roumanie /12, 15, 19, 26, 27/.
Témák et a l. /28 / confirmed the occurrence of HDV infection in 
Hungary in 1985. However, the small number of the cases reported by these 
authors prevented them from determining i t s  incidence rates in individual 
l iv e r  diseases.
In this paper, we intend to analyse the following issues:
1. The ra tio  of HDV infection demonstrable in chronic liv e r  diseases,
2. The ra tio  of active HDV rep lica tion  fo r patients having acquired 
HDV infection,
3. The influence of HDV infection on the severity of chronic liv e r 
diseases,
4. Possible connections between HDV in fection and the serologic mar­
kers of HBV.
P atien ts  and Methods
Our study includes the examination of 118 (86 males and 32 females) patients. The 
diagnosis in a l l  cases was confirmed h is to log ica lly  according to in te rna tiona lly  accepted 
morphological c r ite r ia  /1 , 7 /.  The distribution o f the patients by h isto logica l diagnosis is  
shown in Table I .
The HDV and HBV markers were determined in  the same serum samples. The blood samples 
drawn by venipuncture were immediately centrifuged, the serum samples were stored at -23 °C 
u n t i l  tested. The v irus  markers were determined in  our Radio-Immuno-Assay Laboratory by 
use of commercial Sorin Biomedica k its , v iz . AB-DELTAK (anti-HD) AUK-3 (HBsAg), AB-AUK3 (a n ti-  
HBs), AB-C0REK (anti-HBc), CORE-IGMK (IgM anti-HBc), EBK (HBe, anti-HBe) and AU-IGMK (HBsAg-IgM 
complexes). The IgM anti-HD measurement was performed by Alan G. Shattock in Dublin (Ireland) 
using the Wellcome k i t  in  the ELISA method.
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Table I
The d is tr ibu tion  of patients by h is to log ica l diagnosis
Histo logical diagnosis Number of patients
Chronic persistent hepatitis 2
Chronic active hepatitis 50
Chronic active hepa titis  and 
liv e r  c irrhos is 13
Liver c irrhos is 37
Other liv e r  diseases 
(Steatosis hepatis, 
hepatopathia toxica, 
chronic reactive hepa titis , 
granulomatous hepa titis , 
primary hepatocellular 
carcinoma, 
métastasés hepatis)
16
T o t a l : 118
A ll liv e r  patients admitted to our department are tested fo r HBsAg, anti-HBs and a n ti-  
HBc. I f  a l l  these prove negative, both actual and ea rlie r HBV in fection may be excluded. I f  any 
of the three markers proves positive , we determine the other В and D virus markers as w e ll. 
E arlie r HBV in fection was proven in  a l l  of 118 patients.
Results
The rate of HDV infection fo r each disease group is  shown in Table I I .
Of the 110 patients, 16 (12 males, 4 females) have proved anti-HD 
positive (13.56%), 14 of them suffered from CAH or CAH with liv e r  c i r ­
rhosis.
Of the 16 anti-HD positive patients, IgM anti-HD was determined in 14 
cases. The detailed findings of the В and D virus marker tests of these pa­
tien ts  are shown in Table I I I .
Six (4 males, 2 females) of the 14 patients tested proved IgM anti-HD 
positive (a sign of active HDV in fection). Of these 6 patients, 5 suffered 
from CAH, and the CAH of 1 patient had progressed .to liv e r c irrhosis.
The findings of hepatitis В and D virus marker tests are summarized as 
follows:
A ll the 118 patients examined proved seropositive for anti-HBc, 54 
proved HBsAg positive and 40 anti-HBs positive. Furthermore, 9 patients 
proved positive for both HBsAg and anti-HBs simultaneously.
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Table I I
The ra tio  o f HDV infection In the Individual disease groups
Number of anti-HD
Histological diagnosis Number o f patients positive patients
No. per cent
Chronic persistent hepa titis 2 0 0
Chronic active hepa titis 50 11 22
Chronic active hepa titis  and 
cirrhosis 13 3 23
Liver cirrhosis 37 1 3
Other liv e r diseases 
(steatosis hepatis, 
hepatopathia toxica, 
chronic reactive he pa titis , 
granulomatous he pa titis , 
primary hepatocellular carcinoma, 
métastasés hepatis)
16 1 6
T o t a l : 118 16 13.6
Table I I I
The resu lts o f the detailed hepa titis  В and D virus marker tests
Name
Histological
diagnosis
HBsAG an ti-
HBs
a n ti-
HBc HBe
an ti-
HBe
IgM
an ti-
HBc
HBsAg
IgM
complex
a n ti-
HD
IgM
an ti-
HD
1. B. M. CAH + CIR - - + - - - - + -
2. T. 3. CAH + CIR - + + - - - - + -
3. 0. I . CAH + - + - + - - + 0
4. В. P. CAH + - + - + - + + 0
5. N. S. CAH - + + - + - - + -
6. K. G. 2 CAH - + + - + - - + -
7. N. R. 2 HEP. TOX. - + + - + - - + -
8. G. G. CIR + - + - + - - + -
9. F. F. CAH + - + - + - + + -
10. M. B. CAH - - + - - - - + -
11. V. L. CAH + CIR + - + - + - + + +
12. Z. I . CAH + - + - + - + + +
13. S. I .  2 CAH + - + + - - + + +
14. N. I . CAH + - + - + - + + +
15. L. A. CAH + + - + - - + +
16. H. 3. 2 CAH + - + - + - + + +
Abbreviations: CAH: chronic active hepatitis ; CIR: c irrhos is  hepatis; HEP. TOX: hepatopathia 
toxica
+: positive ; negative; 0: no tes t performed
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Of the 16 anti-HD positive patients, 2 proved positive only fo r anti- 
HBc, 9 for HBsAg, and 4 fo r anti-HBs, in 1 case we observed the simultaneous 
presence of both of the la tte r markers. We emphasize that a l l  IgM anti-HD 
seropositive patients were positive for HBsAg, too.
The presence of HBsAg-IgM complex, a marker indicating the immune re­
sponse to HBsAg was observed in the sera of 34 of the 118 patients. Of the 
34 cases, 7 belonged to the group of the 16 anti-HD positive patients. Of 
the 6 patients suffering from active HDV infection, 5 proved to be sero­
positive fo r the HBsAg-IgM complex.
The sixth — HBsAg-IgM complex seronegative — patient (A .L., patient 
no. 15) — is  identical with the patient in whom we observed the simulta­
neous presence of HBsAg and anti-HBs. Of the two other patients positive 
for HBsAg-IgM complex, one proved negative for IgM anti-HD (F.F., patient 
no. 9), and we were not in the position to examine the other patient (B.P., 
patient no. 4) for IgM anti-HD. IgM anti-HBc, one of the most sensitive 
markers of active HBV in fection, proved positive in 22 of the 118 cases. 
None of the 22 cases belonged to the HDV infected group. The other tested 
marker indicating HBV rep lication, HBe, proved positive in 17 of the 118 
cases. One of these 17 cases belonged to the anti-HD seropositive group. 
This patient (S .I., patient no. 13) proved positive for IgM anti-HD, too.
Discussion
Among our 118 cases, the incidence of HDV infection in  HBV positive 
chronic liv e r  patients was 13.6%.
Of our 16 anti-HD positive patients, 15 suffered from serious active 
liv e r  disease: CAH and/or c irrhosis. I t  should be noted that a l l  the 6 pa­
tien ts  suffering from active HDV infection belonged to the CAH or the 'CAH 
with liv e r  c irrhosis ' group.
Several publications have appeared about a connection between HDV 
infection and chronic liv e r  disease. Arico et a l. examined 2487 symptomless 
HBsAg positive patients, 112 (5%) of whom proved to be seropositive for 
anti-HD. They reported laboratory findings indicating liv e r malfunction 
for 43 of the 112 anti-HD-positive persons (38.4%), while fo r only 215 
cases (9.14%) of the 2375 anti-HD-negative persons. Of the former group, 
h isto log ica l tests were performed in 31 cases. In 19 (61%) of these serious 
liv e r disease (CAH or c irrhosis) was observed, as contrasted with the anti-
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HO-negative cases, in  97 cases of which liv e r  biopsy was performed, and 
h isto logical examination showed serious liv e r  disease in only IB (19%) 
cases /2 /.
Govindarajan et a l . ,  who examined 80 h is to log ica lly  confirmed chronic 
HBs.Ag positive patients, reported similar findings. They found anti-HD 
p o s itiv ity  in patients suffering from CPH in  4.3%, whereas in  patients 
suffering from CAH and/or c irrhosis, they found i t  in 31.5% /12/. According 
to  the data reported by Brunetto et al. on the basis of a study of cirrhosis 
cases distributed by age group, the major aetio log ical factor of cirrhosis 
in  young adults in I ta ly  was HDV infection /3 /.
Our findings, which correspond to those of several other authors and 
the above-mentioned data quoted in the lite ra tu re , confirm the observation 
tha t HDV infection leads to serious live r in ju ry , and enhances the progres­
sion of existing liv e r  disease /2, 3, 5, 10—11, 12, 17, 21, 26/.
Conclusions, based on the analysis of hepa titis  В and Ü virus markers 
of our HDV-infected patients:
IgM anti-HBc p o s it iv ity ,  one of the markers of active HBV infection 
was observed in none of our patients. HBe p o s itiv ity  occurred in only one of 
the 16 cases. Our findings correspond to those reported by other authors in 
tha t the markers of active HBV replication are usually absent in anti-HD- 
seropositive patients, or even in patients showing active virus replication 
at an early stage soon HBe, anti-HBe seroconversion develops /2, 8, 12, 14, 
21, 23, 26/.
Our one and only HBe seropositive patient (S .I.,  patient no. 13) may 
belong to the la tte r group, though during her follow-up — up f i l l  the time 
when our paper was w ritten  — we had not observed seroconversion in her 
case, yet the IgM anti-HBc negativity observed may be interpreted as a sign 
of the suppression of HBV replication.
A ll our patients su ffe ring  from active HDV infection were positive for 
HBsAg, which is inevitab le  in  a ll cases with active HDV rep lication, as 
HBsAg is  a constituent o f the envelope of the delta virus.
We also observed HBsAg-IgM complex seropositiv ity  in 5 of the 6 pa­
tie n ts  suffering from active HDV infection. This marker may be considered 
to be a sign of active immune response to the HBsAg being present in the 
envelope of HDV. The s ix th  patient was negative fo r the HBsAg—IgM complex 
despite his IgM anti-HD seropositiv ity. However, in his case the simulta­
neous presence of HBsAg and anti-HBs suggests tha t, as a resu lt of the 
organism's immune response, chronic virus in fection  reached the stage of
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HBsAg—anti-HBs seroconversion, HBe—anti-HBe seroconversion had taken 
place, the elimination of HBsAg was going on, and the HBsAg-IgM complex had 
disappeared from the c ircu la tion. Negative HBsAg and IgM anti-HD tests to be 
obtained during further examinations can prove the assumption that in th is  
case the e ffic ien t immune response resulted in  the elimination of both 
viruses /6, 13, 16/ and the observed virus marker constellation is  a sign 
of one stage of th is  process. On the basis of what has been mentioned above, 
we believe that HBsAg-IgM complex seropositiv ity observed among other 
markers (IgM anti-HD, HDAg, HDV-RNA) in anti-HD seropositive patients may be 
the evidence of HDV infection with active virus replication.
The main significance of serological diagnostics lie s  in the fact that 
i t  is  c r it ic a l in choosing the appropriate therapy. By the tests described, 
i t  is  possible to exclude or prove active virus replication. In the former 
case, — according to appropriate c rite ria  — immunosuppressive treatment is  
to be considered, while in the la tte r case a n ti-v ira l treatment is  necessa­
ry. For several years a n tiv ira l treatment has been successfully applied in 
liv e r  diseases with active HBV replication, and recently good results of the 
an tiv ira l treatment of active HDV infection have been reported /9 /.
As a summary, the following is  stated:
1. HDV infection was proved in 16 (13.5%) of our 118 HBV positive pa­
tien ts  suffering from h isto log ica lly  proved chronic liv e r  disease.
The rate of anti-HD seropositivity was the highest in the patients 
belonging to the CAH or the 'CAH with c irrhos is ' group (in 14 of the 63 
patients).
2. Of the 16 anti-HD seropositive patients, active HDV rep lication was 
proved — on the basis of IgM anti-HD seropositiv ity  — in 6 cases, a l l  
belonging to the CAH or the 'CAH with c irrhos is ' group.
3. Fifteen of the 16 anti-HD seropositive patients suffered from se­
vere progressive liv e r  in ju ry . This is in accordance with lite ra ry  data and 
is  suggestive of a connection between HDV in fection and the severity of 
liv e r  disease.
4. On the basis of detailed virus serological tests we found that
a) the markers of the active HBV rep lication are usually absent in HDV 
infected patients,
b) a ll cases of active HDV replication are accompanied by HBsAg sero­
p o s itiv ity ,
c) HBsAg-IgM complex seropositivity in anti-HD seropositive liv e r  pa­
tien ts  may support the existence of active HDV infection with virus rep lica­
tion.
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THE SIGNIFICANCE OF DETAILED HEPATITIS B VIRDS SEROLOGY 
IN  CHRONIC LIVER DISEASES
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Hepatitis В v irus (HBV) markers were studied with Sorin RIA k its  in serum samples from 
390 patients suffering from h is to log ica lly  confirmed chronic liv e r  disease. On the basis of 
negative HBsAg, anti-HBs, anti-HBc tests, HBV in fection was excluded in 235 of the cases. The 
diagnosis was fa tty  liv e r  and/or alcoholic hepatitis  in 52%, while chronic active he pa titis  
and/or l iv e r  c irrhosis  only in  21.7%. Part or present HBV in fection  was proven in 155. In 53% 
of these cases the diagnosis was chronic active hepa titis  and/or liv e r cirrhosis, whereas fa tty  
l iv e r  and alcoholic hepa titis  occurred in 27.7%. Detailed HBV marker analysis was performed in 
76 patients. Previous in fection  without rep lication (pos itive  anti-HBs and/or anti-HBc and/or 
anti-HBe) was proven in 48 cases, 12 patients had active HBV in fection (positive HBsAg, HBe, 
IgM anti-HBc), while in 16 cases HBV integration (pos itive  HBsAg, anti-HBc, anti-HBe) was 
proven. HBsAg-IgM complex seropos itiv ity  was shown in  every case with active HBV rep lica tion . 
Because of therapeutic, prognostic and epidemiologic reasons, the significance of detailed HBV 
serology in  chronic liv e r  diseases is  stressed.
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In tro d u c tio n
Trail-blazing work in  the id e n tifica tion  of HBV is associated with the 
names of Blumberg et a l. and Dane et a l. ,  in  the f i r s t  place /3 , 4, 10/. 
A fte r the surface(s) (Australia) antigen-antibody system was described, 
Almeida et a l. reported on the core antigen-antibody system in 1971 /1 /.  In 
1972 Magnius and Epsmark described the ' e ' antigen-antibody system /21/. 
These antigens and antibodies — as a consequence of HBV infection — can be 
detected in the patients' serum and th e ir l iv e r  tissues. According to data 
published in the lite ra tu re , HBV infection may be proved in various chronic 
l iv e r  diseases. The incidence rate of HBV p o s itiv ity  depends on the popula­
tio n  examined and the se ns itiv ity  of the laboratory methods applied /9 , 15, 
23/. The conclusions drawn on the basis of the seropositivity and dynamics 
of HBV antigens and antibodies are of utmost significance in the therapy, 
prognostics and epidemiology of liv e r diseases.
In th is  paper, we make attempts to answer the following questions:
1. In what rate is  earlie r or actual HBV infection detectable in  pa­
tie n ts  with chronic l iv e r  disease?
2. Does HBV in fection affect the severity of liv e r diseases?
3. What conclusions can be drawn from the results of detailed HBV 
marker tests?
4. Is there any connection demonstrable between the various stages of 
HBV in fection  and the severity of liv e r disease?
P a tie n ts  and Methods
Our examinations concerned 390 (333 males, 57 females) patients aged 15—74 (average: 
43.05) yrs . The diagnosis in each case was confirmed h is to log ica lly  according to in te rna tion­
a l ly  accepted morphological c r ite r ia  /2 , 13/. The d is tr ib u tio n  of the patients according to 
h is to lo g ic a l diagnosis is  shown in  Table I .
The various HBV markers were determined in the same serum samples. The blood drawn by 
venipuncture was immediately centrifuged, and the serum samples were stored at -25 °C u n t il 
tested. The virus markers were examined with commercial Sorin Biomedica k its  in  our Radio- 
Immuno-Assay Laboratory, v iz . HBsAg with AUK-3, anti-HBs with AB-AUK-3, anti-HBc w ith AB-COREK, 
IgM anti-HBc with CORE-IGMK, HBe and anti-HBe with EBK and HBsAg-IgM complex with AU-IGMK k its .
A l l  liv e r  patients admitted to our department, as a routine, undergo HBsAg, anti-HBs 
and anti-HBc tests. I f  a l l  three prove negative, both actual and ea rlie r HBV in fection  may be 
excluded. I f  any of the three markers proves pos itive , the other HBV and HDV markers are also 
determined.
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Table I
The d is tr ibu tion  of the patients by h is to log ica l diagnosis
H isto log ica l diagnosis Number of patients
In tact liv e r  tissue 2
Steatosis hepatis and 
alcoholic hepatitis
165
Chrpnic persistent hepatitis 46
Chronic active hepatitis 39
Chronic active hepatitis with 
l iv e r  c irrhos is
31
Cirrhosis hepatis 63
Other l iv e r  diseases 
(nonspecific hepatitis , 
granulomatous hepatitis , 
glycogenosis, 
hepatocellular carcinoma)
44
T o t a l : 390
R esults
Of the 390 patients examined, the HBV marker, a sign of HBV in fection , 
was positive in 155 cases (125 males, 30 females, average age: 48.21 y rs ) ,
i.e . in 39.7%.
On the basis of negative HBsAg, anti-HBs and anti-HBc tests both 
actual and ea rlie r HBV infection was excluded in  235 cases (208 males, 27 
females, aged 15-70, average age 39.65 yrs) (HBV-negative group). In th is  
group acute hepatitis  was lis ted  in the anamnesis of 7.2% of the patients, 
while in the HBV positive group the rate.was as high as 21.3%.
Table I I  shows the d istribution  of the patients in the HBV positive 
and negative groups according to h is to log ica lly  confirmed diagnosis.
The disease of 122 patients (52%) of the 235 belonging to the HBV-neg- 
ative group was steatosis or alcoholic liv e r  disease, while 51 of them 
(21.7%) suffered from serious, progressing liv e r  disease (CAH and/or 
c irrhosis). In the HBV positive group, on the other hand, more than ha lf of 
the patients suffered from serious, active liv e r  disease (CAH and/or 
c irrhosis), and only 27.7% belonged to the milder liv e r  disease group (stea­
tosis or alcoholic liv e r  in ju ry).
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Table I I
The d is tr ib u tio n  of HBV-positive and HBV-negative patients 
by h isto logica l diagnosis
Histological diagnosis HBV negative 
(n = 235)
HBV positive 
(n = 155)
Intact liv e r tissue 2 0
Steatosis hepatis and 1 122 1(52%) 43 (27.7%)alcoholic hepa titis
Chronic persistent hepa titis 29 17
Chronic active he pa titis 15 24
Chronic active h e pa titis  with 12 (21.7%) 19liv e r c irrhosis
Cirrhosis hepatis 24 39
Other liv e r diseases: 31 13
(nonspecific h e pa titis , 
granulomatous hepa titis  
glycogenosis, 
hepatocellular carcinoma)
Table I I I
The results o f the detailed HBV serology o f 76 HBV-positive patients
past
HBV i n f e c t i o n  
active integrated
H is to log ica l diagnosis n positive anti-HBs 
and/or anti-HBc 
and/or anti-HBe
HBe and/or
IgM anti-HBc positive, 
HBsAg and HBsAg-IgM 
complex positive, 
anti-HBc positive
HBsAg, anti-HBc, 
anti-HBe positive, 
HBe, IgM anti-HBc 
negative
Steatosis hepatis and 
alcoholic hepatitis 15 10 2 3
Chronic persistent hepa titis 1 1 0 0
Chronic active hepatitis  or
chronic active hepatitis  
w ith  liv e r  cirrhosis
28 11 9 8
C irrhosis  hepatis 29 24 0 5
Other l iv e r  disease
(granulomatous hepa titis , 
aspecific hepatitis, 
hepatocellular carcinoma)
3 2 1 0
76 48 12 16
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We were in the position to perform a l l  HBV marker tests in only 76 of 
the 155 HBV-positive cases. The results obtained are shown in Table I I I .
With the help of detailed HBV marker tests we were able to confirm 48 
past infections ending with elimination of the virus (positive anti-HBs 
and/or anti-HBc and/or anti-HBe). I t  should be noted that in 2 of the 48 
cases only anti-HBs seropositiv ity was detected, a ll the rest -- 46 pa­
tien ts  — proved anti-HBc seropositive, in 12 of these the presence of only 
th is  single marker proved past HBV infection, while in 25 cases anti-HBc and 
anti-HBs seropositiv ity, and in 3 cases simultaneous pos itiv ity  of a l l  the 
three markers proved previous HBV infection.
HBV infection with active virus rep lication was proved in 12 patients 
(positive HBsAg, anti-HBc, HBe and/or IgM anti-HBc).
In 5 cases virus replication was proved by positive IgM anti-HBc 
tests, in 4 patients by positive HBe, while in the serum of 3 patients both 
markers were positive. A ll the patients suffering from HBV in fection with 
active virus replication proved seropositive fo r HBsAg-IgM complex.
The HBV infection of 16 patients had reached the stage of in tegration 
(positive HBsAg, anti-HBc, anti-HBe and negative HBe and IgM anti-HBc).
Table I I I  also shows the d is tribu tion  of the patients in the various 
stages of the infection according to h is to log ica lly  confirmed diagnosis. The 
incidence rate of the liv e r  diseases of d iffe ren t severity in the various 
stages of infection does not d if fe r  s ign ifican tly .
We studied the marker indicating active immune response to HBsAg: 
HBsAg-IgM complex seropositiv ity. The results obtained are shown in  Table IV.
We did not observe the presence of th is  marker in serum samples from 
any of the patients belonging to the 'fought-off HBV in fection1 group.
Table IV
The results of the detailed HBV serology of 
76 HBV-positive patients
HbsAg-IgM comples
HBV i n f e c t i o n
Past Active Integrated
HBsAg-IgM complex 
seropositiv ity
0/48 12/12 5/16+
+ 4 of the 5 patients suffered from HDV in fection  with active 
virus rep lica tion , which accounts fo r th e ir  HBs-Ag-IgM 
complex p o s it iv ity .
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Whereas, a ll the patients suffering from in fection with active virus re­
p lica tion  were HBsAg-IgM complex seropositive. Five of the 16 patients in 
the 'integration phase' proved HBsAg-IgM complex seropositive, and of these 
4 suffered from HDV infection with active v irus replication. This is  what 
explains the presence of the marker mentioned in  the ir case /19/.
Discussion
The incidence ra te  of HBV infection in  patients suffering from chronic 
disease amounts to 39.7% in the present study. The lite ra ry  data about the 
incidence of HBV in fec tion  in chronic l iv e r  disease very widely. Apart from 
geographical, genetic and social factors, the applied laboratory methods of 
d iffe ren t se ns itiv ity  may account for these differences /6, 9, 15, 16, 20, 
23, 26/. According to our observations, the most sensitive marker is  an ti- 
HBc; i t  proved positive  in a ll cases with active virus rep lica tion  and 
integration. In the overwhelming majority (46 of 48) of the cases of past 
HBV infection anti-HBc was detectable. I t  should be emphasized that in one- 
fourth of the patients belonging to the la t te r  group the seropositiv ity  of 
only th is  one marker proved the earlie r HBV infection. This observation of 
ours — anti-HBc seropositiv ity  being the most sensitive marker of HBV in ­
fection — , which we have already stressed /11, 12/, corresponds to the 
findings of Kater and Vögten /20/, Gerber et a l. /16/, Bories et a l. /6 /, 
and Pár et a l. /23 /.
The incidence ra te  of HBV infection in  cases of steatosis hepatis and 
alcoholic liv e r a ffection  was 26%, a rate roughly corresponding to lite ra ry  
data /22, 23, 26/.
Though in the pathogenesis of these diseases primarily alcohol con­
sumption and metabolic diseases are lis te d , the lite ra ry  data and our obser­
vations show that — among the known in ju rin g  factors — the potentiating 
ro le  of HBV in fection  should also be considered, especially in  cases with 
active virus rep lica tion  and infections reaching the integration phase /12/.
The incidence ra te  of HBV infection in  patients suffering from chronic 
hepatitis  and/or l iv e r  cirrhosis in our study amounted to 55.3%, a rate 
which is  lower than the 82% found by Renner et a l. in Austria /24 /, and the 
rate 71% found by Pár et a l. in Hungary /23 /, but higher than the rate of 
31.6% reported by Coates et a l. /8 /.
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In our study, serious progressive liv e r  diseases occurred two and a 
half times as often in the HBV-positive group than in the HBV-negative group 
/53% vs 21.7%).
In the anamnesis of the patients in the HBV-infected group acute virus 
hepatitis occurred three times as often as in  that of the patients belonging 
to the HBV-negative group. However, even in the former group, only every 
f i f t h  patient had had acute virus hepatitis. This fact, on the one hand, sug­
gests that acute HBV infection in the most part of the cases proceeds la ten t­
ly , in a mild anicteric form /1В/. On the other hand, i t  sheds lig h t  on the 
necessity to considet the poss ib ility  of HBV infection and i ts  pathogenic 
role even in  the lack of relevant data in the anamnesis. We believe th is  is  
a further reason why i t  is  essential to perform the virus-serological tests 
in every liv e r  patient. The main significance of detailed virus serology 
lie s  in the determination of the actual stage of HBV infection.
Past infection ending with elimination of the virus is  marked by a n ti- 
HBc or anti-HBs seropositiv ity alone, or jo in t ly ,  or also combined with 
anti-HBe seropositiv ity. The most sensitive marker of these is  anti-HBc.
In our study, we diagnosed active virus replication on the basis of 
positive HBe and/or IgM anti-HBc tests. However, i t  is  important to note 
that today the tracing of HBV-DNA or HBV-DNA polymerase is  also needed to 
prove or exclude active virus rep lication, as we now know that active HBV 
replication may go on even in  cases with HBe and IgM anti-HBc seronegative 
cases, moreover, even with anti-HBe seropositiv ity. Active virus rep lica tion  
may be proved by HBV-DNA, HBV-DNA polymerase, or by the detection of HBcAg 
in the liv e r  tissue /5 , 25/.
Positive HBsAg, anti-HBc and anti-HBe with simultaneous seronegativity 
of the markers indicating active virus replication show that HBV infection 
has reached the stage of integration, i.e .  the virus genome having in te ­
grated in  the nucleus of the liv e r  ce ll is  responsible for HBsAg production, 
without maintaining active replication of the virus. The inflammatory in ­
f i l t r a t io n  of the liv e r  tissue in the integration phase resembles that in 
autoimmune chronic active hepatitis  /25/.
The lite ra tu re  is  poor in data about the significance of HBsAg-IgM 
complex determination /17/. We observed HBsAg-IgM complex seropositiv ity  in 
17 cases, in 16 of which simultaneous virus replication was also observed 
(4 cases concerned HDV rep lica tion). Thus, our findings show that HBsAg-IgM 
complex seropositiv ity may support the continuance of active v irus rep lica­
tion, i.e .  — i f  HDV infection can be excluded — i t  suggests active HBV
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replication /19/. Careoda et a l. /17/ and Toti et a l. /27/ have reported 
s im ila r findings.
The knowledge of the various stages of HBV infection and proving or 
excluding active v irus replication is  essential to the correct choice of 
therapy, since in the la t te r  case, immunosuppressive therapy is  to be 
considered, while in  the former case a n tiv ira l therapy is  necessary /14/. 
Furthermore, i t  should be borne in mind that in  the integration phase, the 
HBV genome integrated in  the nuclei of the liv e r  ce lls  pose a potential 
threat of hepatocellular carcinoma, so the close follow-up of these patients 
is  needed (abdominal ultrasonography and se ria l alpha-l-fetoprotein level 
te s t ) .
Also, the determination of the actual stage of HBV infection has very 
great epidemiological significance, because i t  is  the only method to decide 
i f  a patient may become source of infection (the presence of the markers 
indicating active v irus replication) and i f  vaccination of the patient or 
endangered person is  necessary or not.
As a summary, the following is  stated:
1. In our material HBV infection was proven in 39.7% of chronic liv e r  
patients.
Acute virus hepa titis  in  the anamnesis of the patients belonging to 
the HBV-positive group is  three times as frequent as in the HBV-negative 
group. However, even in  the HBV-positive group, such data are lis te d  only 
in  the history of every f i f t h  patient. This fact underlines the necessity of 
considering the p o s s ib ility  of HBV infection in  the lack of relevant anam­
nestic information as w e ll.
2. The incidence rate of serious progressing liv e r diseases (CAH 
and/or cirrhosis) in the HBV-positive group is  two and a half times higher 
than in the HBV-negative group.
3. a) With the help of detailed virus serological tests the actual 
stage of HBV infection can be determined. This is  of primary therapeutical, 
prognostical and epidemiological significance.
b) Anti-HBc may be considered the most sensitive of the markers of 
HBV infection.
c) HBsAg-IgM complex seropositivity shows active v irus-rep lication, so 
— i f  HDV infection is  excluded — i t  suggests active HBV infection.
4. In the d iffe re n t stages of HBV in fection , the incidence rate of 
l iv e r  diseases of d iffe re n t severity does not d if fe r  s ign ifican tly .
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HI STOPATHOLDGY
THE DISTRIBUTION OF ABO(H) ISOANTIGENS IN  URINARY BLADDER
TUMOURS
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The d is tr ibu tion  of blood group isoantigens (ABH) was studied with the spe c ific  red 
c e ll adherence tes t (SRCA); the red blood ce lls  were visualized by the benzidine-peroxidase 
reaction. The H antigen was detected with Ulex europaeus agglutin in  I  lec tin  by d irec t immuno­
peroxidase technique.
One hundred and seven bladder tumours were tested. I t  was found that blood group iso ­
antigens diminished with immaturity (grade) and tumour invasiveness (T stadium). Patients with 
ABH blood group isoantigen deletion should be considered to be belong to a p a rticu la rly  high- 
r is k  group. The preservation of blood group antigens in grade I I —I I I  carcinomas may be useful 
in  the choice o f treatment (conservative or rad ica l). In s ix  cases in the area o f squamous 
metaplasia of invasive carcinomas a strong false SRCA reaction was noticed detecting presumably 
the blood group determinants of the epidermal growth factor receptors.
Keywords : Bladder tumour, grade, stage, A, B, 0(H) isoantigens
In tro d u c tio n
The development of a urinary bladder cancer from uroepithelial dyspla­
sia to in f i l t ra t in g  cancer is  a long process.
The normal urinary bladder epithelium s im ila rly  to other e p ith e lia l 
ce lls , carries on the c e ll surface ABO(H) blood group antigens isologous 
with the patien t's  blood group antigens /4 /.
During the development of cancer the ABH antigens decrease in number 
or re a c tiv ity , or even disappear from the c e ll surface /7 /.
O ffp rin t requests should be sent to : F. Baranyay, H-7643 Pécs, Szigeti u. 12.
Akadémiai Kiadó, Budapest
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According to c lin ic a l experience, decreased or lacking ABH reac tiv ity  
is  indicative of an aggressive progression of bladder carcinoma /3 , 5, 6, 8, 
9, 11—18, 21-26, 28/.
In th is  study we examined urinary bladder tumour tissues from 113 pa­
t ie n ts . For detecting the A and B isoantigens we applied the specific  red 
blood ce ll adherence (SRCA) test. The antigen of 0 blood group (H antigen) 
was examined with Ulex europaeus agglutinin I  (UEA-I) by an immunoperoxidase 
method.
M a te ria ls  and Methods
The urinary bladder tumour tissue samples were obtained by transurethral recection in 
years 1983—1992. 2/3 of the biopsy material was sent fo r  routine h is to lig ica l examination. The 
grade and T stadium of the tumours were determined according to the WHO d irec tives  /20 /.
5-6 pm th in  frozen tissue sections (Tissue Тек I I )  were made and a ir-d r ie d , then they 
were incubated with anti-A and anti-B sera (Human, Budapest) in  a humidified chamber and washed 
w ith  phosphate buffered saline (PBS, pH 7.4). Subsequently the cryostat sections were covered 
w ith  erythrocytes (blood group A and B, 1% suspended in  saline) and incubated. Ihe non-adherent 
red blood ce lls  were removed by washing with sa line . Ihe sections were fixed in  (2%) g lu tar- 
aldehyde solution and the benzidine-peroxidase reaction was used to enhance the contrast of 
erythrocytes.
Ihe tissue d is tr ib u tio n  of 0(H) blood group antigen was examined w ith peroxidase- 
conjugated UEA-I le c tin  (Sigma), diluted 1 : 100. Sections were incubated fo r 45 min and washed 
w ith  sa line . Amino-ethyl carbazole was used as chromogen, and Mayer's haematoxylin as counter­
s ta in .
Ihe appearance o f tissue AB0(H) blood group antigens was evaluated in  a plus—minus 
system / 2/ ,  where (+++) means strong ( a l l  the e p ith e lia l ce lls  are covered); (++) medium sized 
(2/3 o f the ce lls  are covered) and (+) weak reaction (1/3 of the ce lls  are covered by 
erythrocytes).
R esults
AB0(H) blood group isoantigens were examined in 107 pap illa ry  uroepi- 
th e lia l cancer and in 6 normal bladder uroepithelia l tissues. The blood 
group d is tribution  of the patients: A: 66, B: 16, AB: 7, 0: 24, which was 
s im ila r to the blood group d is tribu tion  of the Hungarian population.
Our observations show that the lack of the blood group antigens from 
the uroepithelia l surface is  a sensitive marker of malignant transformation 
and tumour progression (Figs 1—3). The d is tribu tion  of ABH antigens accord­
ing to the grade and stage of the tumours is  shown in the Table. However, 
the grade I I  carcinomas showed heterogenous tissue blood group antigen 
d is trib u tio n  from the stage Та to T3a in f i lt ra t io n s  deepness, and a strong 
(+++) to a negative reaction was observed.
ABO(H) ISOANTIGENS IN  URINARY BLADDER TUMOURS 131
Fig. 1. Normal uroepithelium of a patient with 0 blood group reacts strongly (+++) w ith the 
UEA-I le c tin .  Stroma is  negative, cap illa ry  endothelial c e lls  also positive. Immunoperoxidase
reaction, haematoxylin, x 200
Fig, 2, Papillary uroep ithe lia l carcinoma (grade I )  shows strong SRCA reaction (+++). A fte r the 
benzidine-peroxidase reaction the attached red blood ce lls  show high con trast, x 200
132 F . BARANYAY e t  a l .
Fig. 3. Grade I I  p a p illa ry  uroepithelia l carcinoma, (++) positive reaction. 
Benzidine-peroxidase, haematoxylin, x 200
Table I
Grade, stage and ABO(H) blood group antigen distribution 
o f 107 superficial bladder tumours
^Grades^ I I I I I I No. of
Stages - + ++ +++ a l l - + ++ +++ a l l - + ++ +++ a l l patients
pTA 6 15
21
4 4 8 5
21
3 1 1
5 47
PT1 1
1
1 2 3
6 7
pT2 1
1
1 1 2
4
2 1 1 1
5 10
PT3a 7 1 1
9
22 9 3
34 43
Grade
No. of patients 23 40 44 107
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Fig. 4. Grade I I I  pap illa ry  u roep ithe lia l carcinoma, negative SRCA test. The p o s it iv ity  of 
cap illa ry  endothelial ce lls  serves as endogenous contro l. Benzidine-peroxidase, haematoxylin,
X 200
Most of the grade I I I  carcinomas showed very weak or negative reac­
tion. However in 6 cases in squamous metaplasia in  the area of invasive 
carcinomas we met strong (+++) SRCA reaction (Fig. 4). In cases with AB 
blood group antigens A and В tissue antigens decreased paralle l.
Discussion
Ihe prognosis of the tumours is  based on the degree of d iffe ren tia tion  
shown by ce llu la r and tissue morphology. Synthesis of specific products, 
such as keratin and mucins may also be related to d iffe ren tia tion . Increas­
ing evidence exists that cancer is  associated with abnormalities in gene 
regulation expressed in multiple molecules (especially carbohydrates) at the 
ce ll surface membranes /10 /. Ihe deletion of blood group ABO antigen expres­
sion in  bladder carcinoma has attracted attention because its  possible de­
monstration by the SRCA test may serve as a prognostic parameter /7 /.
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F lq . 5, Strong SRCA reaction in  the area of squamous metaplasia of an invasive trans itiona l 
c e ll carcinoma. Benzidine-peroxidase, haematoxylin, x 200
We found that the benzidine-peroxidase reaction of the spec ifica lly  
adhered red blood ce lls  (with the ir dark brown staining) essentia lly in ­
creased the r e l ia b i l i t y  of the SRCA tes t. Testing of 107 bladder tumours 
showed that blood group antigens diminish or disappear para lle l to immaturi­
ty  (grade) or invasiveness (T stadium) (Table).
According to long-term c lin ica l experience, decreased or lacking ABH 
re a c tiv ity  is ind icative an aggressive progression of carcinomas /2 , 17, 18, 
23, 24/.
The diagnostic value of blood group antigen determinations is  based 
upon the fact that isoantigen deletion may precede aneuploidy as measured 
w ith flow-cytometric technique /1 /. Deletion of ABH antigen expression has 
been reported to occur before malignant progression after repeated recur­
rence of bladder tumours /26, 27/. Our findings also show that ABH blood 
group isoantigen deletions should be considered to be a p a rticu la rly  high 
r is k  fo r tumour recurrency, invasiveness and that these patients must be 
followed with special accuracy. The expression of blood group antigens in 
superfic ia l high grade tumours is a strong indication for a conservative 
therapy and i t  is  useful in  the choice of therapy /14 /.
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We observed strong SRCA binding in six cases in the area of squamous 
metaplasia in invasive trans itiona l ce ll carcinoma. From the 10 reported 
squamous ce ll bladder cancer cases four were SRCA positive / c i t .  3/. Martin 
et a l. /19/ found that trans itiona l ce ll carcinomas of the bladder showing 
squamous metaplasia are mainly resistant to radiotherapy. The preservation 
of the ABH antigens in  the area of squamous metaplasia seems to represent a 
false positive reactions with the blood group determinant of the epidermal 
growth factor receptors /18/.
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EXPERI MENTAL  GASTROENTEROLOGY
LONG-TERM PROSTACYCLIN — TREATMENT ACTS ON THE DNA AND RNA CONTENT 
OF RAT GASTRIC (ANTRAL AND FUNDIC) MÜCOSA DOSE-DEPENDENTLY
G. A. BÁLI NT3 , GI ZELLA KARÁCSONY0
aLaboratory of C lin ica l Pharmacology, Dept, of Neurology and Psychiatry,
^F irst Dept, of Medicine,
Albert Szent-Györgyi Medical University, Szeged, Hungary 
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The changes in ga rstric  (an tra l and fundic) mucosal DNA and RNA contents were inves­
tigated in long-term (80 days) treatment of rats with o ra lly  administered prostacyclin. Prosta­
cyclin  caused a dose-dependent, s ign ifican t increase of the DNA levels in both parts o f the 
gastric mucosa together with a s ign ifican t thickening of the fundic mucosa. The observed 
changes (decrease) of the RNA/DNA ra tio  in the fundic as well as antral mucosa, are interpreted 
as a sign of accelerated c e ll renewal, i.e .  hyperplasia.
Keywords: Prostacyclin, long-term treatment, DNA, RNA, ra t, gastric mucosa
In tro d u c tio n
Karácsony et a l. /0 / published that a long-term (80 days) prostacyclin 
(PG-I2 ) treatment caused a marked modification of the ce ll composition of 
ra t gastric mucosa, together with a s ign ifican t increase in the mucosal DNA 
content.
Balint et a l. /4, 12/ gave an account of the effect of PG-^ treatment 
on protein, DNA and RNA content of rat fundic mucosa.
However, these investigations le f t  (at least) two questions open, 
namely:
( i )  What is  the effect of a long-term PG-I2  treatment on the antral 
part of ra t gastric mucosa, and
O ffp rin t requests should be sent to : G. A. B a lin t, H-6701 Szeged, Semmelweis u. 6 , 
P.0. Box 397, Hungary
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( i i )  is  the encountered effect of PG-I2  a genuine pharmacological 
e ffect of the molecule, i.e .  is  i t  dose-dependent or not?
To elucidate these problems, the follow ing investigations were per­
formed.
M a te ria ls  and Methods
Adult female Wistar ra ts  of 220-230 g of in i t i a l  body weight were used.
The animals were assigned in groups each consisting of 10 animals. They received 
standard pellets as food and water was allowed ad lib itu m .
The experimental animals were given PG-I2 o ra lly  fo r  80 days.
The da ily dose o f PH-I2 was n i l  for group I  (con tro l animals),
20 pg/kg fo r group I I ;
100 pg/kg fo r group I I I  and
200 pg/kg fo r group IV.
A stock-solution o f PG-I2-methylester (1 mg/ml) was made-up freshly in  0.05 M T ris - 
bu ffe r of pH 9.6. D ilu tions were made immediately p r io r  to  use in ice-cold isotonic sodium- 
bicarbonate solution and given o ra lly  through a gastric  tube. The control animals received 
iso ton ic sodium-bicarbonate solution, the same volume (also through a gastric tube fo r 80 
days).
During PG-I2 treatment the body weight o f the animals was checked and recorded weekly.
After the treatment period the animals fasted fo r  24 h but allowed water ad lib itu m . 
Subsequently, the fo llow ing investigations were done:
The animals were k il le d ,  the ir stomachs were removed and opened. Specimens fo r h is to lo ­
g ic a l investigation were fixed in formalin, dehydrated in  an ascending alcohol series, 
embedded in pa ra ffin , then s e r ia lly  sectioned and stained by a modified Zimmerman's method 
/1 0 /. Specimens of to ta l mucosal thickness were measured using an ocular micrometer. A minimum 
o f ten areas were checked per s lide . Mucosal thickness was expressed in mm.
Following sampling the gastric fundic (oxyntic c e l l  area) and antra l mucosa was se­
parately scraped o f f ,  and both were divided in to  two parts , which were homogenized e ither in  
ice-co ld  saline fo r prote in determination /9 / or in  0.8 M ice-cold perchloric acid fo r  DNA and 
RNA determination. Emphasis was put throughout on rapid processing, and the whole procedure was 
carried out in  an ice-bath.
The RNA content of the homogenate was determined by the orcinol reaction / 6/ ,  while the 
DNA content was measured by the diphelylamine method /1 , 7 /. Both were expressed in  pg/mg 
p ro te in .
Within each group mean j^S.E. was calculated and analysed s ta t is t ic a lly  using Student's 
t - te s t .  Lim it of significance was P = 0.05.
R esults
The long-term application of PG-I2 enhanced the gastric mucosal DNA 
contents and gastric mucosal thickness s ig n ifica n tly , while no changes were 
seen in the body weight and gastric mucosal RNA levels (Tables I —I I I ) .
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Table I
Body weight of the animals 
(n = 10 in each group)
PG-I2 dose
Body
Before
pg- i 2
w e igh t
After
treatment
N il (Control) 225.3 + 9.88 265.1 + 8.02
20 pg/kg 228.В + 8.92 259.9 + 7.90
100 pg/kg 221.2 + 7.94 260.6 + 8.35
200 pg/kg 224.5 + 8.06 266.4 + 8.41
Mean j^S.E. in  grams
Table I I
Gastric mucosal DNA and RNA changes during long-term PG-It treatment 
(n = 10 in each group)
PG-I2 dose
Antrum
DNA RNA 
pg/mg protein
RNA/DNA
F undus
DNA RNA 
pg/mg protein
RNA/DNA
N il (Control) 20.49 + 1.54 37.70 + 1.61 1.84 14.91 + 1.19 26.95 + 1.70 1.81
20 pg/kg 18.75 + 1.72 31.84 + 2.27 1.70 16.95 + 1.18 22.74 + 1.29 1.34
100 pg/kg 23.68 + 2.22 35.00 + 2.82 1.48 19.87 + 1.64+ 24.08 + 1.38 1.21
200 pg/kg 28.38 + 2.52+ 38.39 + 2.62 1.35 22.64 +_ 2.09+ 28.31 + 2.38 1.25
Mean + S.E.
+P<  0.05 vs Control
Table H I
Gastric mucosal thickness a fte r long-term PC-I-y treatment 
(n = 10 in each group)
P G -I2 dose Antrum Fundus
N il (Control) 0.201 + 0.003 0.465 + 0.011
20 pg/kg 0.193 + 0.005 0.449 + 0.027
100 pg/kg 0.199 + 0.003 0.509 + 0.012+
200 pg/kg 0.209 + 0.004 0.521 + 0.014+
Mean +_ S.E. in mm. 
+P <  0.05 vs Control
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Conclusions
On the basis of our results the follow ing conclusions might be drawn:
1. The long-term PG-I2 treatment showed no effect on the body weight 
of the animals compared to the controls, i .e .  there was no sign of a toxic 
side-effect.
2. After 80 days of PG-I2 treatment there was a s ignificant thickening
of the gastric fundic mucosa, while in  the antral part thickening was 
observed only with the 200 pg/kg dose of PG-I2- In our opinion th is  phenome­
non corresponds to the hyperplasiogenic e ffec t of PG-I2 on the gastric 
(fundic) mucosa /4 , 8 /. This assumption is  strengthened by the results
obtained by checking the DNA and RNA levels in  th is  series of investigations.
3. The data presented with regard to the changes in the DNA and RNA 
content of rat gastric  mucosa, are in accordance with our ea rlie r results 
/3 , 5, 9/ namely tha t:
( i )  The DNA leve l s ign ificantly  increases in both parts of the gastric 
mucosa, while
( i i )  the RNA content remains at the control level, — also in  both 
parts of the mucosa — resulting in a
( i i i )  decreased RNA/DNA ratio .
This ra tio  varies from tissue to tissue (or from species to species) 
but under physiological circumstances i t  is  stable within a given tissue or 
organ. Elevation of th is  ra tio  refers to de novo protein synthesis, while 
i t s  decrease is  a convincing sign of new c e ll formation /3, 11/.
We conclude tha t during long-term PG-I2 treatment new ce ll formation 
takes place in both parts of the gastric mucosa. This phenomenon, together 
with the thickening of the mucosa, is  in accordance with our previously pub­
lished results /4 , 0/ regarding to the fundic mucosa. For the antra l mucosa 
the present series of investigations give the f i r s t  data in which the hyper­
plasiogenic effect of PG-I2 seems to be enlightened. In acute experiments 
/3 , 4/ the antral mucosa reacted d iffe ren tly  as compared to the fundic part, 
namely i t  showed an elevation in the RNA/DNA ra tio , indicating de novo 
protein synthesis, most probably mucus secretion. I t  is  worth mentioning 
tha t in the fundic mucosa in aucte circumstances there is also a new ce ll 
formation.
4. The experimental results suggest tha t during a long-term treatment 
of rats the effect of PG-I2 on the gastric mucosal DNA level and RNA/DNA ra­
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t io  is  a dose-dependent genuine pharmacological action in both parts (an tra l 
and fundic) of the gastric mucosa.
F ina lly , i t  is  notable that in acute experiments there is  a s ig n if i ­
cant RNA level-elevating effect of PG-^ /4 / .  This effect on the RNA level 
was not present in the course of our present, 80 days investigations.
A c k n o w le d g e m e n t : PG-l2-methylester was generously donated by the firm  Chinoin
(Budapest, Hungary).
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Normal reference values of lysosomal enzyme a c tiv it ie s  (alpha-glucosidase, mannosidase, 
fucosidase and arylsulfatase-A) were determined in chorionic v i l l i  obtained from a r te f ic ia l 
abertion in  the f i r s t  trim ester of normal prognancies (gestational weeks 6 to 11). V i l l i  were 
homogenized comparatively e ither in saline or in Triton X-100 detergent. The alpha-glucosidase, 
mannosidase and arylsulfatase-A enzyme a c tiv itie s  s ig n if ic a n tly  diminished i f  homogenization 
was done in  saline instead of Triton-X while the difference in fucosidase a c tiv ity  was not 
s ign ifican t. S ignificant corre lation was detected between alpha-glucosidase a c tiv ity  and week 
of gestation. I t  is  suggested that Triton X-100-homogenization should be used fo r the lysosomal 
enzyme determinations in chorionic v i l l i  because the so lub iliza tion  of enzymes from the lyso­
somes is  complete in th is  case than with homogenization in  saline.
Keywords: reference values, lysosomal enzymes, chorionic v i l l i  (non-cultured), genetical 
enzymopathies.
In tro d u c tio n
Prenatal diagnosis of genetically-determined enzymopathies had become 
available by analysing chorionic v i l l i  obtained in an early period of 
gestation (9-12 weeks) /5 / due to interruption of gravidity. Most lysosomal 
enzyme a c tiv itie s  can be detected in chorionic v i l l i  and in cultured tropho- 
blasts /4 /. Differences in the concentration of lysosomal enzyme a c tiv itie s  
have been detected between chorionic v i l l i  and cultured fibroblasts or 
amniocytes /2 /.
For prenatal diagnosis of lysosomal enzymopathies we have studied the 
normal reference values of enzymes found in frozen, freshly-obtained, non-
O ffprin t requests should be sent to: Aranka László, Paediatric Department A. Szent- 
Györgyi Med. Univ. Szeged, P.0. Box 401. Hungary
Akadémiai Kiadó, Budapest
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cultured chorionic v i l l i  and the pH-dependence of enzyme a c tiv it ie s  in the 
early gestational weeks.
M a te r ia ls  and Methods
After 1 to 4 weeks storage at -80 °C the frozen chorionic v i l l i  obtained a t a r te f ic ia l 
abortion were prepared free from maternal decidua under a dissection microscope. The isolated 
v i l l i  were used for enzyme a c t iv i ty  determinations. Chronionic tissues samples were homogenized 
e ith e r in  saline, or in d e s tille d  water containing 0.1% Triton X-100. Lysosomal enzyme assays 
and prote in concentration measurements were performed in  the supernatant of such homogenates,. 
The alpha-glucosidase, fucosidase, mannosidase and arylsulfatase-A enzyme a c t iv it ie s  were 
determined by colorimetric techniques as described by Poenaru et a l. /6 / .  The a c t iv it ie s  were 
calculated as transformed substrate nmol: protein mg:h. Pearson-type corre lation coe ffic ien ts 
were applied for the detection o f the re la tion of gestational age and enzyme a c t iv it ie s .
Results
The mean values of lysosomal enzyme a c tiv it ie s  are shown in  Table I. 
The alpha-glucosidase, mannosidase, and arylsulfatase-A a c tiv it ie s  of 
chorionic v i l l i  homogenized in saline were s ign ifican tly  diminished compared 
to those of the Triton X-100 homogenate, while the fucosidase a c tiv ity  
seemed to be independent of the homogenizing medium.
Among the lysosomal enzymes only the alpha-glucosidase a c tiv ity  proved 
to be in significant corre lation with the gestational week ( r  = 0.48, 
P <  0.01) (Table I I ) .
Table I
A c tiv ity  o f lysosomal enzymes from chorionic v i l l i  
In T riton  X-100-homogenized chorionic tissue
Gest. weeks 06-glucosidase Fucosidase
nmol/mg
Mannosidase
p ro te in /h
Aryl-sulfatase A
X 9.15 122.9 755.5 147.2 130.7
S . o . 1.69 59.6 164.5 45.0 108.5
jn = 40
In saline-homogenized chorionic tissue
X 19.29 615.6 14.85 79.4
S.D. 3.54 152.5 8.15 22.4
;n = 10
P <C 0.001 > 0 .0 5 <  0.001 < 0.001
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Table I I
A c tiv ity  o f lysosomal enzymes from chrorionic v i l l i  and the corre lation with gestational weeks
In T riton  X-100-homogenized chorionic tissue
Gest. weeks (X-glucosidase Fucosidase 
nmol/mg
Mannosidase
p ro te in /h
Aryl-su lfatase A
X 9.15 122.9 755.5 147.2 130.7
S.D. 1.69 59.6 164.5 45.0 108.5
r x 0.43 0.14 0.32 0.12
p
n = 40
<0.01 >0.05 0.0514 > 0 .05
r x = Pearson-type corre lation coe ffic ien t between the enzyme a c tiv ity  and the gestational week
A pH-dependence of enzyme a c tiv itie s  have been observed (Figs 1—4). 
As shown in the Figures, lin e a rity  in the concentration — and pH — ranges 
is  satisfactory.
pH-dependency of
oc-Glucosidgse 
20jul homogenate
Fig. 1. pH-dependency of alpha-glucosidase a c t iv ity  from chorionic v i l l i
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pH-dependency of 
oc -  Mannosidase
20 ul homogenate 
100u l substrate 5mmol/L
10 20 30 60 50 60 Minutes
Fig. 2, pH-dependency of alpha-mannosidase from chorionic v i l l i  homogenate
pH - dependency
oc- Fucosidase 
20ul homogenate
Fig. 3, pH-dependency of alpha-fucosidase from chorionic v i l l i
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pH-dependency of
Arylsulfgtase -  A
20/ul homogenate 
100pl substrate 5mmol/L
Fig. 4, pH-dependency of chorionic arylsulfatase-A
Discussion
Ben-Yoseph et a l. /1 / investigating the lysosomal enzyme a c it iv it ie s  
in fresh and frozen chorionic v i l l i  and in cultured trophoblasts established 
that freezing of the tissue specimens had no e ffect on hexosaminidase-B and 
alpha-iduronidase a c tiv it ie s  while arylsulfatase-A and beta-galactosidase 
a c tiv it ie s  were s lig h tly  increased and other a c tiv it ie s  were s lig h tly  
decreased on freezing.
In contrast to the few significant differences between fresh and 
frozen tissues, highly s ign ifican t differences were detected by the same 
authors between the values obtained from experiments on tissues and those 
performed with cultured ce lls . Freezing of samples seems to affect only the 
so-called lab ile  enzymes, alpha-galactosidase and neurominidase.
Pulkkinen /7 / reported in own reference values for arylsulfatase-A 
and fo r some steroid-sulfatase in the developing organisms and fo r the 
placenta. Arylsulfatase-A a c tiv ity  was 191 + 11.2 U/g weight in placental 
tissue taken from the fe ta l side.
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According to Fukuda et a l. /3 / the mean level of alpha-glucosidase 
a c tiv ity  was 6.3-times higher and that of beta-glactosidase a c tiv ity  was 
2.6-times lower in chorionic v i l l i  than in  cultured amniotic f lu id  ce lls.
In the present study, enzyme a c tiv it ie s  from normal pregnancies are 
given which were from normal pregnancies are given which were found, in 
saline-homogenized and Triton X-100-homogenized chorionic tissues. Di­
minished ac tiv ities  of alpha-glucosidase, mannosidase and arylsulfatase-A 
were detected in the saline-homogenized chorionic v i l l i  compared to Triton 
X-100-homogenzied ones, while the fucosidase a c tiv ity  did not d if fe r  from 
the Triton X-100-homogenized patterns. S ignificant correlation was detected 
between alpha-glucosidase a c tiv ity  and gestational age.
Because there are no universally-accepted, optimized methods for 
determination of the above-mentioned lysosomal enzymes, i t  is  important to 
determine the normal reference values in each laboratory. We have get in te r­
mediate values for arylsulfatase-A compared to data found by Evans et al. 
/2 /  and those reported by Poenaru et a l. /6 / .  Our alpha-glucosidase values 
are lower than those published by Poenaru et a l. /6 /. In case of alpha- 
fucosidase and mannosidase we obtained enzyme ac tiv itie s  s im ilar to those 
found by other authors /1 , 2, 6/.
Our results seem to be important because normal values are essential 
fo r  promoting and making more specific the prenatal diagnostic of lysosomal 
enzymopathies.
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AUTOPSY IN EPIDEMIOLOGY AND MEDICAL RESEARCH 
Eds: E. Riboli and M. Delendi 
IARC S c ie n tific  Publications No. 112. Lyon, 1991.
Since the earlies t human dissections practised in Alexandria between 
400 and 300 BC autopsy has been one of the oldest methods of medical inves­
tigations. From the fundamental work of Morgagni, autopsy contributed f i r s t  
to the evolution of anatomical knowledge and then to an understanding of the 
organic nature of diseases.
Autopsy means, l i te r a l ly ,  "seeing with one's own eyes", therefore i t  
has been the starting point fo r the development of histology, macro- and 
microscopic pathomorphology and the most recent histopathological tech­
niques. In modern medicine, autopsy is  s t i l l  carried out in order to answer 
two questions: "What was the cause of death of a particular patient?" and 
"What can be learnt from a particular case to improve medical knowledge?". 
Nowadays, autopsy is  the only way for qua lity  control in the public health 
service.
In Trieste ( I ta ly )  between 1901 and 1985, there were highly s ig n if i­
cant increases in the numbers of deaths due to arteriosclerosis and to 
malignant neoplasms in people of each sex. Overall, infectious diseases 
accounted fo r 55% deaths in 1901. In 1905, on the other hand, death was 
caused by infection in  only 3.7%. In Austria, the legal regulations for 
performing autopsies are based on laws dating back to middle of the 18th 
century (Holzner), which were introduced by the Empress Maria Theresa and 
the Protomedicus Gerard van Swieten. So, the autopsy rate is  theore tica lly  
100% in a l l  public hospitals, i.e . hospitals under provincial and municipal 
administration. These include almost a ll the large hospitals in the country. 
Maintenance of an acceptable rate is  important fo r continuous qua lity  con­
t ro l of m ortality s ta tis t ic s  of a population, as well as for continuous 
quality control of c lin ic a l diagnosis in general. I t  is  of great s ig n if i­
cance regarding the malignant neoplasms, too. In 1907 in Austria, autopsies 
were carried out in 49.6% of the deaths that occurred in hospitals and in 
34.5% of those that occurred at home (external deaths). In 1988, in the 
Vienna University Hospital the autopsy rate was 75%. Between 1978 and 1987 
in Austria on the basis of autopsy data, there was no change in the deaths, 
newly diagnosed cases and staging both of stomach and lung carcinoma.
The prevalence of cirrhosis at autopsy is  high in Trieste and shows 
no tendency to decrease, as inferred by some c lin ic a l studies.
Di Bonito et a l, compared the diagnoses on death ce rtifica tion s  with 
the autopsy reports in gynaecological cancers. Complete agreement was found 
only fo r 30% of cervical and corpus tumours and fo r 50% of ovarian tumours. 
The cause of fa ilu re  was f i r s t  erroneous in terpretation of codes, second, 
confusion of the anatomical s ite  of primary cancers. Grundmann and Menke 
found that the concordance between c lin ic a l and autopsy diagnoses was very 
poor with respect to infectious diseases: lues was rarely recognized c l in i ­
ca lly , even though i t  may be fa ta l; 50% of tuberculous patients died of 
m ilia ry tuberculosis without a correct diagnosis. Endocarditis in  a l l  i ts  
forms was underdiagnosed c lin ic a lly  in 75% of the cases. These data, in ­
cluding the h isto log ica l findings provide substantial arguments in  favour 
of autopsy control of c lin ic a l diagnosis. Jonasson and B.jörnsson concluded
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tha t autopsy is  indispensable as an instrument of quality control and for 
generating m ortality and morbidity s ta tis t ic s . The introduction of new 
diagnostic modalities seems not to have improved the accuracy of c lin ic a l 
diagnosis of the immediate cause of death but may s ign ifican tly  have im­
proved the detection of other major diseases. According to Rossi et a l . , 
agreement between the diagnoses was 81% fo r primary disease and 58% for 
cause of death. They concluded that autopsy was a valid tool fo r investiga­
t io n , despite the a v a ila b ility  of sophisticated diagnostic techniques. 
Autopsies can indicate the exposure to asbestos. Mollo et a l. found that 
only post-mortem examination can provide probative data about the presence 
of a lung cancer and i t s  relationship to exposure to asbestos. Autopsy may 
suggest a through investigation of occupational exposure to asbestos. The 
perinata l autopsy is  c learly an undervaluated source of information and 
discovery. L it t le  information is  available from the developing countries 
( Husain and □’Conor) .
The dilemma of Peacock et a l. "The autopsy: a useful too l or an old 
re lic ? " may not be a dilemma. Autopsy is  useful today for monitoring the 
diagnostic processes w ithin wider programmes of assuring the qua lity  of 
c l in ic a l a c tiv it ie s . But without active partic ipa tion  of c lin ic ians  and in 
the absence of a change in some in s titu tio n a l in e rtia , autopsy never reaches 
the goal i t  has set i t s e l f  fo r centuries: "MORTUI VIVOS DOCENT" ( Ferencic 
and Belicza) .
A. BAJTAI
CLINICAL APPLICATION OF RADIOIMMUNOASSAY 
Ferenc A. László and Tamás Oanáky 
Akadémiai Kiadó, Budapest 1992.
The purpose of th is  book is  to provide fo r clin icians with a working 
knowledge of current radioimmunoassays in  d iffe ren t fie lds of medicine. I t  
contains 18 chapters on 184 pages, figures, tables and subject index. Each 
chapter end with a reference l is ts  up to the year 1990.
The f i r s t  part of the book deals with hormones of the hypothalamic- 
hypophyseal system and of th e ir target organs; the next part with the para­
thyro id  hormones and insu lin , followed by gastrointestinal hormones; 
references are only up to 1988. In the chapter of the haemopoietic system we 
can read about vitamin B1 2  fe r r i t in  and fo l ic  acid. In the chapter of tumour 
derivatives only CEA and AFP are mentioned. IgE and hepatitis В v irus are 
dealt with in the next two chapters. The la s t chapter is devoted to pharma­
cology: digoxin, barbiturates and morphine.
The glossary of radioimmunoanalytical procedures seems to be very 
usefu l, but a l i t t l e  b it  too much for p ractitioner clin icians and l i t t l e  for 
spec ia lis ts . In most part of th is  book are very few practical advices for 
the doctors of ward. I t  is  p ity  that there is  very l i t t l e  information from 
the la s t years.
Overall, the book provides new insight in to RIA procedures fo r the 
c lin ic ia n s  who attend patients with endocrine disorders and use the results 
of radioimmunoassays. The Reader w il l be motivated to invest more time and 
in te res t in  th is  f ie ld . I t  is  recommended as an introduction to radio­
immunoassays.
MARIA FARKAS
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ATLAS OF FETAL DIAGNOSIS 
Edited by Zoltán Papp
Elsevier, Akadémiai Kiadó, Budapest 1992. 255 pages
Ihe development in obstetrics of the past few years can be charac­
terized by the "marriage" of obstetrics and genetics. Ihe tru th  of th is  
statement is  proven by the excellent atlas edited by Professor Zoltán Papp.
Broadening knowledge of genetics has led to an increase in the number 
of affected fam ilies requiring genetic care. Among others, the work of the 
Editor and the contributors of th is  book resulted in the creation of genetic 
counselling centers throughout Hungary.
Ihe number of prenatal diagnostic and therapeutic interventions has 
rapidly increased and as a resu lt, we have witnessed the sudden development 
of prenatal ultrasound diagnosis, invasive intrauterine interventions and 
fe ta l pathology. Ihus postgraduate tra in ing of obstetricians working with 
fetuses and pregnancies affected by genetic disorders or developmental 
malformations has become extremely important. The Atlas of Fetal Diagnosis 
is  in compliance with th is  demand and can be considered as a supplement to 
or a continuation of his previous book en titled  Obstetric Genetics (Akadé­
miai Kiadó, Budapest 1990).
The text as well as the illu s tra tio n s  presented in th is new post­
graduate tra in ing manual are of excellent qua lity . The book containing 400 
colour photographs and 100 ultrasound pictures is  a choice co llec tion  of 
fe ta l developmental malformations and chromosome aberrations. Prenatal 
diagnosis of the malformations was mainly performed between 1977 and 1989 at 
the Department of Obstetrics and Gynecology, University Medical School, Deb­
recen (Hungary) and at the Department of Medical Genetics of the Churchill 
Hospital, in Oxford, U.K.
Ihe Editor gives an overview on the wide area of fe ta l malformations 
and genetic diseases discussed in the twelve chapters.
Ihe co-authors of the Atlas are known experts in their f ie ld s , K. Cse­
csei and G. T. Szeifert in fe ta l pathology, R. H. Lindenbaum in  cyto­
genetics, Z. lo th in prenatal ultrasound diagnosis and V. Váradi in  pe­
d ia tr ic  ultrasound.
Ihe high quality professional evaluation of fe ta l malformations is 
rich ly  illu s tra ted  by the excellent photographs, th is atlas is  to be of 
great interest for obstetricians, geneticists, pediatricians and patholo­
gists both in Hungary and abroad. Besides the valuable contents and unique 
illu s tra tio n s , the expertise in typography (A lfö ld i Nyomda, Debrecen) should 
also be praised.
LÁSZLÓ LAMPE
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THE EFFECT OF ATRIAL DILATATION ON REPERFUSION ARRHYTHMIAS: 
DEVELOPS NT OF SUPRAVENTRICULAR TACHYCARDIAS ON REPEREUSION WITH
ATRIAL STRETCHING
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The study was aimed at investigating the e ffec t o f a t r ia l d ila ta tion  on the genesis of 
supraventricular tachyarrhythmias following myocardial reperfusion. Experiments were carried 
out in 26 mongrel dogs under pentobarbital narcosis with a r t i f ic ia l  ven tila tion . Electro- 
physiological study was performed for studying the arrhythmic condition of the heart. Inves­
tiga tions were carried out: (1_) in normal condition, ( i i )  during a tr ia l stretching (balloon 
d ila ta tion  of the le f t  atrium), ( i i i ) in  reperfusion following myocardial ischemia, ( iv )  in 
reperfusion combined with a t r ia l stretching. On reperfusion the i r r i t a b i l i t y  of the atrium 
increased moderately (on a t r ia l ex tras tinu li in 3 dogs non-sustained a tr ia l tachycardia, in 7 
dogs repeated a tr ia l responses could be induced). Reperfusion with a tr ia l stretching, however, 
very markedly enhanced the a tr ia l vu lne rab ility , and in 19 dogs a tr ia l tachycardia appeared 
spontaneously. Comparison of the e ffect of a tr ia l stretching to that of a tr ia l stretching + re- 
perfusion showed that the reperfusion s ig n ifica n tly  augmented the arrhythmia-inducing e ffect of 
a t r ia l stretching. C lin ica l investigations: Aortocoronary bypass operations were followed by 
development of supraventricular tachycardia in 41 out o f 428 operated cases. A tr ia l d ila ta tion  
was detected in 37 cases, mostly before the appearance of a t r ia l tachycardia. The data seem to 
prove that a tr ia l d ila ta tio n  has an important part in the pathogenesis of supraventricular 
tachyarrhythmias following reperfusion of myocardial ischemia.
Keywords : A tr ia l d ila ta tion , supraventricular tachyarrhythmia, reperfusion, a tr ia l
i r r i t a b i l i t y
Abbreviations: EPS = electrophysiologic study; CL = cycle length; QTç = corrected QT 
in te rva l; ACT = in tra a tr ia l conduction time; AERP = a t r ia l refractory period; VERP = ven­
tr ic u la r  refractory period; AVNRP = AV node Wenckebach po in t; CSNRT = corrected sinus node 
recovery time; ES = premature beat
O ffprin t requests should be sent to : F. S o lti,  H-1122 Budapest, Városmajor и. 68,
Hungary
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Introduction
Reperfusion after myocardial ischemia is  regularly followed by ar­
rhythmia, mostly of ventricular origin. The effect of reperfusion on the 
genesis of arrhythmias has already been studied, but only the ventricular 
arrhythmias and the changes in the arrhythmic condition of the ventricle 
have so far been investigated /1, 7, 23, 24, 27, 39/. Although ventricular 
arrhythmias are more common after myocardial ischemia, but supraventricular 
arrhythmias may also occur. Therefore, the aim of th is  study was to inves­
tiga te  the effect of reperfusion on the arrhythmic condition of the atrium. 
In our former investigation the ir r i ta b i l i t y  of the atrium s ign ifican tly  
increased on a tr ia l stretching, and a tr ia l tachycardia could be provoked on 
balloon dilatation of the atrium /34/. The second objective of our inves­
tigations was, therefore, to study the effect of reperfusion on the i r r i t a ­
b i l i t y  of the atrium i f  i t  is  combined with a tr ia l stretching.
Materials and Methods
Experiments were performed in 26 mongrel dogs of both sexes, weighing 14 to 20 kg. The 
animals were anaesthetized w ith sodium pentabarbitone (30 mg kg"^ i . v . ) .  A cuffed endotracheal 
tube was inserted in to the trachea and ventila tion was maintained with room a ir  using volumen 
cycled respirator. The chest was entered through a horizontal sternotomy. For recording 
ep icard ia l electrograms and e le c tr ic a l stimulation of the a tr ia  and ven tric les, unipolar 
ring-shaped electrodes were fixed  by atraumatic sutures to the epicardial surface of both a tria  
and both ventricles. Ihe le f t  an terio r coronary artery was freed proximal to i t s  second major 
oblique branch and the thread loop was placed around i t .  For a tr ia l stretching (d ila ta tio n ) a 
balloon catheter was inserted via  pulmonary vein in to  the le f t  a tr ia l appendix. Ihe balloon was 
in fla te d  u n t il the le f t  a t r ia l pressure increased to 14-15 mmHg, generally 15-20 ml H2O was ne­
cessary fo r a tr ia l d ila ta tio n . For recording a tr ia l and ventricular pressure curves Statham 
transducers were inserted through a catheter into both a tr ia  and the le f t  ven tric le . The force 
changes of the le f t  ven tricu lar wall were registered by a strain-resistance gauge of Walton— 
Brodie type. Ihe cardiac output was measured by the thermodilution technique. A six-channel 
d ire c t w riting recorder — Heilige type — was used fo r recording ECG tracings, pressure curves 
and epicardial electrograms.
In course of electrophysiological study (EPS) for programmed e lec tr ica l s tinu la tion  of 
the a tr ia  and ventricles Medtronic 5925 impulse generator was used. E lectrica l impulses (2.0 ms 
in  duration) were delivered at twice d iasto lic  myocardial threshold. The following e lec trica l 
parameters were measured: ( i )  cardiac cycle length (CL); ( i i )  PQ in terval ( fo r AV conduction 
tim e); ( i i i )  corrected QT time (QTç), determined by using Bazett's formula /5 / ;  ( iv )  in tra - 
a t r ia l  conduction time (ACT); (v) a t r ia l e ffective refractory period (AERP); (v i)  ventricular 
e ffe c tive  refractory period (VERP); (v i i )  AV node Wenckebach point (AVVRP); ( v i i i )  corrected 
sinus node recovery time (CSNRT).
For inducing a t r ia l tachycardia early a tr ia l single and double e le c tr ica l s tim u li were 
used; in normal a t r ia l condition we fa iled  to induce a t r ia l tachycardia in  dogs by th is  
stim ulation technique /33 /. Myocardial ischemia was induced by temporary occlusion of the le f t  
an te rio r coronary artery. The EPS was carried out f i r s t  in  the basal — in i t ia l  — state.
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The EPS was repeated under a tr ia l stretching. The reperfusion period started 15 min a fte r co­
ronary artery release and at las t, the EPS was repeated during the reperfusion combined with 
a t r ia l d ila ta tion . The EPS lasted 2 to 4 min.
C lin ica l study: Four-hundred and twenty-eight aorto-coronary bypass operations were 
performed in the five-year period 1987 to 1991. The appearance of a tr ia l tachycardia (tachy­
arrhythmia) was detected in 41 patients (study group) in the early postoperative period. A con­
t ro l group (387 patients) was matched fo r age, sex, d istribu tion and number o f bypass grafts.
Control group: age = 44.6 (20-72) year; sex: male = 271 (70%), female = 116 (30%); mean 
g ra ft number =2.3.
Study group: age = 45.5 (22-70) year; sex: male = 30 (73%), female = 11 (27%); mean 
g ra ft number =2.4.
S ta tis tica l analysis was performed by using Students's unpaired and paired t  test and 
the variance analysis. Mean (SD) are demonstrated on the Tables.
Results
Under normal conditions — basal state — the electrophysiological 
variables were within the normal range of the dog heart /33/, and no supra­
ventricular tachycardia could be induced. Repetitive a tr ia l responses 
(couplet a tr ia l ES) on early a tr ia l extrastimuli could be detected only in 
three dogs. On the effect of a tr ia l stretching the ACT s ig n ifican tly  in­
creased and the AERP markedly, and s ign ifican tly  shortened (Table I ) .
Table I
Effect of reperfusion and a tr ia l stretching on cardiac e lec trica l parameters. 
Data are mean (SD) expressed in ms
CL PQ QRS QTC ACT CSNRI AERP VERP AVNRP
Control 555 105 65 290 40 40 130 140 285
(basal state) (34) (20) (11) (27) (9) (10) (12) (13) (32)
A tr ia l balloon 565 110 68 300 60x 45 110x 140 295
d ila ta tion (32) (19) (12) (28) (12) (11) (11) (14) (36)
Reperfusion 560 n o 66 315x 45 50 120 120X 290
(34) (19) (11) (27) (10) (15) (12) (13) (34)
Reperfusion + 568 112 68 320x 64xx 50 100xx 120x 295
a tr ia l balloon (34) (IB) (12) (26) (12) (15) (12) (14) (34)
d ila ta tion
CL = Cardiac cycle length, PQ = AV conduction time, QTq = Corrected QT time (e le c tr ica l 
sys to lic  length), ACÎ = In te ra tr ia l conduction time, CSNRT = Sinus node corrected recovery 
time, AERP = A tria l e ffec tive  refractory period, VERP = Ventricular e ffec tive  refractory 
period, AVNRP = AV node Wenckebach point
XP< 0.05 vs control 
xxP-£ 0.01 vs control reperfusion vs reperfusion + a tr ia l stretching
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Table I I
Inducible a tr ia l tachycardia on a tr ia l stretching, with or without reperfusion
(26 dogs)
No.
Balloon d ila ta tion + 'reperfusion Only balloon d ila ta tion
Sustained Non-sustained Sustained Non-sustained
1 1 1
2 1 1
3 1 1
4 1 1
5 1
6 1 1
7 1 1
8 1 1
9 1 1
10 1 1
11 1 1
12 1 1
13 1
14 1 1
15 1
16 1 1
17 1 1
18 1
19 1
20 1 1
21 1 1
22 1 1
23 1
24 1 1
25 1 1
26 1 1
20 6 8 12
On reperfusion, the QTj, s ign ificantly prolonged, and the VERP s ig n if­
ica n tly  shortened. There were however only modest alterations in the elec- 
trophysiological parameters of the atrium; the AERP mostly s ligh tly  short­
ened on reperfusion, but th is  change was s ta t is t ic a lly  not s ign ificant 
(Table I ) .
On reperfusion combined with a tr ia l stretching the a tr ia l e lectrica l 
variables changed very remarkably, the AERP shortened and the ACT in ­
creased.
The decrease in AERP on reperfusion + a tr ia l stretching proved s ig n if­
ican tly  greater than on a tr ia l d ilatation without reperfusion. The QT^, pro­
longed and the VERP shortened very markedly on the effect of reperfusion + 
+ a tr ia l d ila tation. The changes in the e lec tr ica l parameters are summarized 
in  Table I.
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Table I I I
Appearance of spontaneous a tr ia l tachycardia on a tr ia l stretching with or without
reperfusion (26 doqs)
No.
Balloon d ila ta tion + reperfusion Only balloon d ila ta tion
Sustained Non-sustained Sustained Non-sustained
1 1
2 1 1
3 1 1
4
5 1 1
6 1
7 1 1
8 1 1
9
10 1
11
12
13 1
14 1 1
15 1
16 1 1
17
18 1 1
19 1
20 1
21 1
22
23 1 1
24 1
25
26 1
15 4 6 3
The i r r i t a b i l i t y  of the atrium remarkably increased on a tr ia l disten­
sion. In 20 dogs supraventricular tachycardias could be induced by early 
a tr ia l extrastimuli; in 8 cases sustained and in 12 cases non-sustained 
a tr ia l tachycardias were detected (Table I I ) .
Spontaneous a tr ia l tachycardia developed in 9 cases during a tr ia l 
balloon d ila ta tion ; 6 sustained and 3 поп-sustained ones (Table I I I ) .
On reperfusion the arrhythmic condition of the atrium increased only 
s lig h tly , but in 3 dogs non-sustained a tr ia l tachycardia could be induced by 
a tr ia l extrastimuli. The repeated a tr ia l responses were also more frequent 
than in the basal condition of the heart; repeated ES appeared in 7 dogs.
On reperfusion + a tr ia l stretching the vu lnerability and i r r i t a b i l i t y  
of the atrium very markedly augmented. Supraventricular tachycardia was in -
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Fin. 1. Appearance o f a t r ia l f lu t te r  on reperfusion with a tr ia l stretching 
Paper recording speed: 50 , tracing from top: le f t  a tr ia l electrogram; r ig h t a tr ia l
electrogram; righ t ven tricu lar electrogram; bipolar surface lead I I I ,  le f t  ventricular strain 
gauge curve; le f t  ventricular pressure curve.
A t r ia l f lu t te r  spontaneously developed and ceased spontaneously a fte r 60 s. For the end of the 
tachyarrhythmia see the r ig h t side of the figu re : the sinus rhythm restored
ducible in each dog; 20 sustained and 6 non-sustained a tr ia l tachyarrhyth­
mias were detected (Table I I ) .  Comparison of frequency of inducible a tr ia l 
tachycardias on balloon d ila ta tion  with those of reperfusion + balloon d i­
la ta tion  showed a s ign ifican t trend; more frequent and more serious (sus­
tained) tachyarrhythmias were established in the la tte r group by variance 
analysis. Spontaneous tachycardia developed in 19 dogs (15 sustained and 4 
non-sustained) during reperfusion with a tr ia l stretching (Table I I I ) .  A sig­
n ifica n t trend of more inducible and more serious a tr ia l tachyarrhythmias on 
reperfusion + a tr ia l stretching could be revealed by variance analysis. From
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Fin. 2. Appearance o f a tr ia l f ib r i l la t io n  on reperfusion with a tr ia l stretching 
Paper speed: 50 tracing from top: le f t  a t r ia l electrogram; righ t a t r ia l electrogram;
r ig h t ventricular electrogram; bipolar surface lead I I I ;  le f t  ventricular s tra in  gauge curve; 
le f t  ventricular pressure curve. The tachyarrhythmia developed spontaneously and i t  was in te r­
rupted after 80 s by balloon deflation
the supraventricular tachycardias 6 were a tr ia l f lu tte r, 4 a tr ia l f ib r i l l a ­
tion . The appearance of a tr ia l f lu tte r  and a tr ia l f ib r il la t io n  with supra­
ventricular tachyarrhythmias is shown in Figs 1 and 2.
There were no important hemodynamic changes in the course of inves­
tiga tion . The le f t  ventricular force markedly diminished on myocardial 
ischemia and gradually turned back to the in i t ia l  level on reperfusion. The 
le f t  ventricular systolic pressure mostly s lig h tly  increased on reperfusion. 
The cardiac output s lig h tly  (but not s ign ifican tly ) diminished in the re- 
perfusion period. The le f t  a tr ia l pressure markedly increased on balloon d i­
la tation (Table IV).
Appearance of a tr ia l tachycardia following aortocoronary bypass g ra ft­
ing was detected in 41 patients (9.6%). The most important c lin ic a l data and 
electrophysiological characters of th is  study group are outlined in Table V.
A tria l d ila tation was detected in 37 of the 41 cases. Mostly acute, 
transitory a tr ia l d ila ta tion  was revealed p rio r to the development of tachy-
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Table IV
Data are mean (SD)
LAP LVSP LVEDP CO
Control
(basal state) 5 (1)
105 (18) 8 (1) 2.0 (0.4)
A tria l stretching 15 (1) 104 (17) 9 (1) 1.8 (0.5)
Reperfusion 5 (1) 102 (17) 10 (2) 1.4 (0.6)
Reperfusion +
a tr ia l stretching 15 (1)
101 (18) 10 (3) 1.8 (0.7)
LAP = le f t  a t r ia l pressure (mm Hg)  
LVSP = le f t  ven tric le  peak (systolic) pressure (mm Hg) 
LVEDP = le f t  ve n tric le  end diastolic pressure (mm Hg)
CO = cardiac output 1 min"^
Table V
Appearance o f aupraventricular tachycardia following aortocoronary 
bypass operation (41 cases)
Age
(year) Sex
Type of 
tachycardia
A tr ia l dila ta tion
45 male: 30 SVT: 20 37
(22-70) female: 11 TPAF: 5
TAF: 8
SVT = supraventricular — reentry — tachycardia 
TPAF = tachycardia based on paroxysmal a t r ia l f lu t te r  
TAF = tachycardia (tachyarrhythmia) based on paroxysmal a tr ia l 
f ib r i l la t io n
cardia. The supraventricular tachycardias appeared in the early postoper­
ative period, 1-3 days following the operation. The tachycardia lasted 1-2 
days. Permanent tachycardia (a tr ia l f ib r i l la t io n )  developed only in one pa­
tien ts . The supraventricular tachycardia was based mainly on macroreentry 
mechanism (28 pa tien ts), in 5 patients on a tr ia l f lu tte r  and in 8 patients 
on a tr ia l f ib r i l la t io n .  The a tr ia l d ila ta tion  proved the most important risk  
factor for the development of reperfusion a tr ia l arrhythmia. We fa iled  to
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detect any close interrelationship between age, sex d istribu tion , number of 
g ra fts , antecedent myocardial in fa rc tion  and the development of a tr ia l tachy­
cardias following a coronary bypass operation.
Discussion
The arrhythmic condition of the heart is  augmented on myocardial re- 
perfusion, appearance of arrhythmias can regularly be detected. Mostly ven­
tr ic u la r arrhythmias (ventricular ES, ventricular tachycardia, transient- 
ventricular f ib r i l la t io n )  develop, but in  about 10% a tr ia l arrhythmias can 
be observed. The i r r i ta b i l i t y  of the heart on reperfusion is  based on a 
combined mechanism. Oxygen-derived free radicals can play a role in the ge­
nesis of reperfusion arrhythmias /3 , 16, 19, 30/. The extent of prostacyclin 
release due to myocardial ischemia can also affect the arrhythmic condition 
of the heart during reperfusion /8, 37/. An increase of alpha-receptor den­
s ity  in the myocardium /9 /, catecholamine discharge form the heart /18, 31/, 
an accumulation of myocardial calcium /36/ on reperfusion can also increase 
the vu lnerability of the heart. Probably, the pathological changes in  the 
action potential of the myocardial ce lls , due to myocardial hypoxia, repre­
sent the most important pathogenetic factor of reperfusion arrhythmias. On 
myocardial ischemia the action potentia l duration shortens, and the impulse 
conduction slows down; these changes w il l  slowly regress during reperfusion 
/3 , 12/. I t  is  very important that the regression of the action potentia l 
duration w il l be therefore divergent in d ifferent regions of the heart in 
reperfusion; dispersion of the repolarization and refractoriness w i l l  de­
velop. The effect of reperfusion on e lectrica l property of the atrium has 
not yet been studied in deta il; lik e ly ,  sim ilar but s lighter action po­
te n tia l changes develop on reperfusion in the atrium. The data of the pre­
sent study also suggest that f i r s t  of a l l the i r r i t a b i l i t y  of the ventric le  
(marked shortening of the VERP and prolongation of QTjO w il l  increase during 
reperfusion. The arrhythmic condition of the atrium s lig h tly  augments on 
reperfusion, while a tr ia l arrhythmias are manifested but rarely. The ge­
nesis of supraventricular arrhytmias is  based on a complex mechanism. The 
a tr ia l d ila tation results in a very expressed increase in the i r r i t a b i l i t y  
of the atrium. On the effect of marked and permanent a tr ia l d ila ta tion  re­
gularly a tr ia l f lu tte r  or f ib r i l la t io n  w ill develop /7, 15, 25, 28/. On 
a tr ia l stretching the vulnerability of the atrium is  enhanced so that the
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a tr ia l balloon d ila ta tio n  represents a very apt model for studying the 
pathomechanism of supraventricular tachyarrhythmias /34/. On a tr ia l stretch­
ing, pathological a lte ra tion  of the a tr ia l action potential can be observed 
/21, 32, 35/, which may increase the arrhythmic condition of the atrium. 
A mechano-electrical feedback mechanism can also be involved in the develj  
opment of a tr ia l arrhythmias /13, 20/. The prolongation of in tra a tr ia l con­
duction fa c ilita te s  the development of reentry-type supraventricular tachy­
cardia /4, 22, 32/. I t  is  worthy of mentioning that, according to our ex­
perimental data, the in tra a tr ia l conduction time s ign ifican tly  increases on 
a tr ia l d ila tation.
The results of the present study prove that reperfusion s ign ifican tly  
fa c ilita te s  the arrhythmic condition of the atrium. On a tr ia l stretching 
+ reperfusion the AERP more s ign ificantly shortened than on a tr ia l stretch­
ing alone, and supraventricular tachyarrhytmias spontaneously appeared in 
most of the cases.
I t  is remarkable that after aortocoronary bypass grafting the supra­
ventricular tachycardias appear more frequently than ventricular ones. In 
5-10% of the cases supraventricular tachyarrhythmias w il l develop after 
myocardial revascularization /2, 10, 14, 26, 38/. We observed a tr ia l tachy­
arrhythmias (paroxysmal a tr ia l f lu tte r , paroxysmal a tr ia l f ib r i l la t io n  and 
supraventricular tachycardia) in 9.6% of the cases following aortocoronary 
bypass grafting. In our cases a tr ia l d ila ta tion  regularly preceeded the de­
velopment of a tr ia l tachycardias. Dixon et a l. /11/ also detected supra­
ventricular tachycardia frequently a fter coronary heart operation i f  the 
le f t  atrium was enlarged. Our data suggest that a tr ia l d ila ta tion  has a de­
cisive part in the manifestation of a tr ia l tachycardias following coronary 
heart operation.
Conclusion: 1. On reperfusion, not only the ventricular i r r i t a b i l i t y ,  
but also the arrhythmic condition of the atrium augments. 2. Reperfusion 
markedly fa c ilita te s  the a tr ia l i r r i t a b i l i t y  during a tr ia l d ila ta tion . 3. In 
reperfusion the a tr ia l tachycardias mostly w il l be manifested on a tr ia l 
stretching.
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ENDOCRINOLOGY
CIRCADIAN PATTERN OF SERUM ANDROGENS IN  WOMEN WITH 
CUSHING'S SYNDROME
A. KREZE, M. MIKULECKY, Z.  PUTZ,  M. MORAVCIK
Ins titu te  of C linical Endocrinology, Lubochna and 
F irst Medical C lin ic , Comenius University, Bratislava, Slovak Republic
(Received: February IB, 1993)
Circadian p ro file s  of the serum levels of c o rtis o l and five  androgens were studied in 
20 females including 8 contro ls, 7 patients with ACTH-dependent Cushing's syndrome and 5 with 
hypercortisolism due to adrenal adenoma. A s ign ifican t 24-h periodicity was found fo r each 
steroid in a l l  groups. Besides hypercortisolaemia, a s ig n ifica n t increase of 11-hydroxyandro- 
stenedione was shown in both forms of Cushing's syndrome. The most conspicuous find ing was a 
decreased dehydroepiandrosterone and its  sulphate in  adrenal adenoma. The peaks fo r the 
studied steroids were sh ifted from the morning hours towards the noon in ACTH-dependent 
Cushing's syndrome and towards the evening (fo r c o rtis o l)  and night hours (fo r androgens) in 
adrenal adenoma.
Keywords : Serum androgens, cirdadian rhythm, Cushing's syndrome, women
Introduction
Unlike well-documented aberrations of the circadian rhythm of serum 
cortiso l in Cushing's syndrome /5, 8/, the issue of circadian pattern of 
serum androgens in  th is  syndrome has not been investigated so far. The aim 
of the present study was to f i l l  th is gap.
O ffprin t requests should be sent to: A. Kreze, In s titu te  of C linical Endocrinology, 
CS-034 91 Lubochna, Slovak Republic
Akadémiai Kiadó, Budapest
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Patients and Methods
Subjects and Blood Sampling
Seven women with ACTH-dependent Cushing's syndrome, aged 23-53 years, and f iv e  women 
w ith c o rtis o l producing adrenal adenoma, aged 22-52 years, were examined. The diagnoses were 
based on surgical specimens and th e ir  h isto log ica l examinations and/or on c lin ic a l and sec­
re to ry  remission a fte r transsphenoidal microsurgery. The investigations were made p r io r  to  any 
therapy, in the fo ll ic u la r  phase o f the menstrual cycle , unless the patients were amenorrhoic. 
Eight volunteering nonobese healthy women, aged 16-40 years, served as controls. Consent was 
obtained from each of them.
The venous blood samples were withdrawn under standard ambulatory regimen at 8, 16, 20, 
24, and again at 8 o'clock, fo r steroid analysis.
Steroid Analyses
In each serum sample, besides co rtiso l, the follow ing androgens were measured: andro- 
stenedione, 11-hydroxyandrostenedione, dehydroepianrirosterone, dehydroepiandrosterone sulphate 
and testosterone. A ll six steroids were determined by radioimmunoassay (RIA), using antisera 
prepared in our laboratories, and tr it ia te d  radioligands. The reagents and procedures fo r  de­
term ination of cortiso l /13 /, androstenedione /11 /, 11-hydroxyandrostenedione /12 /, dehydro­
epiandrosterone /3 / and testosterone /6 / were described elsewhere. Dehydroepiandrosterone 
sulphate was estimated by the method of Buster and Abraham /2 /.  Only chemicals o f analytica l 
grade were used. Radioactivity was measured on a Packard-Tricarb liqu id  s c in t i lla t io n  spectro­
photometer. The lo g -lo g it p lo t was routinely used fo r calculation of RIA resu lts . The sensi­
t i v i t y  ( i .e .  the lower l im it  o f de tectab ility) and coe ffic ien ts  of variation of the assays are 
presented in Table I .  The l i s t  o f a l l  measured ind iv idua l values is  available on request at the 
authors.
Table I
S ensitiv ity  and average in tra - and interassay coefficients of 
variation for serum steroids
Serum steroid Sensitiv ity
Intraassay
(%)
Interassay
( «
Androstenedione 0.21 nmol/L 5.4 11.6
11-hydroxy-
androstenedione
0.26 nmol/L 6.3 8.8
Dehydroepiandro­
sterone 0.21 nmol/L
6.7 9.8
Dehydroepiandro­
sterone sulphate
0.32 pmol/L 6.4 9.2
Testosterone 0.15 nmol/L 4.5 6.8
Cortisol 24 nmol/L 7.9 10.3
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Biometrical Analyses
Each steroid diurnal p ro file  was processed fo r each diagnostic group by Halberg’ s 
cosinor analysis /1 /,  using o rig ina l programmes /10 /.
The estimated means and the ir 95% confidence in te rva ls  are given for mesor (the rhythm- 
adjusted mean), amplitude (h a lf of the 24-hour v a r ia b ili ty  due to the rhythm) and acrophase 
(the estimated time o f peak value). The significance o f 24-hour rhythmicity was tested by the 
one-sided t  test applied on the difference between amplitude and zero. The significance of 
differences between mesors, amplitudes and acrophases in controls, ACTH-dependent Cushing's 
syndrome and adrenal adenoma was tested with the aid of the Mann-Whitney tes t. The level of 
s ta t is t ic a l significance for tests has been chosen at the probability alpha = 0.05.
Results
The inspection of Fig. 1 reveals an unequivocal finding: conspicuously 
low serum concentrations of dehydroepiandrosterone and particu la rly  of its  
sulphate in patients with cortiso l producing adrenal adenoma.
The biometrical analysis (Table I I )  detected the presence of a sig­
n ifican t 24-hour periodicity for each steroid in a ll groups. Besides, some 
differences were ascertained both between the studied groups and between the 
steroids. A sign ificant elevation of the rhythm-adjusted mean (mesor) was 
found for cortiso l and 11-hydroxyandrostenedione in both forms of Cushing's 
syndrome. On the other hand, the mesor as well as the amplitude of dehydro­
epiandrosterone and i ts  sulphate were s ign ifican tly  lowered in adrenal ade­
noma, compared to controls and to the ACTH-dependent Cushing's syndrome. 
A s ign ifican tly  decreased amplitude was observed also for androstenedione 
in adrenal adenoma versus controls.
Some sign ificant differences concern also the acrophases ( i.e .  the 
estimated times of peak values) of serum androgens (Fig. 2).
The typical morning peaks observed in controls (with some delay for 
dehydroepiandrosterone sulphate), were lacking in adrenal adenoma, where the 
culmination was shifted towards the night hours. The time decomposition was 
less pronounced in ACTH-dependent Cushing's syndrome, where the steroid 
levels (except for testosterone) culminated around the noon. S ta tis t ic a lly
------------------ >■
Eig. 1. The 24-hour steroid p ro files  ( f u l l  c irc les  = measured values, dashed lin e  = estimated 
cosine curve for the group) in controls (n=8), patients with ACTH-dependent Cushing's syndrome 
(n=7), and patients with Cushing's syndrome due to adrenal adenoma (n=5).
Vertica l scales in nmol/L, for dehydroepiandrosterone sulphate in pmol/L. F = c o rtis o l, 
AD = androstenedione, HA = 11-hydroxyandrostenedione, 0 = dehydroepiandrosterone, DS = dehydro­
epiandrosterone sulphate, T = testosterone. Asterisk denotes a missing measurement
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Table I I
Rhythm characteristics fo r serum steroids in  the three groups of serum donors
Serum Group of Mesor Amplitude Acrophase Mean percentage
steroid serum donors (95% conf. lim its ) (95% conf. lim its ) (95% conf. lim its ) rhythm (%)
Cortisol Controls4 308 220 10:47 87
(F) (251-365) (164-277) (09:37-11:58)
CS-ACTHл # 654<§> 151 13:01 56
(496-811) (79-222) (09:11-16:52)
CS-adenoma" i f 807® 205 19:38@ 60
(569-1046) (-7-418) (15:50-23:26)
Androstene- Controls i f 2.5 1.0 10:36 77
dione (1 .6 -3 .4 ) (0 .7 -1 .3 ) (07:53-13:19)
(AD) CS-ACTH i f 2.5 0.7 11:13 40
(1 .8 -3 .2 ) (0 .1 -1 .3 ) (07:55-14:32)
CS-adenoma * 1.6 0.4@ 03:45 42
(0 .8 -2 .5 ) (0 .0 -0 .7 ) (22:04-09:26)
11-hydroxy- Controls # 4.9 3.7 10:33 79
androstene- (3 .6 -6 .2 ) (2 .5 -5 .0 ) (09:21-11:44)
dione CS-ACTH i f 9.5@ 3.0 11:59 51
(HA) (7.9-11.0) (1 .4 -4 .6 ) (09:59-13:59)
CS-adenoma i f 11.2@ 3.0 05:09 86
(4.4-18.0) (1 .2 -4 .9 ) (00:53-09:26)
Dehydroepi- Controls i f 14.3 8.00 09:52 80
androsterone (10.8-17.8) (5.9-10.0) (08:27-11:17)
(D) CS-ACTH i f 13.7 4.9 11:44 49
(8.3-19.1) (2 .5 -7 .3 ) (08:14-15:15)
CS-adenoma i f 4.6@ ,& 1.0@ ,& 04:14 47
(3 .1 -6 .1 ) (0 .6 -1 .5 ) (22:56-09:32)
Dehydroepi- Controls i f 8.1 2.7 13:44 45
androsterone (6.1-10.1) (1.2—4.3) (11:13-16:15)
sulphate CS-ACTH i f 8.4 2.6 11:35 60
(DS) (3.3-13.5) (0 .9 -4 .3 ) (07:30-15:40)
CS-adenoma i f 1.0@ ,& 0.2@ ,& 01:21 @ ,& 61
(-0 .2 -2 .2 ) (0 .0 -0 .4 ) (23:04-03:40)
Testosterone Controls i f 1.2 0.4 07:31 82
(T) (0 .9 -1 .5 ) (0 .2 -0 .6 ) (06:04-08:59)
CS-ACTH i f 1.2 0.4 15:36 (§3 59
(0 .7 -1 .7 ) (0 .1 -0 .6 ) (10:18-20:54)
CS-adenoma i f 1.2 0.4 00:35(5) ,& 56
(0 .5 -2 .0 ) (0.0-07) (21:34-03:36)
Mesor (rhythm adjusted mean), nmol/1, for DS pmol/1
Amplitude (ha lf of the 24-hour v a r ia b ility  due to the rhythm), dtto
Acrophase (the estimated peak time), h:min
@> = s ign ifican t difference against controls, & = dtto  between CS-ACTH and CS-adenoma (two-
sided Mann—Whitney—Wilcoxon test)
i f  = significance of the rhythm (one-sided f te s t )
*n=8; /'Cushing's syndrome, ACTH-dependent (n=7); "Cushing's syndrome, adrenal adenoma (n=5)
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s ign ifican t sh ifts of androgen peaks have been detected, however, only fo r 
dehydroepiandrosterone sulphate and testosterone in  adrenal adenoma versus 
both controls and ACTH-dependent Cushing's syndrome (Table I I ) .
The percentage rhythm, showing the quality of f i t t in g  of data, ranges 
between 40 and 87% of variance, explained by the regression. I t  is  usually 
lower in Cushing's groups than in the controls.
Discussion
Our data add a chronobiological dimension to earlie r descriptions of 
serum androgen levels in  Cushing's syndrome. Thus, the finding of a s ig ­
n ific a n tly  lower mesor o f dehydroepiandrosterone and its  sulphate in cor­
tisol-producing adrenal adenoma extends the frequently-cited observation of 
Yamaji et al. /15/, who demonstrated that the morning values of dehydroepi­
androsterone sulphate were normal or increased in  ACTH-dependent Cushing's 
syndrome, while they were lower than those of normal subjects in a l l  of 
th e ir  patients with hypercortisolism due to adrenal adenoma. In Cushing's 
syndrome due to adrenal adenoma, low serum dehydroepiandrosterone sulphate 
levels in the morning have been reported by some other authors, too /7, 14/. 
In the study of Levine e t a l. /9/ an increased level of serum dehydroepi­
androsterone sulphate was ascertained in one out of six patients with cor­
tisol-producing benign adrenal adenoma. On the other hand, extremely low 
serum levels of th is  androgen were encountered in  one out of our seven pa­
tie n ts  with ACTH-dependent Cushing's syndrome (Fig. 1). Accordingly, low
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serum dehydroepiandrosterone sulphate in cortisol-producing adrenal adenoma 
cannot be considered an absolute rule.
Our finding of increased ll-hydroxyandrostenedione mesor in both 
studied forms of Cushing's syndrome is in agreement with the only previous 
description /4 / of its  increased levels in morning samples of one patient 
with ACTH-dependent Cushing's syndrome and two patients with co rtiso l- 
producing adrenal adenoma.
A pronounced difference between controls and both studied forms of 
Cushing's syndrome has been ascertained in the present study fo r mean acro- 
phases of co rtiso l as well as for those of androgens. They were shifted from 
the physiological morning hours towards the noon in ACTH-dependent Cushing's 
syndrome and towards evening (co rtiso l) and night (androgens) hours in cor­
t is o l producing adrenal adenoma. Thus, a marked time dissociation between 
peak outputs of co rtiso l and androgens appears as a feature of adrenal 
adenoma, not yet described according to our best knowledge.
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T H E R A P Y
COMBINED CYCLOSPORIN-A AND METHYLPREDNISOLONE TREATMENT 
OF GRAVES' OPHTHALMOPATHY
A. LEÖVEY, GY. В A К Ú , J.  SZABÓ, К.  KÁLMÁN, E. FÓRIZS
F irs t Department of Internal Medicine, University Medical School, Debrecen,
Hungary
(Received: December 15, 1992)
Twelve patients with Graves' ophthalmopathy (grade 1-6, ATA c la ss ifica tio n ) were 
treated with Cyclosporin-A, systemically in combination with méthylprednisolone. We observed 
s lig h t or moderate favourable e ffec t in 9 cases. Our data suggest that the benefit was due to 
the méthylprednisolone, the e ffe c t iv ity  of which was enhanced by the cyclosporin even in the 
glucocorticoid-resistant cases.
Keywords: Graves' ophthalmopathy, Cyclosporin-A, méthylprednisolone
Introduction
The unsolved treatment and severe side effects of immunosuppressive 
drugs led to the administration of Cyclosporin-A (a non-myelotoxic immuno­
suppressant used in organ transplantation) in some of the organ-specific 
autoimmune diseases. The f i r s t  publication of successful treatment of 
Graves' ophthalmopathy with Cyclosporin-A appeared in 1983 /13/, and i t  was 
followed by reports on d iffe ren t success /1, 2, 5, 6, 11, 12, 15, 16/. There 
was no significant difference in efficacy between the prednisone and cyclo­
sporin monotherapy in  the study of Kahaly et a l. /7 / and Prummel et al. 
/10/. The combination of prednisolone and cyclosporin seemed to be more ef­
ficacious than the monotherapy /4 /. A reduced dose of corticosteroids in 
th is  combination may be followed by less serious side effects. Despite many 
e ffo rt there is no established protocol for administration of cyclosporin in 
the treatment of Graves' ophthalmopathy.
O ffprin t requests should be sent to: A. leövey, H-4012 Debrecen, P.0. Box 19, Hungary
Akadémiai Kiadú, Budapest
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Materials and Methods
Twelve patients su ffe ring  from Graves' ophthalmopathy (classes 1-6, grading the signs 
w ith in  each class: o, a, b, c, by American Thyroid Association /14 /) were treated with Cyclo- 
sporin-A. The patients proved res is tan t to glucocorticoid monotherapy previously, which was 
performed for 12-16 weeks e ith e r by méthylprednisolone or prednisolone. (Méthylprednisolone was 
administered by the same dose and regimen as combined w ith cyclosporin (see la te r) . The to ta l 
dose o f prednisolone varied between 2000 and 2500 mg.)
The patients, 10 females and 2 males aged between 35 and 50. A ll were euthyroid at the 
beginning of cyclosporin treatment. Earlier, they were given long-term methimazole treatment.
Ophthalmopathy had s ta rted  5 and 3 years ea rlie r in  2^ cases, 1 to 2 years e a rlie r in  5^ 
cases and 3 to 7 months e a r lie r  in  b_ cases.
The following examinations were performed before treatment: FT4, sensitive TSH, T3-up- 
take, TRH stimulation te s t, tes ts  fo r TRAb, and antibodies against thyroglobulin and micro­
somal antigen.
The patients were checked by an ophthalmologist: v isua l acuity, bulbar m o tility  (Hess 
ch a rt) , and proptosis were measured (Herte l), visual f ie ld  te s t (s ta tic  and k in e tic ), s lit-lam p 
examination; ophthalmoscopy, CT-scan or NMR and ultrasonographic examinations of the re tro ­
bulbar area were performed. The contro l of o rb ita l lesions was performed by ultrasonography.
Relying on c lin ic a l observations, we applied cyclosporin in  combination with gluco- 
corticoste ro id  in the treatment o f Graves' ophthalmopathy.
The daily dose o f Cyclosporin-A was 4-10 mg/kg. The drug was administered o ra lly , d i­
vided in to  two doses in  each case. Besides cyclosporin, méthylprednisolone was administered 
v iz .  250 mg intravenously every 2nd or 3rd day ( to ta l amount = 1.5-2 g); a fte r the i . v .  admi­
n is tra tio n  every second day 32 mg doses were given o ra lly  and the above dose was decreased by 
В mg every two-week period.
The maintenance dose o f méthylprednisolone was 8-12 mg/day. Depot ACTH was given at the 
end o f treatment.
The peripheral blood cyclosporin level was checked weekly during treatment. The cyclo­
sporin whole-blood levels varied between 250 and 400 ng/ml (polyclonal antibodies, using the 
Sandoz diagnostic k i t ,  analysed by Abbott TDX). Urine, blood urea nitrogen, serum creatinine, 
serum b iliru b in  and the hepatic transaminases were contro lled, every two weeks.
Results
Among our patients one (No. 1) showed s ign ifican t improvement; her 
d ip lop ia , corneal ulcer and optic neuropathy ceased. She has been in per­
manent remission for 5 years (Table I) .
We observed moderate improvement in two patients (Nos 2 and 9). Their 
d ip lopia improved, corneal and optic nerve involvement ceased.
Six patients (Nos 3, 4, 5, 6, 11, 12) showed only s ligh t, not suf­
f ic ie n t ly  impressive, improvement. Their corneal involvement decreased, 
d ip lopia diminished or was unchanged (Table I I ) .
Ophthalmopathy worsened during the last period of treatment in  3 pa­
tie n ts  (Nos 7, 8, 10): th e ir  optic neuropathy and diplopia worsened.
F irs t of a ll as a consequence of the decrease of soft-tissue signs and 
symptoms, a ll of our patients improved considerably in the f i r s t  2-4 weeks
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Table I
Summarized e ffec t of combined cyclosporin A and méthylprednisolone treatment
Patient Duration
Cyclosporin therapy
Improved Worsened Remarksof G.O. mg/kg/day weeks
1. G. J. 
49 yr 6 m 5 4 remission
2. K. 3. 
58 yr 2 yr 6.5 15 moderate
cataract,
glaucoma
3. V. D. 
48 yr lé m 5 13 mild
recurrent
thyrotoxicosis
4. D. V.
49 yr 17 m 10-5 24 mild
cataract,
glaucoma
5. N. L. 
49 yr 1 yr 5 24 mild
é. F. J. 
45 yr 5 yr 7.5 12 mild glaucoma
7. K. 3. 
45 yr 6 m 6 16 + diabetes m.
8. Sz. B. 
44 yr 3 m 6.5 24 +
eye muscle 
surgery
9. N. 3.
37 yr 3 yr 4 10 moderate
10. Ny. G. 
44 yr 5 m 4 20 -
chr. duodenal 
ulcer
11. K. G. 
41 yr 7 m 7 -5 12 mild
12. Sz. E. 
38 yr 1 yr 6 -5 12 mild
G.O.: Graves' ophthalmopathy, m: month, yr: years(s)
of treatment. Improvement slowed down or stopped la ter, even in 5 cases 
there was a relapse during the last period of the course.
Ihe combined cyclosporin-methylprednisolone treatment ceased the cor­
neal involvement in  a l l  В cases; the optic neuropathy improved in 5 cases, 
but i t  worsened in  one (No. 10) (labié I I ) .
Proptosis did not change sign ificantly  and the diplopia seemed res is ­
tant to the treatment. Diplopia showed some improvement in 6 cases, i t  did 
not change in 4 and i t  worsened in 2 cases.
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Table I I
Changes of ophthalmopathy according to  c lass ifica tion  of A.T.A.
Patient
C la s s i f ic a t io n
Before treatment After treatment
1 2с Зс 4Ь 5Ь 6Ь 2а ЗЬ 4о 5о 6о
2 2с Зс 4Ь 5а 6а 2Ь Зс 4а 5о 6с
3 2с ЗЬ 4Ь 5а 6а 2Ь За 4Ь 5о 6о
4 2с Зс 4с 5Ь 6а 2Ь Зс 4Ь 5о 6а
3 2Ь ЗЬ 4Ь 5а 2Ь ЗЬ 4Ь 5о
6 2с Зс 4Ь ЗЬ 6а 2с ЗЬ 4Ь 5о 6а
7 r :
1:
2Ь ЗЬ 4с 
2с ЗЬ 4с
г :
1 :
2с ЗЬ 4с 
2с ЗЬ 4Ь
8 r :
1 :
2Ь Зо 4а 
2Ь За 4с
г :
1 :
2Ь Зо 4с 
2Ь Зо 4Ь
9 Г : 
1 :
2с За 4Ь 
1 2а
г :
1 :
2о За 4а 
1 2о
10 г :1:
2с За 4Ь 5Ь 6а 
2с За 4Ь
г:
1:
2с За 4Ь 5о 6Ь 
2с За 4Ь 5о 6а
11 Г :
1 :
2Ь За 4с 
2Ь Зо 4с
Г :
1 :
2а Зо 4Ь 
2а Зо 4Ь
12 Г :
1:
2Ь ЗЬ 4Ь 5а 
2Ь За 4Ь 5а
Г :
1 :
2а За 4Ь 5о 
2а Зо 4Ь 5о
r :  r ig h t, 1: le f t
We failed to detect any s ign ificant change in the volume of extra- 
ocular muscles at the end of treatment (Table I I ) .  I t  was unchanged in 3 
cases (Nos 3, 4, 5), tended to decrease in  5 (Nos 6, 7, 8, 9, 11) and in ­
creased in 1 (No. 10); i t  decreased in the le f t  eye and increased in  the 
r ig h t one in 1 case (No. 2). None of these changes were sign ificant.
Visual acuity improved in 4 cases, worsened in 4 and did not change 
in  4. One (No. 4) of four patients whose vision deteriorated had cataract 
which progressed during the 6 months of treatment; in contrast, her so ft- 
tissue involvement showed a mild improvement and the corneal ulcer healed.
Side effects were observed in 6 cases. Mild nephropathy and hepato- 
pathy occurred in the 3rd week of treatment in 1 case (No. 1), which wor­
sened in  the 4th. Cyclosporin treatment was stopped in th is  case. The urine, 
renal function tests, serum b ilirub in  and hepatic transaminase enzymes of
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Table I I I
Side effects of combined cyclosporin A and méthylprednisolone treatment
Patients S i d e  e f f e c t s
1 Transitory mild nephropathy and hepatopathy, hyperesthesia, dysgeusia, hypertrichosis, swelling of the breasts
2 Hyperesthesia, dysgeusia, hypertrichosis
3 0
4 Paresthesia, hypertrichosis
5 0
6 Paresthesia, headache
7 0
8 Oral candidiasis
9 0
10 Hypertrichosis (s lig h t moustache growth)
11 0
12 0
th is  patient normalized (Table I I I )  within 2 weeks. Mild hirsutism appeared 
in 4 cases, and 4 patients had neurological complaints: paresthesia, hyper­
esthesia and/or a disturbance in the sense of taste.
Discussion
Despite its  use since 1983 /13/ the treatment of Graves' ophthalmo­
pathy with cyclosporin is  controversial /3, 8, 10/. The interpretation of 
our results is  d if f ic u l t  and ambiguous. We found that Cyclosporin A has not 
had a su ffic ien tly  convincing effect on our patients in the treatment of 
Graves' ophthalmopathy. The observed s ligh t or moderately favourable effect 
in 9 cases out of 12 can be far more attributed to the méthylprednisolone 
than cyclosporin. The sudden improvement during the f i r s t  period of tre a t­
ment may be explained by the intravenously administered high dose of methyl- 
prednisolone. Namely, cyclosporin needs a longer time to develop i t s  e ffect. 
The dose of méthylprednisolone was increased in some cases i f  the a c tiv ity  
of in f i l t r a t iv e  symptoms had reappeared or increased in the course of tre a t­
ment. In these cases we observed a sudden beneficial e ffect. But we have to
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consider that the previously administered glucocorticoid monotherapy was 
unsuccessful in these cases. Therefore, we think i t  lik e ly  that some addi­
tiona l immunosuppressive and/or immunomodulating qualities of cyclosporin 
have enhanced — under certain conditions — the e ffe c tiv ity  of glucocorti- 
costeroid treatment.
During the 3rd week of treatment the hyperthyroidism relapsed in one 
patient (No. 3), in spite of the improvement of her ophthalmopathy. Because 
of her serious thyrotoxic condition she was operated on. After operation the 
cyclosporin treatment was continued. From pathogenetical point of view, i t  
seems to be worthwhile to mention that, while the ophthalmopathy s ig n if­
ican tly  improved, a severe relapse occurred in her thyroid hyperfunction. 
Earlie r we had another patient suffering from severe thyrotoxicosis and 
diabetes mellitus. This patient was successfully treated with antilympho- 
cy tic  globulin but her ophthalmopathy became active and progressed at the 
same time. These observations confirm the supposition that Graves' ophthal­
mopathy had a d is tin c t pathogenetic en tity  than Graves' disease i ts e lf .
Our data are in  agreement with findings of the Prummel's group, who 
found that prednisolone monotherapy is  more effective than cyclosporin 
alone, and the combination of the two drugs can be effective in  patients 
who do not respond to e ither treatment alone.
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The case history of a 30-year-old female patient is  reported. Following an unknown 
v ira l in fection that had occurred four years e a rlie r, insulin-dependent diabetes m ellitus 
v i t i l ig o ,  Addison's disease, amenorrhoea, hyperthyreosis and, f in a lly ,  severe pancytopenia with 
dominant thrombocytopenia developed. On the basis of c lin ic a l aspects and laboratory findings, 
an infrequent polyglandular autoimnune syndrome (type I I )  was ve rified . Substituent therapy and 
steroid stoss therapy also was introduced, without any sign o f improvement. For the lack of 
therapeutic e ffec t and owing to serious thrombocytopenic bleeding, treatment with Cyclosporin-A 
was indicated, which produced to ta l remission of the illn e s s . Nowadays the patient being on 
follow-up, has no sign of disease a c tiv ity .
Keywords : Polyglandular autoimmune syndrome type I I ,  c lin ic a l symptoms, Cyclosporin-A
Introduction
Polyglandular autoimmune syndrome (PGAS) is  based on an autoimmune 
mechanism resulting in malfunction of two or more endocrine organs. On the 
basis of the presence or absence of adrenal cortex insufficiency, two major 
groups of the disease are distinguished. I f  the symptom complex is , conco­
mitant with Addison's disease, a further well-determined twofold d is tinc tion  
can be made. The two types are d ifferentiated on the basis of age, beginning 
of disease and co-occurrence of certain endocrine diseases /1, 5—8/.
PGAS type I I  is  characterised by the presence of primary adrenal cor­
tex insufficiency, autoimmune thyropathy and/or insulin-dependent diabetes 
mellitus. The key element of the syndrome is  adrenal cortex insuffic iency, 
thought in the past i t  was attributed to tuberculotic orig in, nowadays i t
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is  frequently believed to be a result of an autoimmune process, and is  often 
accompanied by an autoimmune damage of other endocrine glands or nonendo- 
crine organs /6 /.
The present study, through the case history of a young female patient, 
is  intended to draw attention to this rare and manywise manifested disease, 
i t s  pathomechanism and possible treatment. Because th is  syndrome is  very 
rare diagnosed and the Cyclosporin-A treatment had dramatic e ffec t, makes 
th is  case conspicious. I t  should be noted that our e ffo rt to find  sim ilar 
therapeutic strategy fo r PGAS in international medical lite ra tu re  has 
fa ile d .
Case re p o rt
On A pril 1, 1992, I .  Sz. female, aged 30, was admitted to our hospital in  severe con­
d it io n .  Her grandparents died o ld , her father died of lung cancer. Ihe pa tien t's  mother is  
a liv e , in  good health. She has had no sib lings. She is  the mother of a boy being in  good 
health .
In 1982 she had a normal delivery. In 1988, on indication of dysmenorrhea following 
some v ir a l in fection, she had her intrauterine contraceptive device removed, and because of 
поп-severe thrombocytopenia and splenomegaly, she was taken over from the gynaecological ward 
to  our section. Ihe patient was free from complaints, we did not observe bleeding tendency. 
Her p la te le t count was 110 x 10 v l ,  and sternum smear negative. As an autoimmune o rig in  could 
not be excluded, she was summoned fo r control inspection but she did not present. In 1989, she 
was admitted to the medical ward o f the local hospital w ith asthenia, weight loss, polyuria, 
po lyd ipsia and hypotonia. Insulin-dependent diabetes m ellitus (IDDM) with accompanying v it i l ig o  
was diagnosed. On the basis o f c lin ic a l symptoms and hypotension, hypadrenia was suspected but 
not v e r ifie d . The patient was treated with a 4 I.U . Insu lin  Actrapid MC (Novo Nordisk) and 16
I.U . Insu lin  Ultralente MC (Novo Nordisk). In 1990, she was readmitted to medical ward with 
cumulative hypoglycaemic episodes. There was brownish pigmentation on her face and v it i l ig o  
scattered on her body; hepar: 2 cm, lie n : 3 cm under costal arch; blood pressure: 90/70 mmHg, 
tachycardia (120/min) and amenorrhea. She was remarkably th in . High sen s itiv ity  to  in su lin  and 
low le v e l of plasma co rtiso l which did not increase on ACÏH, hyponatraemia, hypochloraemia, 
hyperpotassaemia, low leve l of urine cortiso l and 17-ketosteroid values ju s tif ie d  the diagnosis 
o f Addison's disease. Since the alleged cause of e a rlie r diagnosed IDOM and adrenal cortex in ­
su ffic ie ncy  were of autoimmune o rig in , the patient was submitted to immunochemical tes ts . In 
th a t time besides insuffic iency o f the two endocrine glands, hyperthyrosis was diagnosed. 
Laboratory findings: E.S.R.: 2 mm/h, WBC: 3 .4 x l0 ^ / l ,  Hgb: 124 g/1, p la te le t count: 70x10^/1, 
serum cholesterol: 2.3 mmol/1, plasma co rtiso l: 3.2 |ug/dl, 6 h a fter ACTH: 5.0 pg /d l, 24 h 
a f te r  ACTH: 5.3 fjg /d l, urine c o rt is o l:  8 jjg/24 h, antinuclear antibodies: negative complement 
f ix a t io n  with hepatic antigen: negative, with WBC antigen: negative, circu la tion immunocomplex 
(PEG-precipitate): 340 pg/ml, IgG: 7.6 g/1 (s lig h t ly  lower than normal), IgA: 1.5 g/1, IgM: 
1.0 g/1 (normal), C3: 72 mg/dl (normal), C4: 12 mg/dl (subnormal), antinuclear antibody (with 
in d ire c t immuno-fluorescent method): negative. The patient was discharged with 2 I.U . Insu lin 
Actrapid MC, 2 I.U. Insu lin  U ltra len te MC, 3 x 10 mg thiamazole, 2 x 0.1 mg fluorocortisone 
d a ily  medication.
A fter re-admission with disturbance of carbohydrate metabolism, in February and March, 
1991, she was treated in medical ward and intensive therapy un it, when, following a 13-month 
treatment with thiamazole, thyro id  stimulating hormone (TSH) level normalized, therefore, the 
thiamazole medication was abandoned. With 2 I.U . Insu lin  Actrapid MC 6 I.U . Insu lin  Monotard MC
TREATMENT OF POLYGLANDULAR AUTOIMMUNE SYNDROME 189
(Novo Nordisk), 2 x 0 .1  mg fluorocortisone da ily  substitute medication the patient was free 
from complaints. Then she was, once again, admitted to medical ward. On admission she had the 
following complaints: asthenia (appeared a month before and was constantly increasing), g in­
g iva l haemorrhage, petechias and suffusions on the legs. Hypoplasia of the bone marrow causing 
pancytopenia was diagnosed. The patient was taken over to our section with suspicion o f 
systemic autoimmjne disease. From among the symptoms showed on admission we wish to lay empha­
s is  on purpuras, suffusions, v i t i l ig o  a l l  over the body, fa c ia l pigmentation, anaemic mucosas 
and severe gingival haemorrhage. Liver and spleen palpable 2 cm and 3 cm under the costal 
arch, respectively. Blood pressure: 120/80 mnbg, body weight: 50 kg. Laboratory find ings: 
E.S.R.: 9 mm/h, WBC: 2.1 x lO 'fyl, hgb: 88 g/1, p la te le t count: 50 x 10^/1, pe rifé riá i blood 
smear: seg: 56%, mo: 2%, ly : 42%, bleeding time (with Duke's method): > 20 min, prothronbin 
ra te : 1.08, thrombin time (TT): 27 sec, contro l: 20 sec, p a rtia l thromboplastin time (PTT): 43 
sec, control: 39 sec, to ta l serum protein: 45 g/1, albumin: 32 g/1, Na: 145 mmol/1, K: 4.2 
mmol/1 urin protein: opalescent, Donne's tes t: negative, glucosuria was present, acetonuria was 
present too. Urine sed.: negative. Direct and ind irect Coombs te s t: negative. LE-test: negative. 
Antinuclear antibody: negative, anti-DNA (w ith ELISA method): negative, smooth muscle antibody 
(HRP0 immunohistology): negative, antithrombocyte antibodies (w ith d irect immunofluorescent 
method): positive. On the basis of the iden tified  and treated Addison's disease, IDOM, v i t i l ig o  
and concomitant immunothrombocytopenic purpura, we diagnosed PGAS type I I .  Against immuno- 
thrombocytopenia causing severe bleeding, we applied stoss therapy with methylprednisolon 
natirum succinate (1 g da ily  fo r 3 days, thereafter 250 mg da ily  fo r 4 days). From the 8th day 
we applied 1 mg/kg b.w. methylprednisolon o ra lly . However, on the 3rd day, gastro in testina l 
diffuse mucosal bleeding developed, we added Cimetidine, etamsylate, conserved erythrocyte 
mass, and from the 6th day fresh frozen plasma to the treatment. Because of refractory thronbo- 
cytopenia, on the 8th day we introduced 1 mg V incris tin  su lfa te  intravenously. The poor 
therapeutic e ffect and unceasing severe bleeding causing grave shock necessitated the in tro ­
duction of Cyclosporin-A therapy on the 11th day (dose: 5 mg/kg b.w.). A few days la te r 
bleedings discontinued and the blood counts normalized. On the 20th day the patient was d is ­
charged, she was free from complaints. Since then, she has been under follow-up. Maintenance 
therapy: d ie t with 140 g carbohydrate content, mornings 16 I.U . Insu lin  Actrapid MC + 20 I . U. 
Insu lin  Monotard MC, evenings 8 I.U. Insulin Actrapid MC + 8 I.U . Insu lin Monotard MC, 3 xO .l 
mg fluorocortisone, 16 mg methylprednisolon, 2 mg/kg b.w. Cyclosporin-A (1.25 ml Sandimmun 
Sandoz) o ra lly , potassium citricum , calcium lactogluconate, aluminium-magnesium-carbonate 
da ily . Control inspection findings: WBC: 5 .5 x l0 ^ / l,  Hgb: 141 g/1, p la te le t count: 10.4x10^/1, 
to ta l serum protein: 62 g/1, albumin: 32 g/1, cholesterol: 3.9 mmol/1, plasma c o rtis o l: 6 h: 
580 nmol/1, 24 h: 540 nmol/1. Immunological tests: lymphocyte marker tests (ORTHO-monoclonal 
antibodies): to ta l T count near minimum of normal range (CD 3: 52%), subnormal T helper count 
(CD 4: 20%), T suppressor population: higher than normal (CD 8: 32%), to ta l В count: normal 
(CD 19: 12%). Surface Ig expression of В ce lls : polyclonal. Adrenal cortex antibody, thyro- 
globulin antibody, thyroid microsome antibody, antinuclear antibody, anti-DNA: negative. 
Examinations were carried out a fte r complete therapy. Soluble interleukin-2: 40 pg/0.1 ml 
(normal). HLA-status: HLA-B 8, DR-2 and -3 are positive. For c lin ic a l course see Table I .
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Table I
C lin ica l course 
I .  Sz., female (born 1962)
Year Diagnosis
1982 normal de livery
1988 unidentified v ira l infection
dysmenorrhoea
splenomegaly
1989 diabetes m e llitus type I  
v it i l ig o
latent Addison's disease
1990 manifest Addison's disease
amenorrhoea
hyperthyrosis
1992 immune thrombocytopenia
Discussion
Polyglandular ailment was f i r s t  reported in 1926 by Schmidt /11/, who 
had observed idiopathic adrenal cortex insufficiency and thyropathy in two 
patients. He emphasized the identity of lymphocytic in f i lt ra t io n  in both 
organs /11/. The range of polyglandular diseases broadened when association 
of hyperthyrosis, diabetes mellitus and hypoparathyrosis with Addison's 
disease was recognized /3 /.  In 1954 Bloodworth et al. /2 / a ttributed poly­
glandular diseases to an immune mechanism. Later, in 1956, Roitt et a l. /10/ 
were the f ir s t  to find  anti-thyroid antibodies and circulating adrenal anti­
bodies in patients who suffered from Addison's disease concomitant with 
Hashimoto's th y ro id it is . The term "polyglandular autoimmune syndrome" was 
created by Neufeld et a l. /8 / in 1981. Two major groups of the disease have 
been distinguished on the basis of presence vs absence of adrenal cortex in ­
suffic iency. A further twofold d is tinction  of the syndrome co-occurent with 
Addison's disease was proposed by Leshin /5 / in 1985 (Table I I ) .  C lin ica l 
aspects of PGAS type I  and I I  were systematized by Neufeld et a l. /7 , 8/. 
PGAS I begins in the childhood, hypoparathyrosis, Addison's disease, chronic 
mucocutaneous candidiasis frequently co-occur. PGAS I I ,  also named 
Schmidt's syndrome, is  frequently accompanied by concomitant or subsequent 
adrenal cortex insufficiency and autoimmune thyropathy and/or insulin-de­
pendent diabetes m ellitus. Nowadays, nonetheless, the term covers the combi-
TREATMENT OF POLYGLANDULAR AUTOIMMUNE SYNDROME 191
Table I I
D ivision o f polyglandular autoimmune diseases (Leshin /5 /)
A. Presence of Addison's disease
type I hypoparathyrosis
chronic mucocutaneous candidiasis 
Addison's disease
type I I Addison's disease 
autoimmune thyropathy 
diabetes m ellitus type I
B. Absence of Addison's disease
type I I I autoimmune thyropathy 
diabetes m ellitus type I 
and/or anaemia perniciosa 
myasthenia gravis 
primary b i lia ry  c irrhosis
nation of an autoimmune thyro id itis  and/or diabetes mellitus type I with 
presence of anti-adrenal antibodies and/or positive fam ilia l history, and i t  
also covers primary adrenal cortex insufficiency with hypogonadism. Females 
are at double risk  compared to males. Approximately 70% and 50% of the pa­
tien ts  display autoimmune thyropathy and IDDM, respectively. Autoimmune 
thyropathy is e ither Graves's disease or, jus t as like ly , Hashimoto's 
thy ro id itis . In a ha lf of the cases, Addison's disease appears f i r s t ,  pre­
dominantly after 20 years of age. In 20% of the cases, thyropathy or diabe­
tes mellitus occurs co-temporaneously with Addison's disease, and in 30% 
hypadrenia follows other diseases. In some cases, gonad insufficiency is  the 
f i r s t  symptom and i t  is accompanied by ovarial overweight. The association 
of non-endocrine diseases, among them v it i l ig o ,  anaemia perniciosa, myasthe­
nia gravis and immunothrombocytopenic purpura have been diagnosed very rare 
by /1, 5, 6, 8, 9, 13/.
PGAS I I  is  a re lative rare disease. Its  estimated occurrence is  15 to 
20/one million population /12/. According to recent findings, i t  is  inhe­
rite d  on by dominant autosomes way, often through generations. In its  patho­
genesis, genetic as well as environmental (v ira l)  and other (e.g. hormonal) 
factors play an important role. The fact that females are much more con­
cerned suggests the importance of hormonal factors. As most authors agree, 
the pathophysiology of PGAS I I  is  based on malfunction or insufficiency of 
suppressor T ce lls , and on the development of autoreactive clones /7, 9, 
13, 14/.
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Organ-specific antibodies may help in verifying autoimmune disease 
/13/. In a high proportion of PGAS I I  patients (60 to 90%), anti-adrenal 
antibodies have been found. Parietal ce ll antibodies have been found in 40% 
of the cases, is le t  c e ll antibodies in 25% /1, 19, 14/.
Clinicians have a choice of two possible therapies. Most of the pa­
tien ts  can be successfully treated with hormonal substitution, and immuno­
suppressive therapy can also be applied /1 , 7, 9/. Cyclosporin-A has proved 
to be the most promising immunosuppressive drug. Cyclosporin-A (Sandimmun) 
is  effective at the early stage of antigen perception, i t  hinders the pro­
duction of interleukin-2, the T and В ce ll function, and, also, i t  bars 
autoimmune mechanism. Side effects of Cyclosporin-A (hepatotoxicity, renal 
to x ic ity , gingival hyperplasia, lymphoma induction) can be reduced or 
avoided by applying a low dose /4 /.
In the above case, an autoimmune process affected several organs. 
A year after the in i t ia l  thrombocytopenia (causing dysmenorrhoea) and sple­
nomegaly, v it i l ig o ,  insulin-dependent diabetes mellitus, then manifest Ad­
dison's disease developed concomitantly with hyperthyrosis and amenorrhoea. 
Qwing to substituent therapy, the patient became p a rtia lly  free form com­
p la in ts; nevertheless c lin ica l treatment was necessary because of lab ile  
diabetes mellitus. Two years after the polyglandular disease, a grave gen­
eral bleeding developed, resulting from immune thrombocytopenia. Conti­
nuing substituent therapy and resorting to a ll therapeutic poss ib ilitie s , 
administration of Cyclosporin-A was necessary because of unsatisfactory 
therapeutic effects. Within a short time we observed remission of the dis­
ease. The patient having been under follow-up, is  now in good condition. She 
is  taking 3x2  mg/kg. b.w. Cyclosporin-A weekly.
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The author found, among 329 twin pairs, 50 (15.2%) cases of weight discordancy reaching 
or exceeding 22%. Among the 50 twin pairs, there were 65 boys and 35 g ir ls ,  a sex ra t io  of 
185.7. This degree of weight discordancy appears to be unrelated to maternal age, pa rity  and 
gestational length. Growth retardation of one or both fetuses was s ig n ifica n tly  more frequent 
(80%) among weight-discordant than among concordant one (11.1%). There were more perinatal 
deaths between discordant than concordant twins. Among the twins who were born w ith evidence 
of growth discordancy, there was s lig h tly  increased incidence of abnormal presentation, d e li­
very by cesarean section, and low Apgar score as compared to the concordants.
Keywords: Twin pregnancy, discordant growth
Introduction
Theoretically, the b ir th  weights of twins should be closely identica l, 
taking in to account the fact that they develop in the same uterine milieu. 
Nevertheless, the b irth  weights of twins often d if fe r  s ign ifican tly , usually 
as a result of discordant growth rate. Since marked difference in the b irth  
weights of twins is  of considerable frequency, i t  appeared a matter of in ­
terest to study the frequency of discordancy among twins and its  impact upon 
the circumstances of delivery and the neonatal outcome.
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P atie n ts  and Methods
The charts of childbearing patients of our in s titu t io n  from January 1, 1975, to De­
cember 31, 1992, were reviewed. U tiliz in g  the data o f the delivery books and the medical re­
cords in order to determine the frequency of twin b irth s  and the weight differences between the 
tw in s , the la tte r was determined by multiplying the b ir th  weight expressed in grams, o f the 
smaller of the twins by 100 and dividing the resu lt w ith the b ir th  weight of the larger twin 
/1 1 /. The result was expressed in  per cent. The resu lts  being ^  78%, i.e .  differences >  22%, 
were considered s ign ifican t. A weight difference of ?  21.26% (11.51 + SD 9.75%) is  w ith in the 
range of normal in Hungary /2 0 / .
We investigated the corre la tions between s ig n if ic a n tly  discordant 22%) and con­
cordant twins in terms o f maternal age, parity, gestational length, and sex of the twins. We 
also evaluated the frequency o f abnormal l ie  immediately before delivery, the method applied 
a t de live ry , the 5 minute Apgar score and relationship o f weight to calculated gestation length 
in  the investigated cases along with the respective rates o f neonatal m orta lity . The twin 
neonate was considered growth-retarded i f  his or her b ir th  weight was under the 10th percentile 
applicab le for singletons on the basis of the Deter et a l. /6 /  standards. Sex ra t io  was ca l­
culated as the number o f boys in  re lation to 100 g ir ls .  The s ta t is t ic a l significance was 
calculated on the basis of the chi-square test.
Results
During 18 years 30 671 women gave b irth  in  the obstetric unit of our 
hosp ita l. Of these, 329 (1.1%) delivered twins. From these there was evi­
dence of significant discordancy in b irth  weights (>  22%) in 50 instances 
(15.2%).
In relation to maternal age, the highest rate of weight discordancy 
occurred in the 21-35 year old age group. In re la tion to b irth  order, 1-3 
p a r ity  were found to be associated with the highest rate of weight d is­
cordancy. Relevant to the length of gestation, the highest frequency of 
weight discordancy was found between the 37th and 38th weeks.
In 29 (58%) of the 50 cases, the firs t-b o rn  twin in the remaining 21 
(42%) the second-born were larger.
In relation to gestational length, one or both of the weight-dis­
cordant twins were growth-retarded in 40 (80%) instances. Among the con­
cordant, growth retardation prevailed only in  31 cases (11.1%). This d i f ­
ference is  significant at the P< 0.001 level.
In 34 (68%) of 50 twin pairs, the smaller of the weight-discordant 
twins was growth-retarded. Both twins were growth-retarded in 6 (12%) cases. 
In 10 (20%) instances of weight-discordancy both twins were above the lower­
most 10th percentile. However, in th is group, i t  was only in one instance 
tha t of both twins exceeded 2500 g in weight.
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In the group of s ign ifican tly  weight-discordant and concordant twins 
one or both of the fetuses showed abnormal (breech or transverse) presenta­
tion in 30 cases (60%) and 145 (52%), respectively.
In those cases where there was a s ign ifican t weight-discordancy be­
tween the twins, in 30 (60%) instances was delivery effected by cesarean 
section. In the concordant group abdominal delivery was recorded in 97 
(34.7%) cases (P< 0.005).
An unfavourable 5-min Apgar score (<  7) was noted in 22.7% of the 
weight-discordant twins. In the concordant group, the frequency was 14.1% 
(an insignificant difference).
The sex d is tribu tion  of weight-discordant twin pairs were the fo l­
lowing:
Both boys: 25 Boy — g ir l:  5
Both g ir ls : 10 G irl — boy: 10
The sex ra tio  fo r twins belonging to the same sex was 250. The sex 
d istribution  of a ll weight-discordant twins was 65 boys and 35 g ir ls  (sex 
ra tio  185.7). For the 279 concordant twin pairs, the sex ratio was 108.6. 
The difference between the two was significant at P 0.001. The sex ra tio  
of a l l newborn in our department during the 18 years of the study was 106. 
As compared to th is , the sex ra tio  of 185.7 represented a very s ign ifican t 
difference (P <  0.001). In 15 cases of weight-discordancy between neonates 
of d iffe ren t sexes, the boy was larger than the g i r l  in 7 instances.
Of the 100 newborn deriving from weight-discordant twin pregnancies 
17 (17%) whereas of the 558 concordant twins 60 (10.8%) died perinata lly. 
The twin pair with b irth  weight >2500 g both survived.
The forms of placentation were: 31 dichorionic diamniotic, 16 mono- 
chorionic diamniotic and in 3 cases monochorionic monoamniotic.
Discussion
The difference between the body weights of twins is  generally express­
ed in percentage of the weight of the larger twins. There is no clear agree­
ment with regard to the defin ition  of s ign ifican t weight discordancy. Some 
authors /4, 13/, consider a difference exceeding 15% sign ificant, others 
draw the borderline at 20% /16, 17, 19/ or even at 25% /8, 15/. One study 
used the weight of the larger twins as 100% and considered the difference of 
36% as sign ificant /1 /.
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Naturally, the frequency of weight-discordancy w il l depend upon the 
c r ite r io n  u tilized  fo r de fin ition  of th is  e n tity . In this material, the use 
of a 15% weight difference would have allowed the iden tifica tion  of 83 
(25.2%) discordant twin pairs. The use of 20% weight difference would have 
define 54 (16.4%) twin pairs as discordant. A to ta l of 27 (8.2%) pairs would 
have been discordant i f  the criterion of significance had been considered at 
25% weight difference.
Weight discordancy associated with twin gestation may resu lt from pla­
cental insufficiency, inappropriate implantation site ("crowding"), devel­
opmental defect caused by chromosomal or anatomic abnormality, unequal supp­
ly  with blood, difference in u tiliza tion  of nutrients, and fe to fe ta l trans­
fusion. In princip le, most cases of weight-discordancy derive e ither from 
inadequate u tiliz a tio n , or difference in delivery of fetuses of the avail­
able nutrients. The high sex ra tio  raises the possib ility  that a sex-related 
component may influence the growth rates. This interpretation is  supported 
by the fact that the average weight of boys in singleton pregnancies is  
higher than of g ir ls  /5 , 9/. I t  was found an average weight difference of 
81-142 g in favour of boys /2, 3/. Naturally, th is difference would not 
amount, in its e lf ,  to a s ign ificant weight discordancy.
According to several reports /7, 10, 14/ weight discordancy predis­
poses to increased perinatal mortality. Some studies could not, however, 
fin d  a s ign ificantly  increased risk when the weight difference reached 
20-24% /8, 18/. In our material, among discordant twins, the frequency of 
growth retardation and perinatal mortality increased and involved one or 
both members of the pa ir. In general, the pregnancy outcome was less favour­
able in  association with weight discordancy than in its  absence.
I t  should be emphasized that the growth of the smaller twin may be an 
expression of some underlying pathological condition. For th is reason alone, 
intensive fe ta l surveillance is  necessary, once sonographic evidence of sig­
n if ic a n t weight discordancy has been demonstrated. Aorta and umbilical arte­
ry Doppler velocity waveforms allow recognition of feta l discordant weight 
/16, 17/.
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ANTICARDIOLIPIN ANTIBODIES: ASSOCIATION WITH ANTI-DNA ANTIBODIES, 
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A one-year study was conducted to evaluate the c lin ic a l significance of an tica rd io lip in  
antibody (АСА) whether i t  was a re liab le  predictor fo r thromboertralic events and related d is­
eases in systemic lupus erythematosus (SLE) patients. The corre lation between АСА and anti-ds- 
DNA antibodies and disease a c tiv ity  was also studied. Of particu lar importance was the question 
i f  any association could be found between АСА p o s it iv ity  and renal disorders in SLE patients. 
One hundred and eighty-seven serum samples from 8B SLE patients were assayed fo r АСА. C lin ica l 
records of these patients were reviewed fo r a history of throntioentrolic events, related d is­
eases and renal disorders, 80.7% of the 88 SLE patients were positive fo r АСА. The incidence of 
thrombosis and related diseases w ith in th is  group was 35.1%. Since the corre lation was not 
s ign ifican t, i t  does not seem to be advisable to use elevated АСА values as predictive for 
thromboentoolic events and related diseases. On the other hand, an apparent association between 
АСА levels, anti-ONA antibody levels and disease a c tiv ity  was found.
Keywords: Cardiolipin antibody, anti-ONA antibody, systemic lupus erythematosus
Introduction
Antiphospholipid antibodies in SLE have received considerable atten­
tion. There is  an association between antiphospholipid (or anticard io lip in ) 
antibodies, biological false positive test for syphilis and lupus an ti­
coagulant a c tiv ity . There are characteristic c lin ic a l conditions associated 
with АСА: a rte r ia l and venous thrombosis, thrombocytopenia and recurrent 
fe ta l loss. These associations are also termed antiphospholipid syndrome /5 /.
Abbreviations: АСА: an ticard io lip in  antibody, SLE: systemic lupus erythematosus,
anti(-ds)-DNA: anti(-double-stranded) DNA antibody
O ffprin t requests should be sent to: Péter Gergely, 2nd Department of Medicine, Semmel­
weis University Medical School, H-1088 Budapest, Szentkirályi u. 46, Hungary
Akadémiai Kiadó, Budapest
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Our study aimed at evaluating the c lin ic a l significance of anticardio- 
l ip in  antibody (АСА): the association between АСА and thromboembolic events 
and renal involvement, and the correlation between АСА, anti-ds-DNA an ti­
bodies and disease a c tiv ity .
Patients and Methods
The study was based on a to ta l of 187 serum samples from 88 patients (84 females and 
4 males; median age 38 years ranging from 20 to 59 years). A ll patients sa tis fied  the clas­
s if ic a tio n  c r ite ria  of the American Rheumatism Association (ARA).
A ll samples were tested fo r the presence of АСА, anti-ds-ONA among other blood param­
eters fo r a one year period in  1991 and 1992.
АСА assay was performed by a modification of the method of Loizou et a l. /8 / .
In b rie f, m icro tite r plates were coated with ca rd io lip in  (Sigma, USA, lo t  =/ 60H8377) 
d ilu te d  1:500, washed once w ith Tween-PBS and then blocked by the addition of 100 p l PBS-BSA to 
prevent non-specific binding o f immjnoglobulin. F if ty  jul serum in standard d ilu tio n  was added, 
incubated overnight at 4 °C then washed. F ifty  p i 1:2000 diluted conjugate (anti-human-IgG, 
-IgM, -IgA, -laribda and -kappa) and horseradish peroxidase enzyme were added and the mixture 
was incubated for 1.5 h at 37 °C. Thereafter, 50 p i ELISA buffer was added and the reaction 
was terminated with 50 p i 8 M sulphuric acid. Absorbance was read at 405 and 495 nm. The values 
of АСА were expressed as un its  in  comparison with the standard serum. The resu lt was considered 
to  be positive i f  i t  exceeded by 3 SD the mean value obtained with control serum of healthy 
volunteers. C lin ical records were reviewed for a history o f throntioenbolic events, thrombocyto­
penia, spontaneous abortion, seizures, psychosis, migraine and renal disorders.
Mean values are shown in  the tables. For s ta t is t ic a l analysis the chi-square tes t with 
Yates' correction and regression analysis were used. P values <0.05 were regarded as s ig­
n if ic a n t.
Results
Correlation of АСА levels with history of thromboembolic events, thrombo­
cytopenia, feta l loss, seizures, psychosis and migraine
The mean value plus 3 SD of АСА obtained with control serum was 28 
U/ml (= 8 + 3 X 6.6). Additionally, we subdivided АСА values into low, high 
positive and negative ones as done by Alving et a l. /1 /. Although th is  sub­
d iv is ion  is a rb itrary, i t  is , in our opinion, useful to estimate the major 
ranges of АСА levels and the occurrences of thromboembolic complications and 
related diseases within these ranges.
Positive АСА was detected in 71 (80.7%) of the 88 patients, the re­
maining 17 were found negative (Table I ) .
The correlation between АСА levels and a history of thromboembolic 
events and related diseases was not s ignificant.
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Table I
Comparison of АСА levels with a history 
of thrombosis and related diseases
History of thrombosis
АСА positive
(n=29)
negative 
(n 59)
low positive 17 28
(29-90 U/ml)
high positive 6 14
0  90 U/ml)
negative 6 17
From these results one can only state that positive АСА remains a 
special marker in SLE patients and that the probability to develop thrombo­
embolic complications and related diseases is higher than 50%.
The majority of the 71 patients with positive ASA display low АСА lev­
els. Therefore, i t  seems to be of no benefit using the АСА value in i ts e lf  
as a parameter predictive for developing thromboembolic events or related 
disease.
Correlation of АСА levels with anti-DNA antibody levels
The same procedure and subdivision of АСА levels was used as described 
above. The comparison of anti-ds-ONA antibody levels, subdivided in low, 
high positive and negative values is  shown in Table I I .  There was a s ig ­
n ifican t correlation between АСА levels and anti-ds-DNA levels (correlation 
coefficient г = 0.292, P 0.002).
Table I I
Comparison of АСА levels with anti-DNA antibody levels
АСА
anti-DNA le v e l
low
(18-92 U/ml) 
(n=44)
high
(> 92 U/ml) 
(n=19)
negative
(n=25)
low positive 25 7 13
high positive 8 9 3
negative 11 3 9
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These results are at variance with the observations of Loizou et a l. 
/8 / ,  Harris et a l. /5 / and Colaco et a l. /2 / who fa iled  to find  any cor­
re la tion  between these two parameters.
Furthermore, there were marked fluctuations in АСА levels and anti-ds- 
DNA levels in patients who were monitored more than once. Twenty-five pa­
tie n ts  were controlled in  th is  regard, but the sample was too small for 
calculation.
Association between АСА levels, renal disorders and thromboembolic events 
and related diseases
This problem is  another subject of controversy in the lite ra ture  
available /3, 6, 9 /. Though there was no sign ificant association between the 
parameters investigated (Table I I I ) ,  i t  seems to be lik e ly  that the pos­
s ib i l i t y  to develop renal disorders is  as high as to develop thromboembolic 
complications (or related diseases) or both. This is  partly  in  accordance 
with the findings of Cooper et a l. /3 /,  who found a strong correlation be­
tween АСА levels and renal involvement.
Table I I I
Comparison o f АСА levels with a history of renal disorders and
throrrboembolic events or related diseases
Renal No renal Thrombosis Thrombosis
АСА disease disease positive negative
(n=30) (n=58) (n=29) (n=59)
positive 28 49 27 50
negative 2 9 2 9
Discussion
In this study the most important finding was the close relationship 
between АСА levels and anti-ds-DNA levels. The question why th is  re la tion­
ship exists remains s t i l l  unclear and the background of th is  phenomenon re­
presents a wide f ie ld  fo r further investigations /4, 5, 7, 10/.
Since there was a positive correlation between anti-ds-DNA and АСА 
leve ls , the rise and/or fluctuation in АСА levels might be a good marker for 
disease activ ity  /6 /.  On the other hand, we conclude that the probability to
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develop renal involvement and/or thromboembolic complications or related 
disease in case of moderate or high АСА in connection with moderate or high 
anti-DNA levels is  more than 50%.
However, i t  does not seem to be advisable to use elevated АСА value as 
predictive parameter fo r thromboembolic events and related diseases.
A c k n o w le d g e m e n t :  This work was in part supported by a grant from the M inistry
of Health and Welfare (у/ T-214) and OTKA (#  2612/D).
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LIP ID  ABNORMALITIES IN URAEMIC PATIENTS ON CHRONIC HAEMODIALYSIS
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Patients kept on haemodialysis because of chronic renal insufficiency were investigated 
fo r l ip id  p ro files . The cholesterol level did not d if fe r  as compared to the age-matched con­
t r o l ,  while the trig lyce ride  leve l was elevated* The corre lation was found between the l ip id  
parameters, period spent in d ia lys is  programme and leve l of serum creatinine and urea. In renal 
fa ilu res of d iffe rent o rig in  the l ip id  levels are in relationship with the underlying d is ­
orders.
Keywords : Renal insu ffic iency, cholesterol, tr ig lyce rid e , HDL-C, apoproteins, lip o ­
proteins
In t ro d u c t io n
Recently, an increasing attention has been focussed on lip id  and lip o ­
protein changes developing from secondary hyperlipoproteinaemias in diabetes 
m ellitus and chronic renal disorders, diseases affecting a considerable part 
of the population. The incidence of atherosclerosis is s ig n ifican tly  in ­
creasing in both cases /35, 42, 44/. The life tim e  of patients with chronic 
renal disorder had been determined as distributed by the ir basic disease, 
but in the past few years -- as a result of the widespread haemodialysis 
programme and its  well-developed methods as well as the spreading use of 
kidney transplantation — atherosclerotic complications tend to become the 
main cause of death /25, 29/. In a 13-year follow-up study, Lindner et a l.
O ffprin t requests should be sent to: Gy. Paragh, 4012 Debrecen, P.0. Box 19, Hungary
Akadémiai Kiadó, Budapest
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/35 / observed a m orta lity  rate of 56% in permanently haemodialysed patients, 
and more than 50% of fa ta l cases was considered a result of some athero­
sc le ro tic  complications. Data reported by other authors show that the number 
of patients with chronic renal disorders who die of atherosclerotic compli­
cations is almost id e n tica l with that of the infections common in  patients 
with uraemia /34/. R itz et a l. /44/ claim tha t regarding fa ta l myocardial 
in farction  the chronic dialysed patients are in  danger 9-17-fold more than 
normal population. On the other hand, some studies present an increased 
plasma lip id  level of dialysed patients less important than hypertension as 
fa r as atherosclerosis is  concerned /31, 45, 47/. These data c a ll attention 
to the fact that every factor that may accelerate the development of athero­
sc le ro tic  complications in  renal disorders may have special significance 
la te r from the aspect of therapy. There have been studies recently to 
analyse the development of hyperlipoproteinaemia noticeable in patients with 
chronic renal disorder. That is  why we investigated the lip id  p ro file  in  pa­
tie n ts  with chronic renal fa ilu re .
P atients  and Methods
F ifty  renal patients (36 males, 14 females, 48.6 years old on the average) from a 
chronic haemodialysis programme were studied. The average period of haemodialysis was 34.7 
weeks (range 8 to 181 weeks) (F ig . 1). Twenty-five patien ts suffered from chronic glomerulo­
ne ph ritis , 7 from chronic pyelonephritis, 6 from d iabetic  nephropathy, 12 patients formed a 
separate group including those w ith polycystic renal diseases, Alport-syndrome, Schönlein— 
Henoch nephropathy and to x ic  renal disorders. Forty-six patients formed a control group, which 
included 20 females (40.5 years old on the average) and 26 males (mean age 52.8 years). These 
did  not suffer from diabetes m ellitus or any other metabolic disorder, liv e r or kidney dys­
function.
Each of the patients was tested for serum crea tin ine , urea, glucose, u ric  acid, to ta l 
p ro te in , e lec tro lite  leve ls  and liv e r  enzymes. Serum cholesterol, trig lyceride , HDL-C, LDL, 
apo A l, apo B100 and apo (a) levels were measured, and lipoprotein electrophoresis was 
performed.
Serum cholesterol and tr ig lyce rid e  were assayed w ith a Boehringer enzyme k i t ,  HDL cho­
le s te ro l with the phospho-wolframate-magnesium p rec ip ita tion  method. LDL cholesterol was ca l­
culated by the Friedewald formula when the trig lyceride  concentration was below 4.5 mmol/1 /21/.
Apoprotein examination was performed with radioimmunoassay (RIA) in which the Pharmacia 
k i t  was used, normal values: apo A l: 0.94—2.06 g/1, apo B: 0.38—1.32 g/1.
Serum lipoprotein (a) leve ls  were determined by Pharmacia RIA, normal values: up to 
450 U /l.
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N u m b e r  o f  p a t i e n t s  : 50 D i s e a s e s  :
G N C
w o m e n 25
me n
PNC
7
36 DM
6
12
M e a n  o f  h a e m o d i a l y s i s  t i m e :  3 4 . 7  w e e k s
Fig. 1, D istribution of patients by sex and underlying diseases. GNC (n=25), PNC (n=7),
DM (n=6), Other (n=12)
Abbreviations: GNC = glomerulonephritis, PNC = pyelonephritis, DM = diabetes m ellitus
The trig lyceride  level was sign ificantly  elevated (P < 0.001) in pa­
tien ts  with chronic renal insufficiency, compared to the age-matched healthy 
control group, whereas HDL cholesterol level was s lig h tly  decreased (Fig. 2). 
The relationship between the period of haemodialysis programme and serum 
lip id  level was also analysed (Table I ) .  The trig lyceride  level positive ly 
correlated (P 0.015) with haemodialysis time and increased s ign ifican tly  
(P <  0.001) in patients with chronic glomerulonephritis compared to chronic 
renal fa ilu re  of other o rig in  (Fig. 3). The apo В 100 and apo A1 levels 
were not elevated. The lipoprotein (a) level was elevated in 6 patients 
with diabetic nephropathy (Fig. 4). HDL-cholesterol level s lig h tly  decreased 
as compared to the control. We failed to recognize correlation between serum 
urea, creatinine and l ip id  levels. The serum to ta l protein level showed a 
strong positive correlation with the trig lyce ride  level, while i t  had a 
weaker negative correlation with the HDL-cholesterol level (Table I I ) .
Results
210 GY. PARAGH e t  a l .
И  = p a t i e n t s  ш = h e a l t h y  c o n t r o l s
F ig. 2. The serum lip id  parameters of patients with chronic renal fa ilu re  compared to healthy 
controls (means +_ SD), patients (n=50), healthy controls (n=46)
The connection
Table I
between lenqth of haemodialysis and
serum l ip id levels in chronic renal fa ilu re .
Patients (n=50)
HD-tim e
Г p s.
Cholesterol -0.1963 0.109
HDL-C -0.1772 0.134
Triglyceride 0.3396 0.015 *
Apo В -0.0649 0.343
Apo (a) 0.0052 0.487
Apo A1 0.0634 0.347
r  = corre lation coe ffic ien t, P = probability , 
s. = s ig n ifica tion  
*P< = 0.05,
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( mm o l  /  L )
Fig. 3. The l ip id  parameters in renal fa ilu res of d iffe re n t orig in . GNC (n=25), PNC (n=7),
DIAB. M. (n=6), Other (n=12)
Abbreviations: GNC = glomerulonephritis, PNC = pyelonephritis, DIAB. M. = diabetes m ellitus
(means + SD)
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Apó В, Apó A1 tg/L] ; Apo(a) [1000 U/l ]
□  -6NC (S3 = PNC И  = 01АВ.М. £ 2  = OTHER
Fig . 4, The apolipoprotein levels in renal fa ilu re  patients with d iffe rent aetiology. 
GNC (n=25), PNC (n=7), DIAB. M. (n=6), Other (n=12)
Abbreviations: GNC = glomerulonephritis, PNC = pyelonephritis, DIAB. M. = diabetes m ellitus
C means + SD)
Table I I
The connection between the renal function and lip id  parameters. 
Patients (n-50)
Total Protein Creatinin Urea
Г P s. Г P S . г P S .
Cholesterol 0.16 0.14 0.21 0.08 -0.06 0.34
HDL-C -0.32 0.015 X 0.20 0.09 -0.09 0.26
Triglyceride 0.42 0.002 XX -0.01 0.47 0.07 0.32
Apo В 0.06 0.35 0.09 0.26 -0.08 0.30
Apo (a) 0.01 0.48 -0.10 0.25 0.04 0.39
Apo A1 0.29 0.026 X -0.27 0.036 X -0.01 0.47
r  = correlation c o e ffic ie n t, P = probability , s.= s ign ifica tion  
*P-< = 0.05, **P«C = 0.01
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Discussion
I t  has been observed /2, 24, 36/ that in the background of hyperlipo- 
proteinaemia characteristic of the disease the lipoprotein synthesis, espe­
c ia lly  the apo 0 synthesis of the liv e r is  lik e ly  to increase to compensate 
the protein loss through the kidneys. Some authors /23, 24/ found an in ­
crease in the a c tiv ity  of the hydroxy-methyl-glutaryl-CoA reductase, which 
is the decisive key enzyme in the in trace llu la r cholesterol synthesis in 
experimental nephrosis of the ra t. Others /13/ think that the stimulus of 
increased lipoprotein production may be the hypoalbuminaemia and the conse­
quence of decreased colloidosmotic pressure. In addition, patients suf­
fering from nephrosis lose — through the kidneys — lecith in-cholestero l- 
acyltransferase (LCAT), an enzyme having an important role in l ip id  meta­
bolism, which is  necessary for the e ffic ie n t a c tiv ity  of HDL and cholesterol 
transport /17, 23, 27/.
Another part of research was focussed on the differences existing in 
renal disorders of d iffe ren t orig in. Serum trig lyceride  level was found to 
increase in chronic renal insufficiency /14, 15, 28, 42, 43/. Serum cho­
lestero l level usually remained in the normal range /11, 39, 42/, although 
i t  may s lig h tly  increase, beside hypertriglyceridaemia dominance /5, 12, 14, 
30/. HDL cholesterol values show a 50-75% decrease in non-dialysed, and 
haemodialysed patients with chronic renal fa ilu re  /11, 28, 39/, and th e ir 
C/HOL-C and LDL-C/HOL-C ratios are high /16, 43/.
Vascular disease is  the most important cause of mortality in chronic 
renal insufficiency. Cardiovascular disease is  usually associated with high 
concentrations of plasma cholesterol, LDL-cholesterol and apo-B, and re­
duced concentrations of HDL-cholesterol. According to a Cholesterol Lowering 
Atherosclerosis Study (CLAS) the progression of atherosclerotic lesions in 
patients who had undergone coronary by-pass surgery may be linked to in ­
creased concentrations of trig lyceride-rich  lipoproteins. Earlier studies 
/28/ revealed that patients with renal fa ilu re  had increased levels of 
plasma trig lyceride and VLDL-cholesterol. I t  has recently been reported 
/40, 41/ that patients with chronic renal fa ilu re  have increased concentra­
tions of lipoprote in(a).
A non-dialysable, so-called inh ib ito r factor starts to spread in the 
plasma /18, 37/, resulting in a decrease of the apo CII/apo C III ra tio . 
Apo С I I  is  necessary for the activation of the lipoprotein lipase whereas 
apo C I I I  acts as an inh ib ito r of the lipoprotein lipase enzyme /19, 46/.
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Thus, the decrease of apo C II/apo C I I I  ra tio  results in a decrease of the 
lipoprotein lipase a c tiv ity , leading to an accumulation of lipoproteins rich 
in trig lycerides in  the plasma /7, 8, 10, 41/. The analysis of the par­
t ic u la r  lipoprotein fraction compositions showed that in cases of uraemia i t  
is  the trig lyceride component that increases within certain lipoproteins 
/38 /. In HDL, the apo A I  and apo A I I  concentration decreased /7, 8, 26, 
33/. The apo В and apo С I concentrations were found normal or s lig h tly  de­
creased, whereas apo E level showed no change, or decreased, especially in 
males /1, 6, 8, 26, 33/. Ihe level of apo C I I I  increased s ig n ifican tly  /6, 
8, 26, 48/.
In accordance with lite ra ry  data we found that trig lyceride level in ­
creased in patients with chronic renal insufficiency, whereas the HDL-C 
leve l showed a s lig h t decrease, the inverse relation between trig lyce ride  
and HDL-C being probably responsible fo r the la tte r /4, 32/. Lipoprotein 
lipase ac tiv ity  correlated with serum trig lyce ride  levels inversely and with 
HDL cholesterol levels d irectly  /8, 9, 32/. No significant changes were 
found in the cholesterol and apo В levels, suggesting that i t  is  the damage 
of triglyceride-catabolism that has a primary role in the lip id  abnormali­
t ie s  of uraemic patients. I t  is  rather controversial to consider lipopro­
te ins rich  in trig lyce ride  as risk factors /9 /.  When compared to lite ra ry  
data /3, 9/, the l ip id  parameters in d iffe ren t basic diseases leading to 
chronic renal insuffic iency, were surprising, by d iffering from the l i te ra ­
ture .
Differences found in chronic glomerulonephritis group might be ex­
plained partly by immunosuppressive treatment of the diseases that increase 
l ip id  abnormalities, however, our patients did not get any immunosuppressive 
drugs. There may be metabolical disorders caused by diabetes, increased VLDL 
and apo В production in the background of the serum trigylceride level in ­
crease in diabetes m ellitus patients. Ihe high lipoprotein (a) level noticed 
in these patients can be explained by the small number of patients on the 
one hand, considering, i t  as an accidental feature, but there is  another 
p o ss ib ility , i.e . type-2 diabetes mellitus defined polygenic disorder may 
accompany with the a lteration of other genes, thus of lipoprotein (a) re­
su lting  in the increase of lipoprotein (a).
Ihe main renal complication of diabetes mellitus is the Kimmeistiel— 
Wilson syndrome, which leads to macroalbuminuria. Some earlier studies re­
vealed that macroalbuminuria might be accompanied by increased lipoprotein 
(a) concentration in the serum, however, the lite ra tu re  is controversial in 
th is  respect /22, 49/.
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Some earlie r studies /20/ suggest that trig lyceride level decreases at 
the beginning of haemodialysis, then i t  increases. So we also examined the 
change of serum trig lyceride level as related to the length of time being 
on haemodialysis. The length of haemodialysis time was found not to in f lu ­
ence the d iffe ren t lip id  levels, but serum trig lyceride  levels showed sig­
n ificant positive correlation with the haemodialysis time. E arlie r, Ponti- 
c e ll i et a l. /42/ fa iled to find any connection between plasma trig lyce ride  
level, age, sex, dia lysis time, blood sugar level after an overnight fast 
and insulin  reaction to intravenous glucose.
Our results suggest that the lip id  p ro file  changes in chronic renal 
insufficiency may be one of the causes acclerating cardiovascular disease 
in these patients. I f  we want to be successful in preventing th is  complica­
tion, we should begin the lipid-lowering treatment and start the haemo­
dia lysis programme at the same time.
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PORPHYRIN STUOIES IN CHRONIC RENAL FAILURE ANO 
RENAL TRANSPLANTATION
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Haemoglobin (Hb), free erythrocyte porphyrins (FEPs), protoporphyrin and haem contents 
as well as delta-aminolevulinic acid (ALA)-dehydrase a c tiv ity  were estimated in  blood samples 
from patients with chronic renal fa ilu re  (CRF), from those with renal transplantation, and from 
healthy control subjects. In CRF patients a highly elevated FEPs level and a s ig n if ic a n tly  in ­
creased protoporphyrin concentration were found. A well-defined decrease was observed in the 
mean value of ALA-dehydrase a c t iv ity ,  Hb and haem contents when compared to the contro l values. 
However, in  patients with renal transplantation s ign ifican t decreases were observed in  Hb and 
haem concentrations while the ALA-dehydrase a c tiv ity  and the FEPs and protoporphyrin concentra­
tions were approximately at the control levels.
Keywords: Haemoglobin, free erythrocyte porphyrins, protoporphyrin, haem, delta-amino­
le vu lin ic  acid-dehydrase, chronic renal fa ilu re , renal transplantation
In tro d u c tio n
The lite ra tu re  is  poor in studies on porphyrin biosynthesis in uraemic 
patients, despite the evidence showing the important role of porphyrin in 
haemoglobin biosynthesis. Most of patients on haemodialysis fo r chronic 
renal fa ilu re  were reported to be within normal lim its  when examined fo r ab­
normal porphyrins /6, 10/. On the other hand, several such patients have 
been reported to have high abnormal accumulation of porphyrins in  plasma, 
urine and faeces /7, 11/. Plasma porphyrins and free erythrocyte proto­
porphyrin (FEP) were found to be elevated in some uraemic patients on main­
tenance haemodialysis /11/. Serum delta-aminolevulinic acid (ALA), erythro-
Abbreviations: Hb = Haemoglobin, FEPs - free erythrocyte porphyrins, ALA = delta- 
aminolevulinic acid, CRF = chronic renal fa ilu re , RT = renal transplantation.
O ffp rin t requests should be sent to : M. M. H. El-Sharabasy, Department o f Chemistry, 
Faculty of Science, Damietta, Egypt
Akadémiai Kiadó, Budapest
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cyte coproporphyrin and protoporphyrin were found s ign ifican tly  higher in 
non-dialysed patients than in controls while ALA-dehydrase and uropor- 
phyrinogen-l-synthetase a c tiv it ie s  were inh ib ited in these patients /16/.
The present study was conducted to show whether the abnormalities of 
porphyrin biosynthesis in  uraemic patients are or are not stopped after 
renal transplantation.
M a te ria ls  and Methods
This study was performed on ( i )  20 adult patients, from both sexes, suffering from 
chronic renal fa ilu re . The patients were on maintenance haemodialysis at the Urology and 
Nephrology center, Mansoura Un iversity, Egypt, ( i i )  another group consisting of 16 adult pa­
t ie n ts  of both sexes who had undergone successful renal transplantation at least one year 
before and had been treated w ith  cyclosporin A and azathioprine or some other immunosuppres­
sive agents. A group o f 20 healthy adult subjects, from both sexes, was used as a control 
group. Heparinized blood samples were obtained from a l l  patients and control subjects.
Haemoglobin concentration was determined in whole blood by Drabkin's method /3 / while 
free  erythrocyte porphyrins as w e ll as blood protoporhyrin and haem contents were estimated 
according to the methods described by Piomelli /9 / and Labbe et a l. /8 / ,  respectively. The 
assay of ac tiv ity  ALA-dehydrase was done in whole blood samples, in which haematocrit values 
were determined, according to the method of Weissberg e t a l.  /15 /. For s ta t is t ic a l analysis, 
the standard methods of H i l l  / 5 /  were used.
Results
I t  is apparent from Table I that the mean Hb value was highly sig­
n ific a n tly  (P <  0.001) lower in patients with chronic renal fa ilu re  (CRF) 
than that for control subjects. Similar, but less expressed, difference was 
observed in patients w ith renal transplantation.
ALA-dehydrase a c tiv ity  was highly s ig n ifican tly  inhibited in CRF pa­
tie n ts  while in the group of transplanted patients the a c tiv ity  of th is  
enzyme was practica lly in  the range of be control value (Table I ) .  On the 
other hand, there are h ighly significant and s ign ifican t (P <  0.05) eleva­
tions in  concentrations o f free erythrocyte porphyrins and protoporphyrin, 
respectively, in blood o f CRF patient while in transplanted patients the 
mean values of these porphyrins do not s ig n ifican tly  d iffe r  from the control 
values. In contrast, haem content value was highly s ign ifican tly  decreased 
in  patients with CRF and a similar but less expressed difference was found 
in  patients with renal transplantation.
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Table I
(PP) and haem concentration as well as delta-aminolevulinic acid dehvdrase (ALA-D) a c t iv ity  in
blood of controls and of patients with chronic renal fa ilu re  (CRF) and with renal trans-
plantation (R.T.)
Controls CRF R.T.Item (n) (n) (n)
Hb (g/100 ml) 12.0 + 72 6.3 + 2.56** 8.4 + 5.17*
(20) (20) (16)
FEPs (pg/100 ml) 14.4 + 7.66 20.4 + 3.27** 11.2 + 4.32
(20) (18) (15)
PP (/jmol) (8.9 + 2.93)-10~3 (12.1 + 3.76)-lO“ 3* (7.9 + 2.43) -10~3
(14) (18) (15)
Haem (mol) (11.3 + 1.68)-lO-3 (3.5 + 1.12)-10‘ 3** (5.8 + 3 .75)-10~3*
(14) (18) (15)
ALA-0 (Units)0 11.2 + 5.56 7.2 + 2.25** 15.7 + 9.05
(20) (18) (15)
*P< 0.05, **P<£ 0.001
0 = jumol delta-aminolevulinic acid utilized/m l/m in 
0  = number of subjects
Discussion
As shown from the present results, the decrease Hb concentration in 
patients with CRF indicates characteristic anaemia of these patients. Hence, 
renal anaemia, which increases with progression of renal insufficiency /4 / 
indicates an insu ffic ien t compensatory increase in red ce ll production in 
response to blood loss and haemolysis. Erythropoietin deficiency /12/ and 
uraemic bone marrow intoxication /13/ have been implicated as major caus­
ative factors for the development of renal anaemia. This concept is  in 
agreement with the observation that renal anaemia usually disappears several 
months a fte r transplantation /2 /. This view may be supported by the elevated 
Hb concentration in our patients of renal transplantation which in  higher 
than the CRF value (Table I ) .
On the other hand, as indicated from the present results, one can say 
the Hb deficiency in these two-patients, undergoing th is sutdy, may be re­
lated to the diminished haem synthesis observed in these patients. In th is  
concept, there are increases in free erythrocyte porphyrins in patients with 
CRF and these changes may be attributed to abnormalities of some enzymes of
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the biosynthetic haem pathway. Such increases support an other previous 
find ing in which FEPs were elevated in 70% of uraemic patients on mainten­
ance haemodialysis and plasma porphyrins were increased in 58% of the same 
patients /1 /.
As shown in our results a high elevation was observed in protoporphy­
r in  concentration associated with a high decrease in haem content in  CRF pa­
tie n ts . These abnormalities may be attributed to the inh ib ition  of ferro- 
chelatase and/or deficiency of iron, which is  lo s t from the blood of these 
patients into the dialyzer during maintenance hemodialysis. Furthermore, in 
s im ila r findings in other disease, in which porphyrin prevalent, i t  was 
found a direct inh ib ito ry  effect of protoporphyrin on the enzyme system of 
the haem pathway /14/. This inh ib ition had resulted in the accumulation of 
FEPs. Moreover, a highly significant in h ib itio n  was observed in ALA-de- 
hydrase ac tiv ity  in CRF patients with progressing anaemia. In a previous 
study, erythrocyte ALA-dehydrase ac tiv ity  was found to be highly inh ib ited 
in  non-dialysed uraemic patients, and marked inh ib ition  in other dialysed 
uraemic patients; and a s im ilar pattern, but less significant, was observed 
in  erythrocyte uroporphyrinogen-l-synthetase a c tiv ity . However, addition of 
zinc to the practica lly  zinc-free haemolysates of uraemic patients caused an 
induction of ALA-dehydrase /16/. This la tte r  finding proves that ALA-de- 
hydrase ac tiv ity  is  zinc-dependent.
The observations described here do not support the evidence of der­
matologic manifestations of these studied patients that resembled e ither the 
bullous dermatosis of haemodialysis or porphyria cutanea tarda.
REFERENCES
1. Anderson, C. D., Rossi, E., Garcia-Webb, P.: Porphyrin studies in chronic renal fa ilu re  pa­
tie n ts  on maintenance hemodialysis. Photodermatol. 4, 14—32 (1987)
2. Dagher, F. 3., Ramos, E ., Erslev, A. 3., Alongi, S. V ., Karmi, S. A., Caro, 3 .: Are the 
native kidneys responsible fo r erythrocytosis in renal allografts? Transplantation 28, 
496-498 (1979)
3. Drabkin, D. L., Austin, 3. H.: Spectrophotometric constants for common haemoglobin de ri­
vatives in human, dog and rab b it blood. 3. B io l. Chem. 98^ , 719—733 (1932)
4. Erslev, A. 3.: Anemia of chronic renal disease. Arch. In tern . Med. 126, 774—780 (1970)
5. H i l l ,  S. A. B.: A short te x t book of medical s ta t is t ic s ,  10th ed. The English, S. Society 
Pitman Press, Bath, London, 1979, p. 137
6. Keczkes, K., Farr, M.: Bullous dermatosis of chronic renal fa ilu re . Br. 3. Dermatol. 95, 
541-546 (1976)
PORPHYRIN STUDIES IN  RENAL TRANSPLANTATION 223
7. Korting, G. W.: Uber porphyriä-cutäneä-tärdä-ärtige Häutveränderungen bei Längzeithamo- 
diälysepätienten. Dermatologica 150, 58—61 (1975)
8. Labbe, R. F., Finch, C. A., Smith, N. 0 ., Doan, R. N., Sood, 5. K., Madan, N.: Erythrocyte 
protoporphyrin/haem ra tio  in the assessment of iron status. Clin. Chem. 2£, 87—92 (1979)
9. Piom elli, S.: A micromethod fo r erythrocyte porphyrins. The FEP tes t. Lab. C lin . Med. EU, 
932-940 (1973)
10. Poh-Fitzpatrick, M. B., Masullo, A. S., Grossman, M. E.: Porphyria cutanea tarda associated
with chronic renal disease and hemodialysis. Arch. Dermatol. 116, 191—195 (1980)
11. Poh-Fitzpatrick, M. B., Sosin, A. E., Bemis, 0.: Porphyrin levels in plasma and erythro­
cytes of chronic hemodialysis patients. Amer. Acad. Dermatol. 0. 7_, 100—104 (1982)
12. Radtke, H. W., Claussner, A ., Erbes, R. M., Scheuremann, E. H., Schoeppe, W., Kock, M.: 
Serum erythropoietin concentration in chronic renal fa ilu re : Relationship to degree 
anemia and excretory renal function. Blood 5£, 877—884 (1979)
13. Radtke, H. W., Rege, A. B., La Marche, M. B., Bartos, D., Bartos, F ., Campbell, R. A., 
Fisher, D. W.: Ide n tifica tio n  o f spermine as an in h ib ito r of erythropoiesis in patients 
w ith chronic renal fa ilu re . 3. C lin. Invest. £7, 1623—1629 (1981)
14. San Martin de Viale, L. C., De Calmanovice, R. W., Rios, de Malino M. D. C., Grinstein, M.: 
Studies on porphyrin biosynthesis in lead intoxication rabb it. C lin . Chim. Acta 69_, 
375-379 (1976)
15. Weissberg, 3. G., Lipschutz, F ., Oski, F. A.: ALA-D a c tiv ity  in  c ircu la ting  blood ce lls . 
A sensitive laboratory te s t fo r the detection of childhood lead poisoning. N. Engl. 3. 
Med. 284, 565-569 (1971)
16. Yalouris, A. G., Lyberatos, C., Chalevellakis, G., Theodosiadou, E., B i l l is ,  A ., Raptis, 
S.: Some parameters o f haem synthesis in dialysed and non-dialysed uraemic patients. 
Scand. 3. Haematol. У7, 404—410 (1986)

A cta  M edica H u n g a r ic a , V o l .  4 9 /3 —4 , pp. 225— 231 (1 9 9 2 /9 3 )
THE EFFECT OF TSH AND TSI ON THE THYROGLOBOLIN EXPRESSION 
OF COLTORED HOMAN THYROID CELLS
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Human thyroid ce lls  in culture stimulated by TSH and TSI were used in order to detect 
thyroglobulin expression. A fter three days stimulation the ce lls  were incubated w ith mono­
clonal thyroglobulin antibody and FITC-conjugated an tig lobu lin . Fluorescent index (the in ten­
s ity  of fluorescence related to hundred analysed ce lls ) was estimated for each experimental 
group. The most e ffective stimulation of the thyroglobulin expression was detected a fte r TSH 
stimulation at the concentration of 0.1 mU/ml. TSI from active Graves' patients provoked the 
highest expression of thyroglobulin at concentration o f 1.0 mg/ml, but the fluorescence index 
was lower than a fte r TSH stimulation. The thyroglobulin expression was in tra c e llu la r, large, 
partly  confluent granules were detectable mainly in the perinuclear area. Antigen expression on 
the surface of cultured thyroid ce lls  could not be detected. The morphology of thyroglobulin 
expression as detected by immunofluorescence, was the same a fte r TSH and TSI stim ulation. 
I t  is  concluded, that both stimulating factors, i.e .  TSH and TSI, are involved in  the thyro­
globulin expression of human thyroid ce lls .
Keywords : Human thyroid ce lls , TSH, TSI, thyroglobulin expression, immunofluorescence
In tro d u c tio n
Thyroglobulin (TG), a 660 kD glycoprotein which plays an important 
role in the synthesis and storage of thyroid hormones /6, 7, 13/, is  syn­
thesized in the thyroid fo llic u la r e p ithe lia l ce lls  and stored in  the fo l­
lic u la r lumina. Thyroid-stimulating hormone (TSH) increases TG synthesis in 
the thyroid ce lls and, at the same time, stimulates resorption of the TG by
O ffp rin t requests should be sent to: J. Szabó, F irs t Department of Medicine, University 
Medical School, H-4012 Debrecen, P.0. Box 19, Hungary
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the thyrocytes through endocytosis. Thyroid hormones are released from the 
TG and secreted through proteolysis /1, 4, 5, 13/. TG determination is  of 
great significance in  the diagnosis and follow-up of different thyroid pa­
tie n ts  /6, 7, 9, 14/. The microsomal antigen of the thyroid — another auto- 
antigen which is  also a target of immunological processes in d iffe ren t 
thyroid diseases -- and the factors regulating i t s  expression and synthesis 
have been widely studied /3, 4, 5, 8, 10, 11, 12/. According to the results 
of Chiovato et a l. /3 / ,  TSH and thyroid stimulating immunoglobulin (TSI) 
stimulate the expression and synthesis of microsomal autoantigen in thyroid 
ce lls . In the present study we examined the TG expression in cultured human 
thyroid cells a fter TSH and TSI stimulation, using immunofluorescent method. 
To the best of our knowledge, examinations concerning the effect of both TSH 
and TSI on thyroglobulin expression of cultured human thyroid ce lls  have not 
been published, so fa r.
M ate ria ls  and Methods
Human thyroid ce lls In culture
Surgically removed human euthyroid adenomas and normal human thyroid tissue surrounding 
thyro id  cysts were used. Thyroid tissue was minced, digested in Collagenase Type IV (SIGMA) fo r 
two hours at 37 °C and passed through 200 yum nylon mesh, to eliminate clumps. Cell v ia b i l i t y  was 
checked and was more than 80% in  a l l  preparations used. The ce lls  were seeded at 2 x loVm l 
concentration onto round coverslips plated in wells o f a 24-well plate. The thyroid c e lls  were 
cultured in 5% СО2 and 95 /a ir at 37 °C in RPMI supplemented with 10% FCS and 1% an tib io tics  
(p e n ic ill in  and streptomycin).
Sera and TSH concentrations
Sera from five  patients with Graves' disease were used. A ll sera were positive fo r TSI 
as measured by the generation o f cAMP /2 / and negative fo r anti-TG as well as anti-microsomal 
antibodies using Thymmune-M and Thymnune-T k its  (Wellcome). IgG was prepared by OEA Sephadex 
separation and used at d iffe re n t concentrations: 0.5; 1.0; 2.0 and 5.0 mg/ml. Active Graves' 
disease was diagnosed by conventional c lin ic a l and laboratory c r ite ria  (history taking, phys­
ic a l examination, TRH te s t, sTSH-RIA, FT4-RIA, FT3-RIA and thyroid scintigraphy. TSH (SIGMA, 
Thyrotrop hormone) was used at the following concentrations: 0.01; 0.1 and 1.0 mU/ml.
Experimental procedure
TSH and TSI were added at the time of seeding the c e lls  on coverslips. The c e lls  were 
cultured for 3 days. Immunofluorescence investigation was in itia te d  by washing the thyroid 
c e lls  growing on coverslips. A fte r fixa tion  in paraformaldehyde ce lls  were treated w ith ch illed  
acetone and then incubated in  the sequence with: ( i )  monoclonal mouse anti-human thyroglobulin 
(Dakopatts) at the d ilu t io n  o f 1:50; ( i i )  FITC-labelled anti-mouse IgG and IgM produced in 
sheep (RUB 2nd STEP); ( i i i )  c e lls  were mounted in g lycero l and examined with a fluorescence
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microscope. The incubations were carried out at room temperature for 15 min. A ll incubations 
were made in tr ip lic a te .
Evaluation of immunofluorescence
300 ce lls  of each coverslip were estimated. The fluorescence in tensity o f positive 
ce lls  was graded and marked as follows: lig h t +; medium ++; and strong +++. The resu lts  were 
referred to 100 ce lls  as fluorescence index.
Controls
1_. The same procedure was carried out using sera from healthy volunteers. 2_. Cells 
without adding e ither TSH or sera were incubated with the same monoclonal antibody and then 
with FITC-conjugated anti-mouse immunoglobulin. ~b_. Cells stimulated with TSH and TSI from 
Graves' patients were incubated with FITC-labelled anti-mouse immunoglobulin alone.
Results
Effect of d ifferent TSH concentrations
TSH at the concentration of 0.1 mU/ml caused the most expressed 
thyroglobulin expression in cultured thyroid ce lls  (fluorescence index: 
168^35). At higher concentration — 1.0 mU/ml — the thyroglobulin expres­
sion was less (122 +_22) and the lowest fluorescence index was calculated 
a fte r stimulation with 0.01 mU/ml TSH (68+_9). Results are shown in Fig. 1.
Effect of d iffe rent TSI concentrations
TSI was the most effective at the concentration of 1.0 mg/ml, fluo ­
rescence index: 84+_14. At higher concentration the TSI was less e ffective , 
fluorescence index: 73^24  at 2 mg/ml and 71 ^  12 at 5.0 mg/ml. The least 
e ffect on thyroglobulin expression was caused at the lowest concentration 
(0.5 mg/ml) of TSI (3 2 ^10 ). Thyroid-stimulating immunoglobulins from d i f ­
ferent patients resulted in very sim ilar changes on thyroglobulin expres­
sion. Differences in fluorescence indices were mainly the consequences of 
d iffe ren t TSI concentrations. Results are demonstrated in Fig. 1.
Controls
A ll controls — except incubation of stimulated cells only with FITC- 
conjugated anti-mouse immunoglobulin — showed thyroglobulin expression of
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FLINDEX/100 cells
Fig, 1, The effect of d iffe re n t TSH and TSI concentrations on the thyroglobulin expression of 
cultured human thyroid c e lls , evaluated as fluorescence index/100 ce lls . The resu lts of control 
examinations are demonstrated, too. Ho.Ab + FITC Ig means resu lts without stimulation (no TSH 
or TSI added). FITC Ig means stim ulation with TSH and TSI followed by FITC-conjugated a n ti­
mouse Ig incubation alone. Mean + S.D. are demonstrated
the same low range. Their results are comparable with the e ffect of the 
lowest concentration (0.5 mg/ml) of TSI applied, but are s ign ifican tly  lower 
than the effect of TSH at 0.01 mll/ml concentration. (Results are shown in 
Fig. 1).
Fig. 2, Immunofluorescence a fte r  TSH stimulation at the concentration of 0.1 mll/ml. Small 
fluorescent granules d is tribu ted  in the cytoplasm of thyroid ce lls  and large, pa rtly  confluent, 
granules in  the perinuclear area. Original magnification x 400
F ig. 3. Immunofluorescence a fte r  stimulation with TSI a t 1.0 mg/ml concentration. Small 
granules distributed in the cytoplasm of the thyroid c e lls  and large granules w ith intensive 
fluorescence. Original magnification x 400
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Morphological aspects of thyroglobulin expression
The thyroglobulin expression was restricted to the cytoplasm of cul­
tured thyroid ce lls . The nuclei were negative. Granules of d iffe re n t size 
and fluorescent in tensity distributed in the cytoplasm (Fig. 2) and large, 
here and there confluent, granules located perinuclearly were also detect­
able (Fig. 3). There was no difference in the morphology of fluorescent po­
s i t iv i t y  caused either by TSH or TSI.
D is c u s s io n
Thyroglobulin and antibodies directed against i t  as well as the micro­
somal antigen and its  antibodies play an important pathogenetical role in 
thyroid diseases /5, 7, 10, 12, 15/. Both antigen-antibody systems have been 
widely investigated. Chiovato et a l. /3 / demonstrated the effect of TSH and 
TSI on the expression of microsomal antigen, they used human thyroid cells 
in  culture. We investigated the effect of TSH and TSI on the expression of 
thyroglobulin antigen. Our results indicate a tigh t correlation between the 
presence of TSH in the culture medium and the appearance of thyroglobulin 
antigen in the cultured thyroid ce lls . The most effective concentration of 
TSH was 0.1 mU/ml. TSI from active Graves' patients also provoked an in ­
creased thyroglobulin expression in the thyroid ce lls , but i t s  e ffe c tiv ity  
was lower than that of TSH. A sim ilar difference was described by Chiovato 
et a l.  /3 / regarding the microsomal antigen expression. The morphological 
characteristics of thyroglobulin are d iffe ren t from the microsomal antigen, 
as compared our results with the data of Chiovato et a l. /3 /. Thyroglobulin 
was detected only in form of large granules, frequently confluent and not so 
f in e ly  dispersed as the microsomal antigen. We failed to detect thyro­
g lobulin  antigen on the surface of thyroid ce lls .
In conclusion, we may say that both TSH and TSI are involved in the 
expression of thyroglobulin, but TSI seems to be less effective according to 
our results. Factors other than TSH and TSI (IFN gamma, GF, TNF and others) 
are probably also involved in the thyroglobulin expression, but th e ir pre­
cise effect and the ir connections to the TSH and TSI should be topics of 
fu rthe r examinations.
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IS  THE INCIDENCE OF ACUTE MOUNTAIN SICKNESS (AMS) AT 
MEDIUM ALTITUDE IN THE AUSTRIAN ALPS INFLUENCED BY THE HEIGHT 
OF HOME RESIDENCE OF THE ALPINIST?
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In previous studies the incidence of acute mountain sickness (AMS) at medium a ltitude  
was examined in the Austrian Alps, where many tou ris ts  come from low parts of Europe. This 
study assesses the influence of the height of home residence on the incidence of AMS at medium 
a ltitu de . The severity of h igh-altitude adaptation disorder was quantified by using a scoring 
system a fte r an interview and a c lin ic a l examination in 84 lowlanders, mainly those from Hun­
gary. Forty-two a lp in is ts  with a home residence of 800 to 1000 m served as con tro l. The in ­
cidence of AMS was 1.4% at 2000 m and 7.4% in 3000 m. The most frequent symptoms were s lig h t 
headache and peripheral or pe rio rb ita l oedema. The AMS-score of the Hungarian a lp in is ts  did 
not d if fe r  s ig n ifica n tly  from that of the a lp in is ts  w ith a home residence of height 800 to 
1000 m. Conclusion: in contrast to the s ituation at high a ltitude , at medium height tou ris ts  
from lowlands are not at higher r is k  of AMS than other a lp in is ts .
Keywords: Acute mountain sickness, medium a ltitu d e , lowland dwellers
In tro d u c tio n
Lowland dwellers who rapidly reach high a ltitude may develop one or 
more symptoms such as headache, anorexia and insomnia. The condition char­
acterized by symptoms lik e  progressive vomiting, shortness of breath, severe 
headache and ataxia is  called acute mountain sickness (AMS). Physical exam­
ination of these patients may disclose tachypnoea, pulmonary ra les, and 
perio rb ita l as well as peripheral oedema.
The incidence of AMS at high a ltitude was f i r s t  reported by Hackett et 
a l. /3 / who found 53% of 27B unacclimatized hikers to suffer from AMS at
O ffprin t requests should be sent to : G. Röggla, Währinger Gürtel 18-20, A-1090 Vienna,
Austria
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4243 ш altitude in the Himalayas of Nepal. AMS is  not quite uncommon at me­
dium altitude e ither. An incidence of 3.1% in 2000 m mounting to 53% at 
4559 m has been reported from the Austrian /9 / and Swiss /5 / Alps.
Lowland dwellers are at particular AMS-risk at high a ltitude , fo r in ­
stance in the Himalaya, but up to now no research has been done on AMS- 
prevalence at medium a ltitud e . The aim of our study was to evaluate the in ­
fluence of residentia l height at home on the incidence of AMS in the Aus­
tr ia n  Alps.
Methods
This study was performed in the Austrian Alps. On two levels of a ltitude  (a t 2000 m 
Rax/Schneeberg area and at 3000 m Hohe Tauern) lowland dwellers mainly those from Hungary were 
examined for AMS a fte r reaching the respective summits. The AMS-evaluating system established 
by Hackett et a l. /3 / was used throughout; th is  consists o f a short structured interview and a 
physical examination. Each to u r is t  was asked for headaches ( l ig h t :  one score point; severe: two 
score points), nausea (one p o in t), vomiting (two po in ts), dizziness (one po in t). As part o f the 
a lp in is ts  had not slept in a lp ine huts, insomnia was not recorded. The physical examination put 
emphasis on pe rio rb ita l or peripheral oedema (one s ite :  one point; more than one s ite : two 
points) respiratory rate (more than 25 breaths/min: two po in ts), pulmonary rales (s lig h t: one 
po in t; severe: two points) and ataxia (Romberg-test, finger-nose-test; two points). Presence of 
AMS signs was always revised by a second examiner. Severity of the height adaptation disorder 
was quantified by adding up the score points. Subjects without any sign and symptom of AMS were 
considered healthy, those w ith  one or two score points were considered s lig h tly  to moderately 
affected, and those with three or more score points were regarded as suffering from AMS. A l­
p in is ts  liv in g  at an a ltitu d e  o f 800 to 1000 m in Austria were assumed as a control group.
Chi-square analysis o f contingency tables and unpaired t  tes t. P < 0.05 was considered 
s ig n ifica n t.
Results
128 a lp in is ts, 94 men and 34 women, were examined: 72 probands at 
2000 m altitude and 56 at 3000 m a ltitude. At 2000 m altitude 52 and at 
3000 m altitude 32 of the probands were lowland dwellers. The other examined 
a lp in is ts  were residents at 800 to 1000 m a ltitud e . Age ranged from 19 to 64 
years. Age and sex did not vary s ign ifican tly  between the groups. The exam­
ination was performed on summits, that had to be reached by foot without aid 
of a cable car.
At 2000 m, one a lp in is t (1.4% of a l l  probands) had an AMS score of >  3 
indicating that he suffered from AMS, 7 a lp in is ts  (9.7%) showed s lig h t to 
moderate signs of height adaptation disorders (score 1 or 2) and 64 probands
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Table I
D istribution of score (mean ±  SO) in lowland dwellers (A)
and probands with home residence at 800 to 1000 m altitude
(B), examined at 2000 and 3000 m a ltitude . Nurrbers
(percentages) of a lp in is ts
2000 m 2000 m 3000 m 3000 m
Score A В A В
n = 52 n = 20 n = 32 n = 24
0 46 (88.5) 18 (90) 22 (68.7) 18 (75)
1-2 5 (9.6) 2 (10) 7 (21.9) 5 (20.8)
> 3 1 (1.9) 0 (0) 3 (9.4) 1 (4.2)
mean 0.23 0.15 0.75 0.54
SD 0.73 0.49 1.37 1.06
(88.9%) were without any sign of AMS (score 0). At 3000 m a ltitude , s ig n if­
icantly more a lp in ists showed signs of AMS: four probands (7.2%) had an AMS 
score of > 3 ,  12 probands (21.4%) of 1 or 2 and 40 probands (71.4%) of 0 
(P <  0.05).
The mean AMS-score of both the lowland dwellers and a lp in is ts  with 
home residence at 800 to 1000 m a ltitude rose s ign ifican tly , the percentage 
of unaffected subjects dropped with increasing a ltitude  (P 0.05). The in­
cidence of AMS signs did not d iffe r  s ign ifican tly  between lowland dwellers 
and the other a lp in is ts at either heights (Table I ) .
Table I I  shows the incidence of the AMS signs and symptoms. Slight 
headache and perio rb ita l or peripheral oedema occurred most frequently. In 
the lowland dwellers group, ataxia was shown by two touris ts. None of the 
a lp in is ts  suffered from severe headache or vomiting, only s lig h t pulmonary 
rales were documented in  2 probands.
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Table I I
Numbers (percentages) o f probands with symptoms and signs o f AMS
(A = lowland dwellers, В = tou ris ts  with home residence from 800 to 1000 m)
2000 m 2000 m 3000 m 3000 m
Symptom or sign A В A В
n = 52 n = 20 n = 32 n = 24
Headache :
none 4B (92.2) 18 (90) 27 (84.4) 21 (87.5)
ligh t 4 (7.7) 2 (10) 5 (15.6) 3 (12.5)
severe 0 (0) 0 (0) 0 (0) 0 (0)
Nausea:
no 50 (96.2) 20 (100) 30 (93.7) 23 (95.8)
yes 2 (3.8) 0 (0) 2 (6.3) 1 (4.2)
Vomiting:
no 52 (100) 20 (100) 32 (100) 24 (100)
Dizziness:
no 52 (100) 20 (100) 30 (93.7) 23 (95.8)
yes 0 (0) 0 (0) 2 (6.3) 1 (4.2)
Tachypnoea:
no 51 (98.1) 20 (100) 30 (93.7) 23 (95.8)
yes 1 (1.9) 0 (0) 2 (6.3) 1 (4.2)
Oedema :
none 48 (92.3) 19 (95) 28 (87.5) 20 (83.3)
1 site 4 (7.7) 1 (5) 4 (12.5) 4 (16.7)
2 sites 0 (0) 0 (0) 0 (0) 0 (0)
Pulmonary rales:
none 52 (100) 20 (100) 30 (93.7) 24 (100)
+ 0 (0) 0 (0) 2 (6.3) 0 (0)
+ + 0 (0) 0 (0) 0 (0) 0 (0)
Ataxia :
no 52 (100) 20 (100) 30 (93.7) 23 (100)
yes 0 (0) 0 (0) 2 (6.3) 1 (4.2)
D iscuss io n
A considerable increase in the number of Hungarian mountaineers in the 
Austrian Alps has taken place since the opening of the border. Most of the 
mountain tours performed in  Austria reach summits below 3000 m.
The incidence of AMS in high altitude has been well defined since many 
years, where as for the s ituation  in medium a ltitude  a wide range from 1.4
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to 2.5% was published in the lite ra tu re  /4, 6—8, 10, 11/. Reliable results 
were achieved after the now established AMS-scoring system was introduced 
/3 /. In our study a ll examinations and evaluations were performed a fte r the 
a lp in is ts  had rested for one hour, so that signs and symptoms with no regard 
to AMS (effort-induced tachypnoea and oedema of fingers caused by tig h t 
rucksack-straps) could be excluded. A ll a lp in is ts  examined in th is  study 
were jus t on one-day tours, therefore possible sleeping disorders as sign of 
AMS could not be evaluated. AMS scores correlate inversely with the a rte r ia l 
oxygen saturation /1 /.
AMS scores rose s ign ifican tly  both in lowland dwellers and in a l­
p in is ts with residence at home of 800 to 1000 m increasing a ltitude  without 
s ign ificant difference between the two groups. Although 5 a lp in is ts  reached 
an AMS score of > 3, neither fu l l  blown high-altitude pulmonary oedema nor 
h igh-altitude cerebral oedema was observed. In medium a ltitude the less 
dramatical forms of maladaptation are clearly much more common.
The experience from the Himalaya shows, that careful adaptation to 
height is  necessary in high a ltitude. Lowlanders are at much higher r isk  to 
suffer from AMS, especially a fter rapid ascent. On the contrary in medium 
a ltitude , none of our probands had undergone an adaptation time, a l l  the 
same no s ign ificant difference in the incidence of AMS between mostly Hun­
garian mountaineers and the presumably better adapted mountaineers from 
places between 800 and 1000 m showed.As the number of investigated a lp in is ts  
was not very large in th is  study, the investigation of a larger sample is  
necessary to confirm the results. Furthermore, the investigation of a larger 
sample of hikers at increasing height levels w il l  show from which a ltitude  
on lowlanders and highlanders d iffe r  in the respective AMS incidence.
Outcome: our study confirms that adaptation disorders occur at medium 
a ltitude  not rarely. Although AMS is  not mentioned in the alpine accident 
s ta tis tic s  in Austria /2 /, maladaptation to height may be of importance for 
mountain emergencies. Lowlanders are at no higher AMS risk  than a l l  other 
a lp in is ts  in our study.
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EFFECT OF CHORIOCARCINOMA SUPERNATANT ON NATURAE KILLER 
AND LYMPHOKINE-ACTIVATED KILLER CELL ACTIVITY
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The effect of 3EG-3 choriocarcinoma supernatant on human natural k i l le r  c e ll and 
lymphokine-activated k i l le r  c e ll a c tiv ity  was investigated. Choriocarcinoma supernatants from 
JEG-3 c e ll lines were obtained at the time of th e ir optimal growth. K562 erythroblastoid ce lls  
were used as target ce lls  fo r natural k i l le r  and lymphokine-activated k i l le r  c e ll mediated 
ly s is  in a ^C r release assay. The choriocarcinoma supernatants had a s ign ifican t dose-de- 
pendent suppressive e ffec t on natural k i l le r  and lymphokine-activated k i l le r  c e ll a c t iv ity . 
This suppression was more expressed at high effector:target c e ll ra tios . Therefore, chorio­
carcinoma supernatants appear to have potent inh ib ito ry effects on many aspects o f ce llu la r 
imnunity, although, additional studies should be performed to futher characterize and id en tify  
imnunoregulatory molecule(s) in choriocarcinoma supernatants.
Keywords : Choriocarcinoma supernatant, natural k i l le r  c e ll,  lymphokine-activated
k i l le r  c e ll,  imnunosuppression
In tro d u c tio n
Many experiments have shown that endocrine manipulation of animals 
alters the size and a c tiv ity  of the lymphoid organs /28/. I t  has also been 
claimed that sex hormones have a direct effect on levels of immune respon-
Abbreviations: CCA: choriocarcinoma, CPM: count per minute, -^Cr: sodium -’ ^chromate, 
E/T: e ffector:target ra tio , FCS: fe ta l c a lf serum, hCG: human chorionic gonadotrophin, IL-2: 
in terleukin-2, IL-2-R: interleukin-2 receptor, LAK: lymphokine-activated k i l le r ,  MHC: major 
histocom patibility complex, mRNA: messenger RNA, nK: natural k i l le r ,  PBLs: peripheral blood 
lymphocytes, S.D.: standard deviation, TCM: tissue culture medium
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siveness measured in  v itro  /26/ and they are responsible, at least in part, 
fo r the retention of the fe ta l a llograft /6 /.
A variety of effector ce lls , including cytotoxic T lymphocytes, na­
tu ra l k i l le r  (NK) ce lls  and natural cytotoxic ce lls accumulate at the s ite  
of graft rejection. These ce ll populations might also be activated and in­
volved at the feto-maternal interface because of recognition of semi-allo­
geneic antigens on trophoblast surface. Recent studies /5 / have demonstrated 
that human placental syncytiotrophoblast synthesizes mRNA for IL-2, which 
potentia lly  induces lymphokine-activated k i l le r  (LAK) cells by producing 
IL-2 protein. The NK c e ll and LAK ce ll system is  claimed to be of importance 
in  host defense against viruses, parasites and neoplasia, as well as in re­
gulating the bone marrow /29/. The effector ce lls concerned are capable of 
recognizing tumour tissues and are reduced in ac tiv ity  in pre-eclampsia, 
where increased levels of circulating trophoblast ce lls occur. Drake et a l. 
/9 / have reported that trophoblast ce lls are also susceptible to LAK-cell- 
mediated k ill in g . In a previous publication, re lating to breast cancer /30/, 
chance observations implicated sex hormones in  the regulation of the NK and 
LAK effector systems.
DEG-3 choriocarcinoma (CCA) cells are considered a pure c e ll model for 
human trophoblast and fo r the ir steroidogenic potential. Human chorionic 
gonadotrophin (hCG) is also a constant and predictable secretory product of 
trophoblast ce lls. Matsuzaki et a l. /19/ reported the biochemical charac­
teriza tion  of a choriocarcinoma-derived factor and determined i ts  immuno­
suppressive ac tiv ity  in human T ce ll responses. NK and LAK ce lls , unlike 
cytotoxic T lymphocytes, are not dependent on the major histocompatibility 
complex (MHC) class I  antigen for target ce ll recognition /21/. Because 
trophoblast ce lls do not express class I MHC antigens, NK and LAK ce lls  may 
be the principal maternal immune defense ce lls  capable of mounting and im­
munologic response to trophoblast tissue /3, 4/. In our early experiments 
/12, 13/ molar v illous flu id , which is  the concentrated product of molar 
trophoblast ce lls , suppressed ly t ic  a c tiv ity  of mononuclear ce lls . In the 
present study we investigated the direct e ffect of cultured human 3EG-3 CCA 
supernatant on the NK and LAK effector systems in v itro .
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Materials and Methods
Cell lines and growth conditions. K562 and JEG-3 CCA ce lls  were kindly supplied from 
the Japanese Cancer Research Resources Bank, Tokyo and from Chiba University, Chibacity, Tokyo 
(Dr. M. Sekiya). JEG-3 c e ll lin e  was maintained as continuous monolayer cultures in  75 cm^  
flasks (Corning, Iwaki Glass, Japan) containing 35 ml or 20 ml of a tissue culture medium (TCM) 
consisting of RPMI 1640 medium, 15% fe ta l c a lf serum (FCS), pe n ic illin  G sodium (100 U/ml), 
streptomycin sulfate (100 /jg/ml) and 2 nW L-glutamine (S c ie n tific  Product Laboratories Co. 
LTD., Ekimaebiru, O jiya -c ity , Niigata, Japan) at 37 °C in  a humidified atmosphere o f 5% CO2 and 
95% a ir .  Culture supernatants were collected from CCA c e ll lines  immediately a fte r the cultures 
reached confluence. K562 ce lls  were maintained in suspension in upright flasks in TCM under the 
same conditions.
Preparation of effector ce lls . Human peripheral blood lymphocytes (PBLs) containing the 
NK c e ll papulation were separated from freshly drawn heparinized blood by centrifugation on 
Ficoll-Paque (Pharmacia LKB Biotechnology Inc ., Piscataway, NJ). For NK experiments, the in te r­
face containing PBLs was collected, washed twice in RPMI, and resuspended in TCM. Macrophages, 
which can have an inh ib ito ry  e ffec t on the NK c e ll a c t iv ity ,  were removed by allowing them to 
adhere to FCS-coated p e tri dishes fo r 1 h at 37 °C. A fte r th is  step the concentration o f the 
c e ll suspension was adjusted to 1 x 10  ^ cells/m l in TCM. For LAK assays, PBLs were resuspended 
at a concentration of 1.5x10^ cells/m l in complete medium consisting of RPMI 1640 supplemented 
with 10% heat-inactivated human AB serum (INC Biomedicals, In c ., Costa Mesa, CA 92626), peni­
c i l l in  G sodium (100 U/ml), streptomycin sulfate (100 ug/ml), 2 nM L-glutamine ( th is  medium is 
subsequently referred to as RPMI-10 AB medium) and 1000 U/ml recombinant human IL-2 (Takeda 
Medical Co., Osaka, Japan). PBLs were activated to generate LAK cells by adding 10 ml from 
th is  c e ll suspension to 25 cm^  flasks (Corning, Iwaki Glass, Japan) and incubating ho rizonta lly  
for 4 to 5 days at 37 °C in a humidified atmosphere of 5% CO2 in 95% a ir .  The c e lls  were then 
washed twice and resuspended in the same culture medium without IL-2. Prior to cytotoxic assays 
LAK c e lls  were adjusted to a concentration of 1x10^ ce lls /m l in TCM.
Assay of NK c e ll and LAK ce ll a c tiv ity  on K562 c e lls . K562 ce ll suspension cultures 
were routine ly s p lit  in to  TCM in a ra tio  of 1:4 one day p r io r  to the NK assay. Cells were then 
washed twice in RPMI and labeled with 200/iCi sodium -^chromate (^C r; New England Nuclear, 
Boston, MA) in 1 ml c e ll suspension. After incubation fo r 1.5 h at 37 °C, ce lls  were layered 
over 3 ml of undiluted FCS and centrifuged for 10 min at 1500 rpm, washed twice in  TCM, ad­
justed to 3.33 x 10  ^ cells/m l TCM and kept on ice u n t il used. Assays were performed in  96-well 
round-bottomed plates (Sumilon, Japan). One hundred m ic ro lite rs  of less or more concentrated 
CCA supernatant or TCM was added f i r s t ,  followed by 100 /Л  of NK ce ll preparation or LAK c e ll 
preparation (e ffector ce lls ) and 50 >ul of radiolabeled ta rge t ce lls  (K562) in e ffec to r:ta rge t 
(E/T) ra tios  of 15:1, 30:1, and 60:1. Each tes t was conducted in tr ip lic a te . Plates were 
centrifuged at 500 rpm for 4 min, and then incubated at 37 °C for 6 h. Plates were centrifuged 
again immediately before harvesting, and 100 ,ul of supernatant was collected in glass counting 
tubes from each well and assessed for released ^C r in a gamma counter (Aloka; Auto Well Gamma 
System, ARC-300).
In both NK and LAK experiments, spontaneous ^Cr-release was measured in wells con­
ta in ing target ce lls  alone. Total incorporation was determined by counting the to ta l radio­
a c tiv ity  of the wells containing labeled target c e lls . Each assay was set up in t r ip l ic a te  and 
the percentage of specific ly s is  (^C r release) was calculated as follows:
% specific ly s is  = CPM -^Cr (experimental) - CPM ^C r (spontaneous)  ^
CPM 51cr ( to ta l)  - CPM -^CR (spontaneous)
The data were expressed as mean + standard deviation o f the percentage of spec ific  ly s is .
V ia b ility  of NK and LAK ce lls  in presence of TCM or CCA supernatants. NK and LAK ce lls  
were incubated at 37 °C for 6 h in  the presence of e ithe r TCM, RPMI-10 AB, or CCA supernatants, 
and v ia b il i ty  was assessed by the trypan blue exclusion te s t.
S ta tis tica l analysis. For NK and LAK assays, data were analysed with Statview I I  sta­
t is t ic a l  software on a Macintosh I l / c i  computer. Differences among groups were determined by
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two-way analysis of variance (ANOVA) followed by F isher's protected least s ig n ifica n t d i f ­
ference (PLSD) post-hoc tes ting .
R e s u lts
Spontaneous release of ^C r was less than 5% for cytotoxicity assays 
using K562 cells as targets. Experiments of NK and LAK ce ll a c tiv ity  with 
K562 cells as targets were performed at E/T ra tios of 15:1, 30:1, and 60:1, 
and a ll experiments showed optimal cy to toxic ity  at the E/T ra tio  60:1. For 
NK assays the percentage cytotoxicity was 28, 39, and 47% for E/T ra tios of 
15:1, 30:1, and 60:1, respectively (Fig. 1). In case of LAK assays the per­
centage of cyto toxic ity  was 69, 77, and 85%, respectively, under the same 
conditions (Fig. 2). CCA supernatants (less and more concentrated) were 
studied in the NK and LAK assays at E/T ra tios  of 15:1, 30:1, and 60:1 and 
optimal suppression of k il l in g  activ ity  was observed at an E/T ra tio  of 
60:1. Supernatants from two kinds of JEG-3 CCA ce ll cultures (containing
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Fig. 1, Compared to contro l (TCM), JEG-3 choriocarcinoma (CCA) supernatants (less concen­
tra ted = 35 ml, more concentrated = 20 ml) s ig n ifica n tly  suppressed natural k i l le r  c e l l  cyto­
to x ic ity  in the K562 target c e l l  assay at each effector : target ra tio  (P < 0.05). The suppres­
sion was more expressed at e ffec to r : target ra tios 30:1 and 60:1 than at 15:1. The f in a l con­
centration of CCA supernatant in  the cultures was 40%. The difference in the suppression of NK 
c e l l a c tiv ity  between the two d iffe rent concentrations o f CCA supernatant was s ig n ifica n t 
(P-< 0.05). Mean + S.D. values for tr ip lic a te  samples from a representative experiment
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35 ml = less concentrated and 20 ml = more concentrated supernatant) were 
added undiluted to the NK and LAK assays. The less concentrated supernatant 
contains less concentration of sex hormones and other factors produced by 
CCA ce lls than the more concentrated one. Figures 1 and 2 show that the 
suppression of both CCA supernatants was dose dependent and at E/T ra tios 
of 30:1 and 60:1 the ir suppression was more s ign ificant than at E/T ra tio  of 
15:1 (P <C 0.05). The suppression of the less and more concentrated CCA 
supernatants reached its  maximum at E/T ra tios of 60:1 in a ll experiments. 
The differences in the suppression of NK and LAK activ ity  of the less and 
more concentrated CCA supernatants were sign ificant at each E/T ra tio  
(P <  0.05). In NK assays the percentage of cytotoxicity in the presence of 
the less concentrated CCA supernatant was 23, 28, and 33% and for the more 
concentrated CCA supernatant was 16, 22, and 26% at E/T ratios of 15:1, 
30:1, and 60:1, respectively. In LAK experiments the percentage of cytoto­
x ic ity  was 49, 54, and 54% for the less concentrated and 38, 40, and 44% for
L A K  c o n t r o l  ( TCM )
Fig. 2. Compared to contro l (TCM), 3EG-3 choriocarcinoma (CCA) supernatants (see Fig. 1) 
s ign ifican tly  suppressed lymphokine-activated k i l le r  (LAK) c e ll cytotoxicity in the K562 target 
c e ll assay at each e ffec to r : target ra tio  (P •< 0.05). The suppression was more expressed at 
effector : target ra tios  30:1 and 60:1 than at 15:1. The f in a l concentration of CCA supernatant 
in the cultures was 40%. The difference in the suppression of LAK c e ll a c tiv ity  between the two 
d iffe ren t concentrations of CCA supernatant was s ig n ifica n t ( P<  0.05). Mean + S.D. values fo r 
tr ip l ic a te  samples from a representative experiment
e f f e c t o r / t a r g e t  c e l l  r a t i o
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the more concentrated JEG-3 CCA supernatant at E/T ratios of 15:1, 30:1, and 
60:1. V ia b ility  of NK and LAK cells a fte r culture in CCA supernatants was 
greater than 93% and did not d iffe r s ig n ifican tly  from TCM and RPMI-10 AB 
controls.
Discussion
Reportedly, a CCA-derived factor has immunosuppressive a c tiv ity  in 
human T ce ll responses /19 /. Possible iden tity  of a CCA-derived factor with 
the one obtained from normal trophoblast has also been published /18 /. I t  
suppresses IL-2-dependent T ce ll mediated responses, acting spec ifica lly  on 
the events in the p ro life ra tion  phase, but not those in the activation phase 
of IL-2 and IL-2-R mediated T ce ll responses. T cells activated by recogni­
tio n  of paternal alloantigens, however, may stimulate the IL-2-dependent as 
well as IL-2-independent pathways. I t  is , therefore, of importance to under­
stand the factor-mediated immunoregulation of feto-maternal interaction in 
order to examine whether the pregnancy-associated factors suppress T ce ll 
immune responses as well as NK and LAK c e ll a c tiv ity . The implantation s ite  
in  molar pregnancy is  in f ilt ra te d  by several types of immunocompetent ce lls  
including cytotoxic T lymphocytes, helper/inducer T cells, NK ce lls  /17/ 
and, potentia lly, LAK ce lls  /5, 20, 22/. These ce lls may influence tropho­
b last pro lifera tion , v ia b il ity  and function through direct cy to tox ic ity  or 
release of cytokines. The current study demonstrated that CCA supernatants 
s ig n ifican tly  suppress both NK-cell and LAK-cell cytotoxic functions and may 
play an important role in  the immunobiology of normal and molar pregnancy 
and gestational trophoblastic tumours.
NK cells lyse tumour cells by recognition of an unknown target struc­
ture and activation of unique cytoplasmatic signal transduction pathways, 
subsequently releasing cy to ly tic  (perforin) granules /16, 25/. LAK a c tiv ity  
may be mediated by members of both T and NK c e ll lineage, the effector ce lls  
responsible for malignant trophoblast lys is  are predominantly lymphokine- 
activated NK ce lls . These LAK cells and NK ce lls  recognize the same target 
molecule; the ir cytotoxic effects are quantita tive ly, but not qua lita tive ly , 
d iffe re n t. After IL-2 stimulation, these LAK ce lls  release a greater quanti­
ty  of natural k i l le r  cytotoxic factor against target cells and therefore 
exh ib it a higher level of cytotoxicity than NK ce lls  /15/.
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Similarly to our previous results /27/, in th is  study we demonstrated 
a s ignificant inh ib itory effect of two kinds of JEG-3 CCA supernatants on NK 
and LAK cell-mediated lys is  of classical K562 target ce lls. Under the same 
culture conditions equal number of JEG-3 CCA ce lls  were grown and maintained 
in 20 ml and 35 ml TCM in the same type of flasks for four days. The inten­
s ity  of CCA ce ll p ro life ra tion  was approximately the same under the 20 ml 
and 35 ml volume of TCM. Therefore, the concentration of sex hormones and 
other factors produced by CCA cells was obviously higher in the 20 ml TCM 
than in the 35 ml one. We found that both the less and the more concentrated 
CCA supernatants at a 40% fin a l concentration in culture markedly inhibited 
the ly t ic  ac tiv ity  of NK and LAK cells. This suppression was more expressed 
at higher E/T ratios than at lower ones. Furthermore, in case of higher con­
centrations of CCA cell-derived factors the suppression was also s ig n if­
icantly greater. These data suggest that JEG-3 CCA supernatant contains 
factor(s) that suppress both NK- and LAK-cell-mediated lys is .
Studies have been performed to characterize the suppressive factors(s) 
in CCA supernatants. The hCG present in culture at physiological levels has 
been shown to depress a range of p ro life ra tive  responses /14/ and also in ­
duces regulatory T-cell a c tiv ity  /11/. Careful studies have reported how­
ever, that re la tive ly  high progesterone and estrogen concentrations are ne­
cessary for suppression of NK and LAK ce ll a c tiv ity  /8, 10, 24/. The data 
presented in this paper suggest that hCG, which is  known to act via a common 
receptor, markedly suppresses lys is  of K562 target ce lls when present in the 
culture at a wide range of concentrations.
Several studies indicate that the mechanism of immunosuppression by 
CCA supernatants involves inh ib ition  of the IL-2 signal transduction pathway 
/1, 2, 7, 23/. Although we did not study th is  mechanism d irec tly , our re­
sults support th is hypothesis, for IL-2 is an in it ia t io n  signal for effector 
functions of both NK ce lls  and LAK cells /5 /.
CCA supernatants appear to have potent suppressive effects on many 
aspects of ce llu lar immunity. Although we have demonstrated that CCA super­
natants s ign ificantly in h ib it NK and LAK cytotoxic ity in v itro , additional 
studies should be performed to further characterize and identify immunore- 
gulatory molecule(s) in CCA supernatants.
Several pregnancy-associated factors which are produced by either 
trophoblast or decidual ce lls  might regulate a variety of maternal immuno­
competent ce lls, including NK and LAK ce lls , at the feto-maternal interface 
by d ifferent mechanisms. In combination with decidual suppressor ce lls  they
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may contribute to the establishment and maintenance of pregnancy. Presum­
ably, the 3EG-3 factor(s) may also act on the immune system of patients 
with choriocarcinoma, preventing tumour re jection by the host.
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